﻿<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2024v5.5">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2026-02-05T16:55:13-06:00</ReturnTs>
    <TaxPeriodEndDt>2025-03-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>331374517</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>PKF O'CONNOR DAVIES ADVISORY LLC</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>245 PARK AVENUE 12TH FLOOR</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10167</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990PF</ReturnTypeCd>
    <TaxPeriodBeginDt>2024-04-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>137184401</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>THE LEONA M AND HARRY B HELMSLEY</BusinessNameLine1Txt>
        <BusinessNameLine2Txt>CHARITABLE TRUST</BusinessNameLine2Txt>
      </BusinessName>
      <BusinessNameControlTxt>LEON</BusinessNameControlTxt>
      <PhoneNum>2126793600</PhoneNum>
      <USAddress>
        <AddressLine1Txt>230 PARK AVENUE 659</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10169</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>NICHOLAS J SCHIAVO</PersonNm>
      <PersonTitleTxt>CFO</PersonTitleTxt>
      <PhoneNum>2126793600</PhoneNum>
      <SignatureDt>2026-02-03</SignatureDt>
      <DiscussWithPaidPreparerInd>1</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <IRSResponsiblePrtyInfoCurrInd>0</IRSResponsiblePrtyInfoCurrInd>
    <PreparerPersonGrp>
      <PreparerPersonNm>THOMAS BLANEY</PreparerPersonNm>
      <PTIN>P00234022</PTIN>
      <PhoneNum>2122862600</PhoneNum>
      <PreparationDt>2026-02-03</PreparationDt>
    </PreparerPersonGrp>
    <TaxYr>2024</TaxYr>
    <BuildTS>2025-03-06 01:10:19Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="19">
    <IRS990PF documentId="RetDoc1235000001" referenceDocumentId="RetDoc1175200001">
      <Organization501c3ExemptPFInd>X</Organization501c3ExemptPFInd>
      <FMVAssetsEOYAmt>7108379897</FMVAssetsEOYAmt>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AnalysisOfRevenueAndExpenses>
        <ScheduleBNotRequiredInd>X</ScheduleBNotRequiredInd>
        <InterestOnSavRevAndExpnssAmt>3123289</InterestOnSavRevAndExpnssAmt>
        <InterestOnSavNetInvstIncmAmt>3123289</InterestOnSavNetInvstIncmAmt>
        <DividendsRevAndExpnssAmt>69499667</DividendsRevAndExpnssAmt>
        <DividendsNetInvstIncmAmt>141050038</DividendsNetInvstIncmAmt>
        <NetGainSaleAstRevAndExpnssAmt>388637842</NetGainSaleAstRevAndExpnssAmt>
        <GrossSalesPriceAmt>669040022</GrossSalesPriceAmt>
        <CapGainNetIncmNetInvstIncmAmt>270254392</CapGainNetIncmNetInvstIncmAmt>
        <OtherIncomeRevAndExpnssAmt referenceDocumentId="RetDoc2001500001">35998860</OtherIncomeRevAndExpnssAmt>
        <OtherIncomeNetInvstIncmAmt>24476876</OtherIncomeNetInvstIncmAmt>
        <TotalRevAndExpnssAmt>497259658</TotalRevAndExpnssAmt>
        <TotalNetInvstIncmAmt>438904595</TotalNetInvstIncmAmt>
        <CompOfcrDirTrstRevAndExpnssAmt>3489555</CompOfcrDirTrstRevAndExpnssAmt>
        <CompOfcrDirTrstNetInvstIncmAmt>1116119</CompOfcrDirTrstNetInvstIncmAmt>
        <CompOfcrDirTrstDsbrsChrtblAmt>2340081</CompOfcrDirTrstDsbrsChrtblAmt>
        <OthEmplSlrsWgsRevAndExpnssAmt>20708479</OthEmplSlrsWgsRevAndExpnssAmt>
        <OthEmplSlrsWgsNetInvstIncmAmt>4393931</OthEmplSlrsWgsNetInvstIncmAmt>
        <OthEmplSlrsWgsDsbrsChrtblAmt>16117382</OthEmplSlrsWgsDsbrsChrtblAmt>
        <PensionEmplBnftRevAndExpnssAmt>10117682</PensionEmplBnftRevAndExpnssAmt>
        <PensionEmplBnftNetInvstIncmAmt>2130594</PensionEmplBnftNetInvstIncmAmt>
        <PensionEmplBnftDsbrsChrtblAmt>8160451</PensionEmplBnftDsbrsChrtblAmt>
        <LegalFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002100001">555243</LegalFeesRevAndExpnssAmt>
        <LegalFeesNetInvstIncmAmt>184836</LegalFeesNetInvstIncmAmt>
        <LegalFeesDsbrsChrtblAmt>434251</LegalFeesDsbrsChrtblAmt>
        <AccountingFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002200001">303925</AccountingFeesRevAndExpnssAmt>
        <AccountingFeesNetInvstIncmAmt>6023</AccountingFeesNetInvstIncmAmt>
        <AccountingFeesChrtblPrpsAmt>228750</AccountingFeesChrtblPrpsAmt>
        <OtherProfFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002300001">17084502</OtherProfFeesRevAndExpnssAmt>
        <OtherProfFeesNetInvstIncmAmt>14847388</OtherProfFeesNetInvstIncmAmt>
        <OtherProfFeesDsbrsChrtblAmt>2538508</OtherProfFeesDsbrsChrtblAmt>
        <InterestNetInvstIncmAmt>3396683</InterestNetInvstIncmAmt>
        <TaxesRevAndExpnssAmt referenceDocumentId="RetDoc2002500001">1302511</TaxesRevAndExpnssAmt>
        <TaxesNetInvstIncmAmt>3875590</TaxesNetInvstIncmAmt>
        <TaxesDsbrsChrtblAmt>0</TaxesDsbrsChrtblAmt>
        <DeprecAndDpltnRevAndExpnssAmt>883605</DeprecAndDpltnRevAndExpnssAmt>
        <DeprecAndDpltnNetInvstIncmAmt>96753</DeprecAndDpltnNetInvstIncmAmt>
        <OccupancyRevAndExpnssAmt>1733287</OccupancyRevAndExpnssAmt>
        <OccupancyNetInvstIncmAmt>7513</OccupancyNetInvstIncmAmt>
        <OccupancyDsbrsChrtblAmt>1998276</OccupancyDsbrsChrtblAmt>
        <TravConfMeetingRevAndExpnssAmt>2631178</TravConfMeetingRevAndExpnssAmt>
        <TravConfMeetingNetInvstIncmAmt>247403</TravConfMeetingNetInvstIncmAmt>
        <TravConfMeetingDsbrsChrtblAmt>2325918</TravConfMeetingDsbrsChrtblAmt>
        <OtherExpensesRevAndExpnssAmt referenceDocumentId="RetDoc2003200001">16592645</OtherExpensesRevAndExpnssAmt>
        <OtherExpensesNetInvstIncmAmt>56278149</OtherExpensesNetInvstIncmAmt>
        <OtherExpensesDsbrsChrtblAmt>2489275</OtherExpensesDsbrsChrtblAmt>
        <TotOprExpensesRevAndExpnssAmt>75402612</TotOprExpensesRevAndExpnssAmt>
        <TotOprExpensesNetInvstIncmAmt>86580982</TotOprExpensesNetInvstIncmAmt>
        <TotOprExpensesDsbrsChrtblAmt>36632892</TotOprExpensesDsbrsChrtblAmt>
        <ContriPaidRevAndExpnssAmt>346765830</ContriPaidRevAndExpnssAmt>
        <ContriPaidDsbrsChrtblAmt>440927206</ContriPaidDsbrsChrtblAmt>
        <TotalExpensesRevAndExpnssAmt>422168442</TotalExpensesRevAndExpnssAmt>
        <TotalExpensesNetInvstIncmAmt>86580982</TotalExpensesNetInvstIncmAmt>
        <TotalExpensesDsbrsChrtblAmt>477560098</TotalExpensesDsbrsChrtblAmt>
        <ExcessRevenueOverExpensesAmt>75091216</ExcessRevenueOverExpensesAmt>
        <NetInvestmentIncomeAmt>352323613</NetInvestmentIncomeAmt>
      </AnalysisOfRevenueAndExpenses>
      <Form990PFBalanceSheetsGrp>
        <CashBOYAmt>89496038</CashBOYAmt>
        <CashEOYAmt>58011746</CashEOYAmt>
        <CashEOYFMVAmt>58011746</CashEOYFMVAmt>
        <SavAndTempCashInvstBOYAmt>55980540</SavAndTempCashInvstBOYAmt>
        <SavAndTempCashInvstEOYAmt>71184590</SavAndTempCashInvstEOYAmt>
        <SavAndTempCashInvstEOYFMVAmt>71184590</SavAndTempCashInvstEOYFMVAmt>
        <AcctRcvblAmt>285890</AcctRcvblAmt>
        <AcctRcvblBOYAmt>604736</AcctRcvblBOYAmt>
        <AcctRcvblEOYAmt>285890</AcctRcvblEOYAmt>
        <AcctRcvblEOYFMVAmt>285890</AcctRcvblEOYFMVAmt>
        <PrepaidExpensesBOYAmt>1033231</PrepaidExpensesBOYAmt>
        <PrepaidExpensesEOYAmt>1117294</PrepaidExpensesEOYAmt>
        <PrepaidExpensesEOYFMVAmt>1117294</PrepaidExpensesEOYFMVAmt>
        <CorporateStockBOYAmt>643618129</CorporateStockBOYAmt>
        <CorporateStockEOYAmt referenceDocumentId="RetDoc2018900001">797048528</CorporateStockEOYAmt>
        <CorporateStockEOYFMVAmt>797048528</CorporateStockEOYFMVAmt>
        <OtherInvestmentsBOYAmt>6446813297</OtherInvestmentsBOYAmt>
        <OtherInvestmentsEOYAmt referenceDocumentId="RetDoc2018100001">6125814330</OtherInvestmentsEOYAmt>
        <OtherInvestmentsEOYFMVAmt>6125814330</OtherInvestmentsEOYFMVAmt>
        <LandBldgEquipCostOrOtherBssAmt>10602402</LandBldgEquipCostOrOtherBssAmt>
        <LandBldgEquipAccumDeprecAmt>4745371</LandBldgEquipAccumDeprecAmt>
        <LandBOYAmt>6670262</LandBOYAmt>
        <LandEOYAmt referenceDocumentId="RetDoc2059000001">5857031</LandEOYAmt>
        <LandEOYFMVAmt>5857031</LandEOYFMVAmt>
        <OtherAssetsBOYAmt referenceDocumentId="RetDoc2046600001">55861389</OtherAssetsBOYAmt>
        <OtherAssetsEOYAmt referenceDocumentId="RetDoc2046600001">49060488</OtherAssetsEOYAmt>
        <OtherAssetsEOYFMVAmt referenceDocumentId="RetDoc2046600001">49060488</OtherAssetsEOYFMVAmt>
        <TotalAssetsBOYAmt>7300077622</TotalAssetsBOYAmt>
        <TotalAssetsEOYAmt>7108379897</TotalAssetsEOYAmt>
        <TotalAssetsEOYFMVAmt>7108379897</TotalAssetsEOYFMVAmt>
        <AccountsPayableBOYAmt>11499434</AccountsPayableBOYAmt>
        <AccountsPayableEOYAmt>3968491</AccountsPayableEOYAmt>
        <GrantsPayableBOYAmt>564121729</GrantsPayableBOYAmt>
        <GrantsPayableEOYAmt>469960352</GrantsPayableEOYAmt>
        <OtherLiabilitiesBOYAmt referenceDocumentId="RetDoc2065700001">45857428</OtherLiabilitiesBOYAmt>
        <OtherLiabilitiesEOYAmt referenceDocumentId="RetDoc2065700001">40418243</OtherLiabilitiesEOYAmt>
        <TotalLiabilitiesBOYAmt>621478591</TotalLiabilitiesBOYAmt>
        <TotalLiabilitiesEOYAmt>514347086</TotalLiabilitiesEOYAmt>
        <OrganizationFollowsFASB117Ind>X</OrganizationFollowsFASB117Ind>
        <NoDonorRstrNetAssestsBOYAmt>6678599031</NoDonorRstrNetAssestsBOYAmt>
        <NoDonorRstrNetAssestsEOYAmt>6594032811</NoDonorRstrNetAssestsEOYAmt>
        <TotNetAstOrFundBalancesBOYAmt>6678599031</TotNetAstOrFundBalancesBOYAmt>
        <TotNetAstOrFundBalancesEOYAmt>6594032811</TotNetAstOrFundBalancesEOYAmt>
        <TotalLiabilitiesNetAstBOYAmt>7300077622</TotalLiabilitiesNetAstBOYAmt>
        <TotalLiabilitiesNetAstEOYAmt>7108379897</TotalLiabilitiesNetAstEOYAmt>
      </Form990PFBalanceSheetsGrp>
      <ChgInNetAssetsFundBalancesGrp>
        <TotNetAstOrFundBalancesBOYAmt>6678599031</TotNetAstOrFundBalancesBOYAmt>
        <ExcessRevenueOverExpensesAmt>75091216</ExcessRevenueOverExpensesAmt>
        <OtherIncreasesAmt referenceDocumentId="RetDoc2049700001">2181205</OtherIncreasesAmt>
        <SubtotalAmt>6755871452</SubtotalAmt>
        <OtherDecreasesAmt referenceDocumentId="RetDoc2049800001">161838641</OtherDecreasesAmt>
        <TotNetAstOrFundBalancesEOYAmt>6594032811</TotNetAstOrFundBalancesEOYAmt>
      </ChgInNetAssetsFundBalancesGrp>
      <CapGainsLossTxInvstIncmDetail>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SALE OF PUBLICLY TRADED SECURITIES</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>100776909</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>49067</CostOrOtherBasisAmt>
          <GainOrLossAmt>100727842</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>100727842</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-21</SoldDt>
          <GrossSalesPriceAmt>8137</GrossSalesPriceAmt>
          <GainOrLossAmt>8137</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>8137</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-12</SoldDt>
          <GrossSalesPriceAmt>170334</GrossSalesPriceAmt>
          <GainOrLossAmt>170334</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>170334</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-28</SoldDt>
          <GrossSalesPriceAmt>60891</GrossSalesPriceAmt>
          <GainOrLossAmt>60891</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>60891</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-09</SoldDt>
          <GrossSalesPriceAmt>194429</GrossSalesPriceAmt>
          <GainOrLossAmt>194429</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>194429</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-06</SoldDt>
          <GrossSalesPriceAmt>95530</GrossSalesPriceAmt>
          <GainOrLossAmt>95530</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>95530</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-20</SoldDt>
          <GrossSalesPriceAmt>285950</GrossSalesPriceAmt>
          <GainOrLossAmt>285950</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>285950</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-20</SoldDt>
          <GrossSalesPriceAmt>790579</GrossSalesPriceAmt>
          <GainOrLossAmt>790579</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>790579</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-27</SoldDt>
          <GrossSalesPriceAmt>93382</GrossSalesPriceAmt>
          <GainOrLossAmt>93382</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>93382</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-04</SoldDt>
          <GrossSalesPriceAmt>110121</GrossSalesPriceAmt>
          <GainOrLossAmt>110121</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>110121</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-09</SoldDt>
          <GrossSalesPriceAmt>110121</GrossSalesPriceAmt>
          <GainOrLossAmt>110121</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>110121</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-19</SoldDt>
          <GrossSalesPriceAmt>110346</GrossSalesPriceAmt>
          <GainOrLossAmt>110346</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>110346</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-07</SoldDt>
          <GrossSalesPriceAmt>267610</GrossSalesPriceAmt>
          <GainOrLossAmt>267610</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>267610</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-21</SoldDt>
          <GrossSalesPriceAmt>260384</GrossSalesPriceAmt>
          <GainOrLossAmt>260384</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>260384</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-12</SoldDt>
          <GrossSalesPriceAmt>56579</GrossSalesPriceAmt>
          <GainOrLossAmt>56579</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>56579</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-12</SoldDt>
          <GrossSalesPriceAmt>44712</GrossSalesPriceAmt>
          <GainOrLossAmt>44712</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>44712</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-08</SoldDt>
          <GrossSalesPriceAmt>339577</GrossSalesPriceAmt>
          <GainOrLossAmt>339577</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>339577</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-12</SoldDt>
          <GrossSalesPriceAmt>169631</GrossSalesPriceAmt>
          <GainOrLossAmt>169631</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>169631</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-12</SoldDt>
          <GrossSalesPriceAmt>134020</GrossSalesPriceAmt>
          <GainOrLossAmt>134020</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>134020</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL XII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-01</SoldDt>
          <GrossSalesPriceAmt>310941</GrossSalesPriceAmt>
          <GainOrLossAmt>310941</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>310941</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL XII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-14</SoldDt>
          <GrossSalesPriceAmt>223664</GrossSalesPriceAmt>
          <GainOrLossAmt>223664</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>223664</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL XII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-28</SoldDt>
          <GrossSalesPriceAmt>66765</GrossSalesPriceAmt>
          <GainOrLossAmt>66765</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>66765</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-10</SoldDt>
          <GrossSalesPriceAmt>554375</GrossSalesPriceAmt>
          <GainOrLossAmt>554375</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>554375</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-17</SoldDt>
          <GrossSalesPriceAmt>135239</GrossSalesPriceAmt>
          <GainOrLossAmt>135239</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>135239</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-06</SoldDt>
          <GrossSalesPriceAmt>581363</GrossSalesPriceAmt>
          <GainOrLossAmt>581363</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>581363</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-09</SoldDt>
          <GrossSalesPriceAmt>5422148</GrossSalesPriceAmt>
          <GainOrLossAmt>5422148</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>5422148</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-13</SoldDt>
          <GrossSalesPriceAmt>506086</GrossSalesPriceAmt>
          <GainOrLossAmt>506086</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>506086</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-10</SoldDt>
          <GrossSalesPriceAmt>5475799</GrossSalesPriceAmt>
          <GainOrLossAmt>5475799</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>5475799</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-08</SoldDt>
          <GrossSalesPriceAmt>1007639</GrossSalesPriceAmt>
          <GainOrLossAmt>1007639</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1007639</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-05</SoldDt>
          <GrossSalesPriceAmt>488086</GrossSalesPriceAmt>
          <GainOrLossAmt>488086</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>488086</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-16</SoldDt>
          <GrossSalesPriceAmt>445055</GrossSalesPriceAmt>
          <GainOrLossAmt>445055</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>445055</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-17</SoldDt>
          <GrossSalesPriceAmt>37200</GrossSalesPriceAmt>
          <GainOrLossAmt>37200</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>37200</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-13</SoldDt>
          <GrossSalesPriceAmt>408164</GrossSalesPriceAmt>
          <GainOrLossAmt>408164</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>408164</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV PARALLEL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-17</SoldDt>
          <GrossSalesPriceAmt>307142</GrossSalesPriceAmt>
          <GainOrLossAmt>307142</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>307142</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV PARALLEL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-10</SoldDt>
          <GrossSalesPriceAmt>401912</GrossSalesPriceAmt>
          <GainOrLossAmt>401912</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>401912</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV PARALLEL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-13</SoldDt>
          <GrossSalesPriceAmt>727034</GrossSalesPriceAmt>
          <GainOrLossAmt>727034</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>727034</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV PARALLEL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-16</SoldDt>
          <GrossSalesPriceAmt>792745</GrossSalesPriceAmt>
          <GainOrLossAmt>792745</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>792745</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV PARALLEL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-05</SoldDt>
          <GrossSalesPriceAmt>337469</GrossSalesPriceAmt>
          <GainOrLossAmt>337469</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>337469</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV PARALLEL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-08</SoldDt>
          <GrossSalesPriceAmt>247006</GrossSalesPriceAmt>
          <GainOrLossAmt>247006</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>247006</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV PARALLEL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-10</SoldDt>
          <GrossSalesPriceAmt>433039</GrossSalesPriceAmt>
          <GainOrLossAmt>433039</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>433039</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV PARALLEL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-13</SoldDt>
          <GrossSalesPriceAmt>342430</GrossSalesPriceAmt>
          <GainOrLossAmt>342430</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>342430</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV PARALLEL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-09</SoldDt>
          <GrossSalesPriceAmt>461124</GrossSalesPriceAmt>
          <GainOrLossAmt>461124</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>461124</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH IV PARALLEL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-06</SoldDt>
          <GrossSalesPriceAmt>1035544</GrossSalesPriceAmt>
          <GainOrLossAmt>1035544</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1035544</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH LSV I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-10</SoldDt>
          <GrossSalesPriceAmt>439031</GrossSalesPriceAmt>
          <GainOrLossAmt>439031</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>439031</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH LSV I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-11</SoldDt>
          <GrossSalesPriceAmt>543327</GrossSalesPriceAmt>
          <GainOrLossAmt>543327</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>543327</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH LSV I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-06</SoldDt>
          <GrossSalesPriceAmt>484717</GrossSalesPriceAmt>
          <GainOrLossAmt>484717</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>484717</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH LSV I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-06</SoldDt>
          <GrossSalesPriceAmt>412821</GrossSalesPriceAmt>
          <GainOrLossAmt>412821</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>412821</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH LSV I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-09</SoldDt>
          <GrossSalesPriceAmt>475224</GrossSalesPriceAmt>
          <GainOrLossAmt>475224</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>475224</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BAYVIEW</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-08</SoldDt>
          <GrossSalesPriceAmt>676375</GrossSalesPriceAmt>
          <GainOrLossAmt>676375</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>676375</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BAYVIEW</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-10</SoldDt>
          <GrossSalesPriceAmt>124950</GrossSalesPriceAmt>
          <GainOrLossAmt>124950</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>124950</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BAYVIEW</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-31</SoldDt>
          <GrossSalesPriceAmt>50495</GrossSalesPriceAmt>
          <GainOrLossAmt>50495</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>50495</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-04</SoldDt>
          <GrossSalesPriceAmt>20000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>18609900</CostOrOtherBasisAmt>
          <GainOrLossAmt>1390100</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1390100</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-27</SoldDt>
          <GrossSalesPriceAmt>15000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>13391867</CostOrOtherBasisAmt>
          <GainOrLossAmt>1608133</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1608133</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-24</SoldDt>
          <GrossSalesPriceAmt>14245</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>13611</CostOrOtherBasisAmt>
          <GainOrLossAmt>634</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>634</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-03</SoldDt>
          <GrossSalesPriceAmt>15000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>13384573</CostOrOtherBasisAmt>
          <GainOrLossAmt>1615427</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1615427</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-22</SoldDt>
          <GrossSalesPriceAmt>12127</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>10961</CostOrOtherBasisAmt>
          <GainOrLossAmt>1166</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1166</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-22</SoldDt>
          <GrossSalesPriceAmt>13647</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>12559</CostOrOtherBasisAmt>
          <GainOrLossAmt>1088</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1088</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-24</SoldDt>
          <GrossSalesPriceAmt>10756</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>9826</CostOrOtherBasisAmt>
          <GainOrLossAmt>930</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>930</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CAMBER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-31</SoldDt>
          <GrossSalesPriceAmt>15000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>9232493</CostOrOtherBasisAmt>
          <GainOrLossAmt>5767507</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>5767507</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-17</SoldDt>
          <CostOrOtherBasisAmt>516</CostOrOtherBasisAmt>
          <GainOrLossAmt>-516</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-516</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>10000516</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>4632028</CostOrOtherBasisAmt>
          <GainOrLossAmt>5368488</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>5368488</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-31</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>2228298</CostOrOtherBasisAmt>
          <GainOrLossAmt>2771702</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2771702</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM OFFSHORE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-31</SoldDt>
          <GrossSalesPriceAmt>5000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>2261774</CostOrOtherBasisAmt>
          <GainOrLossAmt>2738226</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2738226</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM OFFSHORE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>10000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>4738543</CostOrOtherBasisAmt>
          <GainOrLossAmt>5261457</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>5261457</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-20</SoldDt>
          <GrossSalesPriceAmt>581635</GrossSalesPriceAmt>
          <GainOrLossAmt>581635</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>581635</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-28</SoldDt>
          <GrossSalesPriceAmt>114941</GrossSalesPriceAmt>
          <GainOrLossAmt>114941</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>114941</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-16</SoldDt>
          <GrossSalesPriceAmt>86683</GrossSalesPriceAmt>
          <GainOrLossAmt>86683</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>86683</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-12</SoldDt>
          <GrossSalesPriceAmt>96318</GrossSalesPriceAmt>
          <GainOrLossAmt>96318</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>96318</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-03</SoldDt>
          <GrossSalesPriceAmt>178332</GrossSalesPriceAmt>
          <GainOrLossAmt>178332</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>178332</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-10</SoldDt>
          <GrossSalesPriceAmt>298045</GrossSalesPriceAmt>
          <GainOrLossAmt>298045</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>298045</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER VII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>2733736</GrossSalesPriceAmt>
          <GainOrLossAmt>2733736</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2733736</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER VII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-21</SoldDt>
          <GrossSalesPriceAmt>1439065</GrossSalesPriceAmt>
          <GainOrLossAmt>1439065</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1439065</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER VII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-26</SoldDt>
          <GrossSalesPriceAmt>940500</GrossSalesPriceAmt>
          <GainOrLossAmt>940500</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>940500</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER VII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-07</SoldDt>
          <GrossSalesPriceAmt>3196572</GrossSalesPriceAmt>
          <GainOrLossAmt>3196572</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3196572</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER VII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-27</SoldDt>
          <GrossSalesPriceAmt>1182116</GrossSalesPriceAmt>
          <GainOrLossAmt>1182116</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1182116</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CRESTVIEW III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-23</SoldDt>
          <GrossSalesPriceAmt>716723</GrossSalesPriceAmt>
          <GainOrLossAmt>716723</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>716723</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CRESTVIEW III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-18</SoldDt>
          <GrossSalesPriceAmt>350515</GrossSalesPriceAmt>
          <GainOrLossAmt>350515</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>350515</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CRESTVIEW IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-18</SoldDt>
          <GrossSalesPriceAmt>217828</GrossSalesPriceAmt>
          <GainOrLossAmt>217828</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>217828</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY FUND XVI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-16</SoldDt>
          <GrossSalesPriceAmt>96495</GrossSalesPriceAmt>
          <GainOrLossAmt>96495</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>96495</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY FUND XVI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-28</SoldDt>
          <GrossSalesPriceAmt>345347</GrossSalesPriceAmt>
          <GainOrLossAmt>345347</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>345347</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY XV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-25</SoldDt>
          <GrossSalesPriceAmt>351294</GrossSalesPriceAmt>
          <GainOrLossAmt>351294</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>351294</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY XVII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-31</SoldDt>
          <GrossSalesPriceAmt>57950</GrossSalesPriceAmt>
          <GainOrLossAmt>57950</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>57950</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY XVII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-28</SoldDt>
          <GrossSalesPriceAmt>23663</GrossSalesPriceAmt>
          <GainOrLossAmt>23663</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>23663</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY XVII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-06</SoldDt>
          <GrossSalesPriceAmt>431455</GrossSalesPriceAmt>
          <GainOrLossAmt>431455</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>431455</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY XVII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-30</SoldDt>
          <GrossSalesPriceAmt>406437</GrossSalesPriceAmt>
          <GainOrLossAmt>406437</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>406437</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY XVII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-31</SoldDt>
          <GrossSalesPriceAmt>3056</GrossSalesPriceAmt>
          <GainOrLossAmt>3056</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3056</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY XVII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-10</SoldDt>
          <GrossSalesPriceAmt>218737</GrossSalesPriceAmt>
          <GainOrLossAmt>218737</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>218737</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EMERGENCE III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-03</SoldDt>
          <GrossSalesPriceAmt>5086839</GrossSalesPriceAmt>
          <GainOrLossAmt>5086839</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>5086839</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EMERGENCE OPP I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-12</SoldDt>
          <GrossSalesPriceAmt>342981</GrossSalesPriceAmt>
          <GainOrLossAmt>342981</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>342981</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EMERGENCE OPP I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-12</SoldDt>
          <GrossSalesPriceAmt>223517</GrossSalesPriceAmt>
          <GainOrLossAmt>223517</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>223517</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS ELEC CO INV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-21</SoldDt>
          <GrossSalesPriceAmt>616412</GrossSalesPriceAmt>
          <GainOrLossAmt>616412</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>616412</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS ELEC CO INV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-26</SoldDt>
          <GrossSalesPriceAmt>505163</GrossSalesPriceAmt>
          <GainOrLossAmt>505163</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>505163</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-26</SoldDt>
          <GrossSalesPriceAmt>55373</GrossSalesPriceAmt>
          <GainOrLossAmt>55373</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>55373</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-28</SoldDt>
          <GrossSalesPriceAmt>58548</GrossSalesPriceAmt>
          <GainOrLossAmt>58548</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>58548</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-21</SoldDt>
          <GrossSalesPriceAmt>251128</GrossSalesPriceAmt>
          <GainOrLossAmt>251128</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>251128</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-20</SoldDt>
          <GrossSalesPriceAmt>18351</GrossSalesPriceAmt>
          <GainOrLossAmt>18351</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>18351</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-30</SoldDt>
          <GrossSalesPriceAmt>1163419</GrossSalesPriceAmt>
          <GainOrLossAmt>1163419</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1163419</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FORTISSIMO V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-14</SoldDt>
          <GrossSalesPriceAmt>3256380</GrossSalesPriceAmt>
          <GainOrLossAmt>3256380</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3256380</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER IX</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-14</SoldDt>
          <GrossSalesPriceAmt>68206</GrossSalesPriceAmt>
          <GainOrLossAmt>68206</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>68206</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER IX</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-14</SoldDt>
          <GrossSalesPriceAmt>90172</GrossSalesPriceAmt>
          <GainOrLossAmt>90172</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>90172</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER IX</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-07</SoldDt>
          <GrossSalesPriceAmt>422015</GrossSalesPriceAmt>
          <GainOrLossAmt>422015</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>422015</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER OVERAGE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-20</SoldDt>
          <GrossSalesPriceAmt>416477</GrossSalesPriceAmt>
          <GainOrLossAmt>416477</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>416477</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER PUBLIC FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-20</SoldDt>
          <GrossSalesPriceAmt>544640</GrossSalesPriceAmt>
          <GainOrLossAmt>544640</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>544640</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER PUBLIC FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-23</SoldDt>
          <GrossSalesPriceAmt>3316055</GrossSalesPriceAmt>
          <GainOrLossAmt>3316055</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3316055</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER X</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-07</SoldDt>
          <GrossSalesPriceAmt>164995</GrossSalesPriceAmt>
          <GainOrLossAmt>164995</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>164995</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER X</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-19</SoldDt>
          <GrossSalesPriceAmt>91483</GrossSalesPriceAmt>
          <GainOrLossAmt>91483</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>91483</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER XI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-07</SoldDt>
          <GrossSalesPriceAmt>415117</GrossSalesPriceAmt>
          <GainOrLossAmt>415117</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>415117</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER XI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-26</SoldDt>
          <GrossSalesPriceAmt>153232</GrossSalesPriceAmt>
          <GainOrLossAmt>153232</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>153232</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER XI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-18</SoldDt>
          <GrossSalesPriceAmt>134642</GrossSalesPriceAmt>
          <GainOrLossAmt>134642</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>134642</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GAVEA V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-14</SoldDt>
          <GrossSalesPriceAmt>125558</GrossSalesPriceAmt>
          <GainOrLossAmt>125558</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>125558</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GAVEA V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-21</SoldDt>
          <GrossSalesPriceAmt>28701</GrossSalesPriceAmt>
          <GainOrLossAmt>28701</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>28701</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GAVEA V PLUS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-20</SoldDt>
          <GrossSalesPriceAmt>296683</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>1820727</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1524044</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1524044</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2013</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-23</SoldDt>
          <GrossSalesPriceAmt>262194</GrossSalesPriceAmt>
          <GainOrLossAmt>262194</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>262194</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2013</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-09</SoldDt>
          <GrossSalesPriceAmt>778044</GrossSalesPriceAmt>
          <GainOrLossAmt>778044</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>778044</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2013</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-15</SoldDt>
          <GrossSalesPriceAmt>687815</GrossSalesPriceAmt>
          <GainOrLossAmt>687815</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>687815</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2013</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-01</SoldDt>
          <GrossSalesPriceAmt>2448001</GrossSalesPriceAmt>
          <GainOrLossAmt>2448001</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2448001</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2013</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-17</SoldDt>
          <CostOrOtherBasisAmt>1203436</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1203436</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1203436</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2013</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-18</SoldDt>
          <CostOrOtherBasisAmt>251741</CostOrOtherBasisAmt>
          <GainOrLossAmt>-251741</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-251741</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2013</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-27</SoldDt>
          <CostOrOtherBasisAmt>318109</CostOrOtherBasisAmt>
          <GainOrLossAmt>-318109</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-318109</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2013</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-29</SoldDt>
          <GrossSalesPriceAmt>214699</GrossSalesPriceAmt>
          <GainOrLossAmt>214699</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>214699</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2013</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-20</SoldDt>
          <GrossSalesPriceAmt>352356</GrossSalesPriceAmt>
          <GainOrLossAmt>352356</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>352356</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2013</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-10</SoldDt>
          <CostOrOtherBasisAmt>300519</CostOrOtherBasisAmt>
          <GainOrLossAmt>-300519</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-300519</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2013</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-22</SoldDt>
          <GrossSalesPriceAmt>602031</GrossSalesPriceAmt>
          <GainOrLossAmt>602031</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>602031</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2018</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-23</SoldDt>
          <GrossSalesPriceAmt>248139</GrossSalesPriceAmt>
          <GainOrLossAmt>248139</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>248139</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2018</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-19</SoldDt>
          <CostOrOtherBasisAmt>62458</CostOrOtherBasisAmt>
          <GainOrLossAmt>-62458</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-62458</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2018</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-09</SoldDt>
          <GrossSalesPriceAmt>7824</GrossSalesPriceAmt>
          <GainOrLossAmt>7824</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>7824</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2018</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-23</SoldDt>
          <CostOrOtherBasisAmt>150412</CostOrOtherBasisAmt>
          <GainOrLossAmt>-150412</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-150412</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2018</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-10</SoldDt>
          <CostOrOtherBasisAmt>300340</CostOrOtherBasisAmt>
          <GainOrLossAmt>-300340</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-300340</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2018</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-08</SoldDt>
          <GrossSalesPriceAmt>4965</GrossSalesPriceAmt>
          <GainOrLossAmt>4965</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4965</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2018</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-21</SoldDt>
          <GrossSalesPriceAmt>253065</GrossSalesPriceAmt>
          <GainOrLossAmt>253065</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>253065</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2018</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-18</SoldDt>
          <GrossSalesPriceAmt>24276</GrossSalesPriceAmt>
          <GainOrLossAmt>24276</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>24276</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERL ATLANTIC 2018</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-13</SoldDt>
          <CostOrOtherBasisAmt>20669</CostOrOtherBasisAmt>
          <GainOrLossAmt>-20669</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-20669</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL LATAM B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-28</SoldDt>
          <GrossSalesPriceAmt>1923570</GrossSalesPriceAmt>
          <GainOrLossAmt>1923570</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1923570</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL LATAM B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-09</SoldDt>
          <GrossSalesPriceAmt>1271</GrossSalesPriceAmt>
          <GainOrLossAmt>1271</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1271</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL LATAM C</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-28</SoldDt>
          <GrossSalesPriceAmt>1923570</GrossSalesPriceAmt>
          <GainOrLossAmt>1923570</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1923570</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL LATAM C</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-09</SoldDt>
          <GrossSalesPriceAmt>1271</GrossSalesPriceAmt>
          <GainOrLossAmt>1271</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1271</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG CAPITAL V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-10</SoldDt>
          <GrossSalesPriceAmt>2238351</GrossSalesPriceAmt>
          <GainOrLossAmt>2238351</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2238351</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG CAPITAL V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-27</SoldDt>
          <GrossSalesPriceAmt>108903</GrossSalesPriceAmt>
          <GainOrLossAmt>108903</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>108903</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG GROWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-18</SoldDt>
          <GrossSalesPriceAmt>6589895</GrossSalesPriceAmt>
          <GainOrLossAmt>6589895</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>6589895</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG GROWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-30</SoldDt>
          <GrossSalesPriceAmt>428825</GrossSalesPriceAmt>
          <GainOrLossAmt>428825</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>428825</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG GROWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-18</SoldDt>
          <GrossSalesPriceAmt>2981167</GrossSalesPriceAmt>
          <GainOrLossAmt>2981167</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2981167</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG GROWTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-24</SoldDt>
          <GrossSalesPriceAmt>15245</GrossSalesPriceAmt>
          <GainOrLossAmt>15245</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15245</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MID MARKET II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-10</SoldDt>
          <GrossSalesPriceAmt>4540155</GrossSalesPriceAmt>
          <GainOrLossAmt>4540155</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4540155</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MID MARKET III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-28</SoldDt>
          <GrossSalesPriceAmt>2730340</GrossSalesPriceAmt>
          <GainOrLossAmt>2730340</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2730340</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MID MARKET III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-23</SoldDt>
          <CostOrOtherBasisAmt>80215</CostOrOtherBasisAmt>
          <GainOrLossAmt>-80215</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-80215</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MID MARKET III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-07</SoldDt>
          <GrossSalesPriceAmt>983432</GrossSalesPriceAmt>
          <GainOrLossAmt>983432</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>983432</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MID MARKET III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-23</SoldDt>
          <GrossSalesPriceAmt>643259</GrossSalesPriceAmt>
          <GainOrLossAmt>643259</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>643259</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MID MARKET III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-27</SoldDt>
          <GrossSalesPriceAmt>495998</GrossSalesPriceAmt>
          <GainOrLossAmt>495998</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>495998</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-30</SoldDt>
          <GrossSalesPriceAmt>98500</GrossSalesPriceAmt>
          <GainOrLossAmt>98500</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>98500</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-31</SoldDt>
          <GrossSalesPriceAmt>101636</GrossSalesPriceAmt>
          <GainOrLossAmt>101636</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>101636</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-30</SoldDt>
          <GrossSalesPriceAmt>99653</GrossSalesPriceAmt>
          <GainOrLossAmt>99653</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>99653</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-31</SoldDt>
          <GrossSalesPriceAmt>104842</GrossSalesPriceAmt>
          <GainOrLossAmt>104842</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>104842</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-31</SoldDt>
          <GrossSalesPriceAmt>105581</GrossSalesPriceAmt>
          <GainOrLossAmt>105581</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>105581</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>108549</GrossSalesPriceAmt>
          <GainOrLossAmt>108549</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>108549</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-31</SoldDt>
          <GrossSalesPriceAmt>101394</GrossSalesPriceAmt>
          <GainOrLossAmt>101394</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>101394</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-30</SoldDt>
          <GrossSalesPriceAmt>100737</GrossSalesPriceAmt>
          <GainOrLossAmt>100737</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>100737</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-31</SoldDt>
          <GrossSalesPriceAmt>98786</GrossSalesPriceAmt>
          <GainOrLossAmt>98786</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>98786</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-31</SoldDt>
          <GrossSalesPriceAmt>100783</GrossSalesPriceAmt>
          <GainOrLossAmt>100783</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>100783</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-28</SoldDt>
          <GrossSalesPriceAmt>100535</GrossSalesPriceAmt>
          <GainOrLossAmt>100535</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>100535</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-31</SoldDt>
          <GrossSalesPriceAmt>101235</GrossSalesPriceAmt>
          <GainOrLossAmt>101235</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>101235</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-08</SoldDt>
          <GrossSalesPriceAmt>10000000</GrossSalesPriceAmt>
          <GainOrLossAmt>10000000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>10000000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-31</SoldDt>
          <GrossSalesPriceAmt>41808</GrossSalesPriceAmt>
          <GainOrLossAmt>41808</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>41808</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-31</SoldDt>
          <GrossSalesPriceAmt>42158</GrossSalesPriceAmt>
          <GainOrLossAmt>42158</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>42158</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>43332</GrossSalesPriceAmt>
          <GainOrLossAmt>43332</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>43332</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-31</SoldDt>
          <GrossSalesPriceAmt>28085</GrossSalesPriceAmt>
          <GainOrLossAmt>28085</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>28085</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-07</SoldDt>
          <GrossSalesPriceAmt>20000000</GrossSalesPriceAmt>
          <GainOrLossAmt>20000000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>20000000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-07</SoldDt>
          <GrossSalesPriceAmt>20000000</GrossSalesPriceAmt>
          <GainOrLossAmt>20000000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>20000000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-30</SoldDt>
          <GrossSalesPriceAmt>13000</GrossSalesPriceAmt>
          <GainOrLossAmt>13000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-06</SoldDt>
          <GrossSalesPriceAmt>16366469</GrossSalesPriceAmt>
          <GainOrLossAmt>16366469</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16366469</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-06</SoldDt>
          <GrossSalesPriceAmt>40967</GrossSalesPriceAmt>
          <GainOrLossAmt>40967</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>40967</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-30</SoldDt>
          <GrossSalesPriceAmt>45862</GrossSalesPriceAmt>
          <GainOrLossAmt>45862</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>45862</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-31</SoldDt>
          <GrossSalesPriceAmt>47403</GrossSalesPriceAmt>
          <GainOrLossAmt>47403</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>47403</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-30</SoldDt>
          <GrossSalesPriceAmt>46398</GrossSalesPriceAmt>
          <GainOrLossAmt>46398</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>46398</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN GROWTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-28</SoldDt>
          <GrossSalesPriceAmt>2324829</GrossSalesPriceAmt>
          <GainOrLossAmt>2324829</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2324829</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN GROWTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-16</SoldDt>
          <GrossSalesPriceAmt>158779</GrossSalesPriceAmt>
          <GainOrLossAmt>158779</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>158779</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN GROWTH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-05</SoldDt>
          <GrossSalesPriceAmt>356150</GrossSalesPriceAmt>
          <GainOrLossAmt>356150</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>356150</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN GROWTH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-11</SoldDt>
          <GrossSalesPriceAmt>267294</GrossSalesPriceAmt>
          <GainOrLossAmt>267294</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>267294</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN GROWTH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-27</SoldDt>
          <GrossSalesPriceAmt>469601</GrossSalesPriceAmt>
          <GainOrLossAmt>469601</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>469601</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN GROWTH IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-03</SoldDt>
          <GrossSalesPriceAmt>1462758</GrossSalesPriceAmt>
          <GainOrLossAmt>1462758</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1462758</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN GROWTH V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-06</SoldDt>
          <GrossSalesPriceAmt>886290</GrossSalesPriceAmt>
          <GainOrLossAmt>886290</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>886290</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN GROWTH V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-20</SoldDt>
          <GrossSalesPriceAmt>387389</GrossSalesPriceAmt>
          <GainOrLossAmt>387389</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>387389</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN GROWTH V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-03</SoldDt>
          <GrossSalesPriceAmt>120258</GrossSalesPriceAmt>
          <GainOrLossAmt>120258</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>120258</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN VTR IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-07</SoldDt>
          <GrossSalesPriceAmt>1724725</GrossSalesPriceAmt>
          <GainOrLossAmt>1724725</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1724725</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN VTR V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-27</SoldDt>
          <GrossSalesPriceAmt>1572764</GrossSalesPriceAmt>
          <GainOrLossAmt>1572764</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1572764</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN VTR V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-06</SoldDt>
          <GrossSalesPriceAmt>976372</GrossSalesPriceAmt>
          <GainOrLossAmt>976372</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>976372</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN VTR VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-04</SoldDt>
          <GrossSalesPriceAmt>272166</GrossSalesPriceAmt>
          <GainOrLossAmt>272166</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>272166</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN VTR VII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-23</SoldDt>
          <GrossSalesPriceAmt>226056</GrossSalesPriceAmt>
          <GainOrLossAmt>226056</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>226056</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG CHINA CAP III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-26</SoldDt>
          <GrossSalesPriceAmt>356085</GrossSalesPriceAmt>
          <GainOrLossAmt>356085</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>356085</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG CHINA CAP III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-23</SoldDt>
          <GrossSalesPriceAmt>692441</GrossSalesPriceAmt>
          <GainOrLossAmt>692441</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>692441</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG CHINA VTR IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-27</SoldDt>
          <GrossSalesPriceAmt>1431875</GrossSalesPriceAmt>
          <GainOrLossAmt>1431875</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1431875</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG CHINA VTR IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-26</SoldDt>
          <GrossSalesPriceAmt>1540318</GrossSalesPriceAmt>
          <GainOrLossAmt>1540318</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1540318</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG CHINA VTR IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-26</SoldDt>
          <GrossSalesPriceAmt>629533</GrossSalesPriceAmt>
          <GainOrLossAmt>629533</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>629533</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG-ACCEL CHINA CAP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-28</SoldDt>
          <GrossSalesPriceAmt>153499</GrossSalesPriceAmt>
          <GainOrLossAmt>153499</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>153499</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG-ACCEL CHINA CAP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-27</SoldDt>
          <GrossSalesPriceAmt>347979</GrossSalesPriceAmt>
          <GainOrLossAmt>347979</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>347979</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG-ACCEL CHINA GWTH</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-27</SoldDt>
          <GrossSalesPriceAmt>342633</GrossSalesPriceAmt>
          <GainOrLossAmt>342633</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>342633</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IRON POINT IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-26</SoldDt>
          <GrossSalesPriceAmt>98074</GrossSalesPriceAmt>
          <GainOrLossAmt>98074</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>98074</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IRON POINT IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-31</SoldDt>
          <GrossSalesPriceAmt>116088</GrossSalesPriceAmt>
          <GainOrLossAmt>116088</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>116088</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IRON POINT IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-31</SoldDt>
          <GrossSalesPriceAmt>589300</GrossSalesPriceAmt>
          <GainOrLossAmt>589300</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>589300</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>JPM PEG SECONDRY III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-11</SoldDt>
          <GrossSalesPriceAmt>832831</GrossSalesPriceAmt>
          <GainOrLossAmt>832831</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>832831</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>JPM PEG SECONDRY III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-20</SoldDt>
          <GrossSalesPriceAmt>260094</GrossSalesPriceAmt>
          <GainOrLossAmt>260094</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>260094</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-31</SoldDt>
          <GrossSalesPriceAmt>16782</GrossSalesPriceAmt>
          <GainOrLossAmt>16782</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16782</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-31</SoldDt>
          <GrossSalesPriceAmt>16269</GrossSalesPriceAmt>
          <GainOrLossAmt>16269</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16269</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-30</SoldDt>
          <GrossSalesPriceAmt>16198</GrossSalesPriceAmt>
          <GainOrLossAmt>16198</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16198</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-31</SoldDt>
          <GrossSalesPriceAmt>15942</GrossSalesPriceAmt>
          <GainOrLossAmt>15942</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15942</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>42967</GrossSalesPriceAmt>
          <GainOrLossAmt>42967</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>42967</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-03</SoldDt>
          <GrossSalesPriceAmt>85991115</GrossSalesPriceAmt>
          <GainOrLossAmt>85991115</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>85991115</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-04</SoldDt>
          <GrossSalesPriceAmt>11000000</GrossSalesPriceAmt>
          <GainOrLossAmt>11000000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>11000000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-10</SoldDt>
          <GrossSalesPriceAmt>3420000</GrossSalesPriceAmt>
          <GainOrLossAmt>3420000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3420000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-30</SoldDt>
          <GrossSalesPriceAmt>15402</GrossSalesPriceAmt>
          <GainOrLossAmt>15402</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15402</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-28</SoldDt>
          <GrossSalesPriceAmt>20503</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>33936</CostOrOtherBasisAmt>
          <GainOrLossAmt>-13433</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-13433</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-31</SoldDt>
          <GrossSalesPriceAmt>19904</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>47400</CostOrOtherBasisAmt>
          <GainOrLossAmt>-27496</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-27496</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-30</SoldDt>
          <GrossSalesPriceAmt>15602</GrossSalesPriceAmt>
          <GainOrLossAmt>15602</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15602</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-31</SoldDt>
          <GrossSalesPriceAmt>16197</GrossSalesPriceAmt>
          <GainOrLossAmt>16197</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16197</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-28</SoldDt>
          <GrossSalesPriceAmt>15997</GrossSalesPriceAmt>
          <GainOrLossAmt>15997</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15997</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-31</SoldDt>
          <GrossSalesPriceAmt>17165</GrossSalesPriceAmt>
          <GainOrLossAmt>17165</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>17165</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-31</SoldDt>
          <GrossSalesPriceAmt>17262</GrossSalesPriceAmt>
          <GainOrLossAmt>17262</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>17262</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>17624</GrossSalesPriceAmt>
          <GainOrLossAmt>17624</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>17624</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-31</SoldDt>
          <GrossSalesPriceAmt>17198</GrossSalesPriceAmt>
          <GainOrLossAmt>17198</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>17198</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-30</SoldDt>
          <GrossSalesPriceAmt>18342</GrossSalesPriceAmt>
          <GainOrLossAmt>18342</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>18342</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-31</SoldDt>
          <GrossSalesPriceAmt>21118</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>34954</CostOrOtherBasisAmt>
          <GainOrLossAmt>-13836</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-13836</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MARATHON GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-31</SoldDt>
          <GrossSalesPriceAmt>113216</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>120019</CostOrOtherBasisAmt>
          <GainOrLossAmt>-6803</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-6803</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MARATHON GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-31</SoldDt>
          <GrossSalesPriceAmt>121799</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>117793</CostOrOtherBasisAmt>
          <GainOrLossAmt>4006</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4006</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MARATHON GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-28</SoldDt>
          <GrossSalesPriceAmt>117910</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>118743</CostOrOtherBasisAmt>
          <GainOrLossAmt>-833</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-833</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MARATHON GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-31</SoldDt>
          <GrossSalesPriceAmt>106095</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>98764</CostOrOtherBasisAmt>
          <GainOrLossAmt>7331</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>7331</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MARATHON GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-30</SoldDt>
          <GrossSalesPriceAmt>106715</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>98641</CostOrOtherBasisAmt>
          <GainOrLossAmt>8074</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>8074</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MARATHON GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-31</SoldDt>
          <GrossSalesPriceAmt>104541</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>99327</CostOrOtherBasisAmt>
          <GainOrLossAmt>5214</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>5214</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MARATHON GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>107477</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>98535</CostOrOtherBasisAmt>
          <GainOrLossAmt>8942</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>8942</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MARATHON GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-31</SoldDt>
          <GrossSalesPriceAmt>105618</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>99118</CostOrOtherBasisAmt>
          <GainOrLossAmt>6500</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>6500</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MARATHON GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-31</SoldDt>
          <GrossSalesPriceAmt>99672</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>101153</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1481</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1481</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MARATHON GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-31</SoldDt>
          <GrossSalesPriceAmt>103314</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>99863</CostOrOtherBasisAmt>
          <GainOrLossAmt>3451</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3451</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MARATHON GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-30</SoldDt>
          <GrossSalesPriceAmt>98157</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>101736</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3579</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3579</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MARATHON GLOBAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-28</SoldDt>
          <GrossSalesPriceAmt>101595</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>100460</CostOrOtherBasisAmt>
          <GainOrLossAmt>1135</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1135</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR AXIOM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-10</SoldDt>
          <GrossSalesPriceAmt>8756041</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>7122665</CostOrOtherBasisAmt>
          <GainOrLossAmt>1633376</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1633376</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR AXIOM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-23</SoldDt>
          <GrossSalesPriceAmt>6549708</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>5404893</CostOrOtherBasisAmt>
          <GainOrLossAmt>1144815</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1144815</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR AXIOM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-25</SoldDt>
          <GrossSalesPriceAmt>4200693</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>3346112</CostOrOtherBasisAmt>
          <GainOrLossAmt>854581</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>854581</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR AXIOM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-15</SoldDt>
          <GrossSalesPriceAmt>7449691</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>6060005</CostOrOtherBasisAmt>
          <GainOrLossAmt>1389686</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1389686</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR AXIOM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>13146060</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>10728930</CostOrOtherBasisAmt>
          <GainOrLossAmt>2417130</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2417130</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR AXIOM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-26</SoldDt>
          <GrossSalesPriceAmt>10799601</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>8610687</CostOrOtherBasisAmt>
          <GainOrLossAmt>2188914</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2188914</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR INST PARTNERS IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-26</SoldDt>
          <GrossSalesPriceAmt>70584</GrossSalesPriceAmt>
          <GainOrLossAmt>70584</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>70584</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>NEWMARKET IIFC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-05</SoldDt>
          <GrossSalesPriceAmt>2534924</GrossSalesPriceAmt>
          <GainOrLossAmt>2534924</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2534924</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ASIA III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-08</SoldDt>
          <GrossSalesPriceAmt>981047</GrossSalesPriceAmt>
          <GainOrLossAmt>981047</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>981047</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ASIA III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-12</SoldDt>
          <GrossSalesPriceAmt>1568863</GrossSalesPriceAmt>
          <GainOrLossAmt>1568863</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1568863</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ASIA IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-27</SoldDt>
          <GrossSalesPriceAmt>6453395</GrossSalesPriceAmt>
          <GainOrLossAmt>6453395</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>6453395</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ASIA IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-09</SoldDt>
          <CostOrOtherBasisAmt>134561</CostOrOtherBasisAmt>
          <GainOrLossAmt>-134561</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-134561</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ISRAEL II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-18</SoldDt>
          <GrossSalesPriceAmt>1675630</GrossSalesPriceAmt>
          <GainOrLossAmt>1675630</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1675630</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PI IX</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-17</SoldDt>
          <GrossSalesPriceAmt>3560122</GrossSalesPriceAmt>
          <GainOrLossAmt>3560122</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3560122</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PI VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-13</SoldDt>
          <GrossSalesPriceAmt>414196</GrossSalesPriceAmt>
          <GainOrLossAmt>414196</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>414196</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PI VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-20</SoldDt>
          <GrossSalesPriceAmt>198429</GrossSalesPriceAmt>
          <GainOrLossAmt>198429</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>198429</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PI VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-23</SoldDt>
          <GrossSalesPriceAmt>1541464</GrossSalesPriceAmt>
          <GainOrLossAmt>1541464</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1541464</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PI VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-30</SoldDt>
          <CostOrOtherBasisAmt>163168</CostOrOtherBasisAmt>
          <GainOrLossAmt>-163168</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-163168</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PI VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-22</SoldDt>
          <GrossSalesPriceAmt>398545</GrossSalesPriceAmt>
          <GainOrLossAmt>398545</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>398545</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PI VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-24</SoldDt>
          <GrossSalesPriceAmt>23202</GrossSalesPriceAmt>
          <GainOrLossAmt>23202</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>23202</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ROYALTY II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-06</SoldDt>
          <CostOrOtherBasisAmt>1141698</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1141698</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1141698</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ROYALTY II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-06</SoldDt>
          <GrossSalesPriceAmt>293</GrossSalesPriceAmt>
          <GainOrLossAmt>293</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>293</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEAK XV V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-04</SoldDt>
          <GrossSalesPriceAmt>192662</GrossSalesPriceAmt>
          <GainOrLossAmt>192662</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>192662</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEAK XV V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-16</SoldDt>
          <GrossSalesPriceAmt>354728</GrossSalesPriceAmt>
          <GainOrLossAmt>354728</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>354728</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEAK XV V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-26</SoldDt>
          <GrossSalesPriceAmt>192266</GrossSalesPriceAmt>
          <GainOrLossAmt>192266</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>192266</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEAK XV V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-14</SoldDt>
          <GrossSalesPriceAmt>120937</GrossSalesPriceAmt>
          <GainOrLossAmt>120937</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>120937</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEAK XV V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-30</SoldDt>
          <GrossSalesPriceAmt>200242</GrossSalesPriceAmt>
          <GainOrLossAmt>200242</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>200242</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEAK XV V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-12</SoldDt>
          <GrossSalesPriceAmt>481436</GrossSalesPriceAmt>
          <GainOrLossAmt>481436</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>481436</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEAK XV V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-20</SoldDt>
          <GrossSalesPriceAmt>375158</GrossSalesPriceAmt>
          <GainOrLossAmt>375158</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>375158</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEAK XV VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-07</SoldDt>
          <GrossSalesPriceAmt>45646</GrossSalesPriceAmt>
          <GainOrLossAmt>45646</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>45646</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEAK XV VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-24</SoldDt>
          <GrossSalesPriceAmt>292130</GrossSalesPriceAmt>
          <GainOrLossAmt>292130</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>292130</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEAK XV VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-11</SoldDt>
          <GrossSalesPriceAmt>42054</GrossSalesPriceAmt>
          <GainOrLossAmt>42054</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>42054</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PITANGO VTR VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-08</SoldDt>
          <GrossSalesPriceAmt>2748514</GrossSalesPriceAmt>
          <GainOrLossAmt>2748514</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2748514</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>RIDGEWOOD III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-21</SoldDt>
          <GrossSalesPriceAmt>3738082</GrossSalesPriceAmt>
          <GainOrLossAmt>3738082</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3738082</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>RIDGEWOOD III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-26</SoldDt>
          <GrossSalesPriceAmt>2224439</GrossSalesPriceAmt>
          <GainOrLossAmt>2224439</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2224439</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>RIDGEWOOD III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-25</SoldDt>
          <GrossSalesPriceAmt>3696054</GrossSalesPriceAmt>
          <GainOrLossAmt>3696054</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3696054</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>RIDGEWOOD IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-26</SoldDt>
          <GrossSalesPriceAmt>700091</GrossSalesPriceAmt>
          <GainOrLossAmt>700091</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>700091</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>RIDGEWOOD IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-21</SoldDt>
          <GrossSalesPriceAmt>1383990</GrossSalesPriceAmt>
          <GainOrLossAmt>1383990</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1383990</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>RIDGEWOOD IV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-25</SoldDt>
          <GrossSalesPriceAmt>1471699</GrossSalesPriceAmt>
          <GainOrLossAmt>1471699</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1471699</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>S CAPITAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-23</SoldDt>
          <GrossSalesPriceAmt>4737</GrossSalesPriceAmt>
          <GainOrLossAmt>4737</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4737</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>S CAPITAL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-23</SoldDt>
          <GrossSalesPriceAmt>7385395</GrossSalesPriceAmt>
          <GainOrLossAmt>7385395</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>7385395</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-25</SoldDt>
          <GrossSalesPriceAmt>349840</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>289035</CostOrOtherBasisAmt>
          <GainOrLossAmt>60805</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>60805</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-25</SoldDt>
          <GrossSalesPriceAmt>427320</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>353048</CostOrOtherBasisAmt>
          <GainOrLossAmt>74272</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>74272</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-25</SoldDt>
          <GrossSalesPriceAmt>35600</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>29412</CostOrOtherBasisAmt>
          <GainOrLossAmt>6188</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>6188</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-31</SoldDt>
          <GrossSalesPriceAmt>43950</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>36311</CostOrOtherBasisAmt>
          <GainOrLossAmt>7639</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>7639</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-31</SoldDt>
          <GrossSalesPriceAmt>63079</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>52115</CostOrOtherBasisAmt>
          <GainOrLossAmt>10964</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>10964</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-28</SoldDt>
          <GrossSalesPriceAmt>286232</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>220713</CostOrOtherBasisAmt>
          <GainOrLossAmt>65519</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>65519</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-30</SoldDt>
          <GrossSalesPriceAmt>43950</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>36163</CostOrOtherBasisAmt>
          <GainOrLossAmt>7787</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>7787</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-30</SoldDt>
          <GrossSalesPriceAmt>249200</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>205050</CostOrOtherBasisAmt>
          <GainOrLossAmt>44150</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>44150</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-30</SoldDt>
          <GrossSalesPriceAmt>142440</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>117204</CostOrOtherBasisAmt>
          <GainOrLossAmt>25236</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>25236</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-04</SoldDt>
          <GrossSalesPriceAmt>569760</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>468817</CostOrOtherBasisAmt>
          <GainOrLossAmt>100943</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>100943</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-31</SoldDt>
          <GrossSalesPriceAmt>63607</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>52189</CostOrOtherBasisAmt>
          <GainOrLossAmt>11418</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>11418</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-31</SoldDt>
          <GrossSalesPriceAmt>35600</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>29210</CostOrOtherBasisAmt>
          <GainOrLossAmt>6390</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>6390</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-16</SoldDt>
          <GrossSalesPriceAmt>43950</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>35880</CostOrOtherBasisAmt>
          <GainOrLossAmt>8070</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>8070</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-16</SoldDt>
          <GrossSalesPriceAmt>71200</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>58126</CostOrOtherBasisAmt>
          <GainOrLossAmt>13074</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13074</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-27</SoldDt>
          <GrossSalesPriceAmt>922304</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>752943</CostOrOtherBasisAmt>
          <GainOrLossAmt>169361</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>169361</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-31</SoldDt>
          <GrossSalesPriceAmt>284880</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>232568</CostOrOtherBasisAmt>
          <GainOrLossAmt>52312</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>52312</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-31</SoldDt>
          <GrossSalesPriceAmt>84105</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>68661</CostOrOtherBasisAmt>
          <GainOrLossAmt>15444</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15444</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-28</SoldDt>
          <GrossSalesPriceAmt>712200</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>549176</CostOrOtherBasisAmt>
          <GainOrLossAmt>163024</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>163024</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-31</SoldDt>
          <GrossSalesPriceAmt>462931</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>343809</CostOrOtherBasisAmt>
          <GainOrLossAmt>119122</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>119122</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-31</SoldDt>
          <GrossSalesPriceAmt>35600</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>26439</CostOrOtherBasisAmt>
          <GainOrLossAmt>9161</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>9161</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-31</SoldDt>
          <GrossSalesPriceAmt>63079</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>46847</CostOrOtherBasisAmt>
          <GainOrLossAmt>16232</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16232</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-30</SoldDt>
          <GrossSalesPriceAmt>43950</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>40512</CostOrOtherBasisAmt>
          <GainOrLossAmt>3438</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3438</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-30</SoldDt>
          <GrossSalesPriceAmt>63079</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>58145</CostOrOtherBasisAmt>
          <GainOrLossAmt>4934</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4934</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-19</SoldDt>
          <GrossSalesPriceAmt>249270</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>229771</CostOrOtherBasisAmt>
          <GainOrLossAmt>19499</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>19499</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-30</SoldDt>
          <GrossSalesPriceAmt>106800</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>98446</CostOrOtherBasisAmt>
          <GainOrLossAmt>8354</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>8354</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-30</SoldDt>
          <GrossSalesPriceAmt>63607</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>58631</CostOrOtherBasisAmt>
          <GainOrLossAmt>4976</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4976</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-31</SoldDt>
          <GrossSalesPriceAmt>142400</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>112834</CostOrOtherBasisAmt>
          <GainOrLossAmt>29566</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>29566</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-31</SoldDt>
          <GrossSalesPriceAmt>397545</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>315003</CostOrOtherBasisAmt>
          <GainOrLossAmt>82542</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>82542</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-31</SoldDt>
          <GrossSalesPriceAmt>142440</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>112866</CostOrOtherBasisAmt>
          <GainOrLossAmt>29574</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>29574</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-20</SoldDt>
          <GrossSalesPriceAmt>178049</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>141082</CostOrOtherBasisAmt>
          <GainOrLossAmt>36967</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>36967</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-30</SoldDt>
          <GrossSalesPriceAmt>159018</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>126002</CostOrOtherBasisAmt>
          <GainOrLossAmt>33016</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>33016</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-30</SoldDt>
          <GrossSalesPriceAmt>71200</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>56417</CostOrOtherBasisAmt>
          <GainOrLossAmt>14783</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>14783</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-12</SoldDt>
          <GrossSalesPriceAmt>43950</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>34825</CostOrOtherBasisAmt>
          <GainOrLossAmt>9125</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>9125</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-12</SoldDt>
          <GrossSalesPriceAmt>178049</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>141082</CostOrOtherBasisAmt>
          <GainOrLossAmt>36967</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>36967</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-31</SoldDt>
          <GrossSalesPriceAmt>231400</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>183356</CostOrOtherBasisAmt>
          <GainOrLossAmt>48044</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>48044</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-31</SoldDt>
          <GrossSalesPriceAmt>63079</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>49982</CostOrOtherBasisAmt>
          <GainOrLossAmt>13097</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13097</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-31</SoldDt>
          <GrossSalesPriceAmt>43950</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>34825</CostOrOtherBasisAmt>
          <GainOrLossAmt>9125</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>9125</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-31</SoldDt>
          <GrossSalesPriceAmt>106829</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>84649</CostOrOtherBasisAmt>
          <GainOrLossAmt>22180</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>22180</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-06</SoldDt>
          <GrossSalesPriceAmt>95411</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>75601</CostOrOtherBasisAmt>
          <GainOrLossAmt>19810</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>19810</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-12</SoldDt>
          <GrossSalesPriceAmt>127214</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>100801</CostOrOtherBasisAmt>
          <GainOrLossAmt>26413</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>26413</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-31</SoldDt>
          <GrossSalesPriceAmt>556563</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>441007</CostOrOtherBasisAmt>
          <GainOrLossAmt>115556</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>115556</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-31</SoldDt>
          <GrossSalesPriceAmt>149561</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>118508</CostOrOtherBasisAmt>
          <GainOrLossAmt>31053</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>31053</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>249271</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>217871</CostOrOtherBasisAmt>
          <GainOrLossAmt>31400</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>31400</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>35600</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>31116</CostOrOtherBasisAmt>
          <GainOrLossAmt>4484</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4484</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GBL GRTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-22</SoldDt>
          <GrossSalesPriceAmt>225234</GrossSalesPriceAmt>
          <GainOrLossAmt>225234</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>225234</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GBL GRTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-22</SoldDt>
          <GrossSalesPriceAmt>145975</GrossSalesPriceAmt>
          <GainOrLossAmt>145975</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>145975</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GBL GRTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-12</SoldDt>
          <GrossSalesPriceAmt>241753</GrossSalesPriceAmt>
          <GainOrLossAmt>241753</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>241753</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GBL GRTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-01</SoldDt>
          <GrossSalesPriceAmt>106342</GrossSalesPriceAmt>
          <GainOrLossAmt>106342</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>106342</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GBL GRTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-01</SoldDt>
          <GrossSalesPriceAmt>16718</GrossSalesPriceAmt>
          <GainOrLossAmt>16718</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16718</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GBL GRTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-14</SoldDt>
          <GrossSalesPriceAmt>47923</GrossSalesPriceAmt>
          <GainOrLossAmt>47923</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>47923</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GBL GRTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-16</SoldDt>
          <GrossSalesPriceAmt>816743</GrossSalesPriceAmt>
          <GainOrLossAmt>816743</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>816743</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GBL GRTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-06</SoldDt>
          <GrossSalesPriceAmt>582029</GrossSalesPriceAmt>
          <GainOrLossAmt>582029</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>582029</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GBL GRTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-04</SoldDt>
          <GrossSalesPriceAmt>548708</GrossSalesPriceAmt>
          <GainOrLossAmt>548708</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>548708</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GBL GRTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-25</SoldDt>
          <GrossSalesPriceAmt>505809</GrossSalesPriceAmt>
          <GainOrLossAmt>505809</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>505809</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GBL GRTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-03</SoldDt>
          <GrossSalesPriceAmt>353024</GrossSalesPriceAmt>
          <GainOrLossAmt>353024</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>353024</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GBL GRTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-11</SoldDt>
          <GrossSalesPriceAmt>675056</GrossSalesPriceAmt>
          <GainOrLossAmt>675056</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>675056</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GBL GRTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-18</SoldDt>
          <GrossSalesPriceAmt>299295</GrossSalesPriceAmt>
          <GainOrLossAmt>299295</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>299295</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GLB GROWTH</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-18</SoldDt>
          <GrossSalesPriceAmt>313584</GrossSalesPriceAmt>
          <GainOrLossAmt>313584</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>313584</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GLB GROWTH</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-31</SoldDt>
          <GrossSalesPriceAmt>319901</GrossSalesPriceAmt>
          <GainOrLossAmt>319901</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>319901</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GLB GROWTH</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-14</SoldDt>
          <GrossSalesPriceAmt>922194</GrossSalesPriceAmt>
          <GainOrLossAmt>922194</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>922194</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GLB GRWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-09</SoldDt>
          <GrossSalesPriceAmt>298310</GrossSalesPriceAmt>
          <GainOrLossAmt>298310</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>298310</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GLB GRWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-02</SoldDt>
          <GrossSalesPriceAmt>154892</GrossSalesPriceAmt>
          <GainOrLossAmt>154892</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>154892</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GLB GRWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-31</SoldDt>
          <GrossSalesPriceAmt>121872</GrossSalesPriceAmt>
          <GainOrLossAmt>121872</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>121872</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GLB GRWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-11</SoldDt>
          <GrossSalesPriceAmt>581737</GrossSalesPriceAmt>
          <GainOrLossAmt>581737</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>581737</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GLB GRWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-03</SoldDt>
          <GrossSalesPriceAmt>1027919</GrossSalesPriceAmt>
          <GainOrLossAmt>1027919</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1027919</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA GLB GRWTH II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-19</SoldDt>
          <GrossSalesPriceAmt>881711</GrossSalesPriceAmt>
          <GainOrLossAmt>881711</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>881711</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA SCOUT III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-29</SoldDt>
          <GrossSalesPriceAmt>58909</GrossSalesPriceAmt>
          <GainOrLossAmt>58909</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>58909</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US GROWTH V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-11</SoldDt>
          <GrossSalesPriceAmt>126528</GrossSalesPriceAmt>
          <GainOrLossAmt>126528</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>126528</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US GROWTH V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-18</SoldDt>
          <GrossSalesPriceAmt>55501</GrossSalesPriceAmt>
          <GainOrLossAmt>55501</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>55501</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US GROWTH V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-25</SoldDt>
          <GrossSalesPriceAmt>92839</GrossSalesPriceAmt>
          <GainOrLossAmt>92839</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>92839</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US GROWTH V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-04</SoldDt>
          <GrossSalesPriceAmt>100044</GrossSalesPriceAmt>
          <GainOrLossAmt>100044</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>100044</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US GROWTH V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-06</SoldDt>
          <GrossSalesPriceAmt>105609</GrossSalesPriceAmt>
          <GainOrLossAmt>105609</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>105609</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US GROWTH V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-16</SoldDt>
          <GrossSalesPriceAmt>147690</GrossSalesPriceAmt>
          <GainOrLossAmt>147690</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>147690</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US GRWTH VII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-31</SoldDt>
          <GrossSalesPriceAmt>102785</GrossSalesPriceAmt>
          <GainOrLossAmt>102785</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>102785</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US GRWTH VII</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-19</SoldDt>
          <GrossSalesPriceAmt>261085</GrossSalesPriceAmt>
          <GainOrLossAmt>261085</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>261085</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US GWTH VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-30</SoldDt>
          <GrossSalesPriceAmt>264174</GrossSalesPriceAmt>
          <GainOrLossAmt>264174</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>264174</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US GWTH VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-05</SoldDt>
          <GrossSalesPriceAmt>88705</GrossSalesPriceAmt>
          <GainOrLossAmt>88705</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>88705</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US GWTH VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-26</SoldDt>
          <GrossSalesPriceAmt>325459</GrossSalesPriceAmt>
          <GainOrLossAmt>325459</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>325459</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US GWTH VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-09</SoldDt>
          <GrossSalesPriceAmt>590261</GrossSalesPriceAmt>
          <GainOrLossAmt>590261</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>590261</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US GWTH VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-14</SoldDt>
          <GrossSalesPriceAmt>144996</GrossSalesPriceAmt>
          <GainOrLossAmt>144996</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>144996</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US VTR XIV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-30</SoldDt>
          <GrossSalesPriceAmt>1785910</GrossSalesPriceAmt>
          <GainOrLossAmt>1785910</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1785910</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US VTR XIV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-26</SoldDt>
          <GrossSalesPriceAmt>1808952</GrossSalesPriceAmt>
          <GainOrLossAmt>1808952</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1808952</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US VTR XIV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-05</SoldDt>
          <GrossSalesPriceAmt>849984</GrossSalesPriceAmt>
          <GainOrLossAmt>849984</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>849984</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US VTR XV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-31</SoldDt>
          <GrossSalesPriceAmt>34863</GrossSalesPriceAmt>
          <GainOrLossAmt>34863</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>34863</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US VTR XV</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-15</SoldDt>
          <GrossSalesPriceAmt>59055</GrossSalesPriceAmt>
          <GainOrLossAmt>59055</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>59055</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SILCHESTER INTL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-04-30</SoldDt>
          <GrossSalesPriceAmt>76619</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>59146</CostOrOtherBasisAmt>
          <GainOrLossAmt>17473</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>17473</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SILCHESTER INTL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-06-28</SoldDt>
          <GrossSalesPriceAmt>76804</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>59052</CostOrOtherBasisAmt>
          <GainOrLossAmt>17752</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>17752</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SILCHESTER INTL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-05</SoldDt>
          <GrossSalesPriceAmt>10000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>7613469</CostOrOtherBasisAmt>
          <GainOrLossAmt>2386531</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2386531</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SILCHESTER INTL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-31</SoldDt>
          <GrossSalesPriceAmt>79271</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>58654</CostOrOtherBasisAmt>
          <GainOrLossAmt>20617</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>20617</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SILCHESTER INTL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-07-31</SoldDt>
          <GrossSalesPriceAmt>75772</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>55236</CostOrOtherBasisAmt>
          <GainOrLossAmt>20536</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>20536</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SILCHESTER INTL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-08-31</SoldDt>
          <GrossSalesPriceAmt>77190</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>52756</CostOrOtherBasisAmt>
          <GainOrLossAmt>24434</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>24434</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SILCHESTER INTL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-28</SoldDt>
          <GrossSalesPriceAmt>74929</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>52965</CostOrOtherBasisAmt>
          <GainOrLossAmt>21964</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>21964</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SILCHESTER INTL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-01-31</SoldDt>
          <GrossSalesPriceAmt>74532</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>53061</CostOrOtherBasisAmt>
          <GainOrLossAmt>21471</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>21471</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SILCHESTER INTL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-03-31</SoldDt>
          <GrossSalesPriceAmt>75928</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>52770</CostOrOtherBasisAmt>
          <GainOrLossAmt>23158</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>23158</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SILCHESTER INTL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-10-31</SoldDt>
          <GrossSalesPriceAmt>75014</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>53060</CostOrOtherBasisAmt>
          <GainOrLossAmt>21954</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>21954</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SILCHESTER INTL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-11-30</SoldDt>
          <GrossSalesPriceAmt>73288</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>53336</CostOrOtherBasisAmt>
          <GainOrLossAmt>19952</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>19952</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SILCHESTER INTL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-31</SoldDt>
          <GrossSalesPriceAmt>72652</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>53425</CostOrOtherBasisAmt>
          <GainOrLossAmt>19227</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>19227</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SILCHESTER INTL</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>78402</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>52540</CostOrOtherBasisAmt>
          <GainOrLossAmt>25862</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>25862</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SPDR TRUST SERIES I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-05-30</SoldDt>
          <GrossSalesPriceAmt>9950569</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>8832019</CostOrOtherBasisAmt>
          <GainOrLossAmt>1118550</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1118550</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SQUOIA GG 3 US IN AX</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-20</SoldDt>
          <GrossSalesPriceAmt>69881</GrossSalesPriceAmt>
          <GainOrLossAmt>69881</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>69881</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SQUOIA GG 3 US IN AX</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-12-31</SoldDt>
          <GrossSalesPriceAmt>368722</GrossSalesPriceAmt>
          <GainOrLossAmt>368722</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>368722</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SQUOIA GG 3 US IN AX</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2025-02-19</SoldDt>
          <GrossSalesPriceAmt>1040506</GrossSalesPriceAmt>
          <GainOrLossAmt>1040506</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1040506</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>STARWOOD XI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>221679</GrossSalesPriceAmt>
          <GainOrLossAmt>221679</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>221679</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>STARWOOD XI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-09-30</SoldDt>
          <GrossSalesPriceAmt>686978</GrossSalesPriceAmt>
          <GainOrLossAmt>686978</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>686978</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>136</GrossSalesPriceAmt>
          <GainOrLossAmt>136</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>136</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>2120</GrossSalesPriceAmt>
          <GainOrLossAmt>2120</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2120</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>134</GrossSalesPriceAmt>
          <GainOrLossAmt>134</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>134</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>4</GrossSalesPriceAmt>
          <GainOrLossAmt>4</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>123269</CostOrOtherBasisAmt>
          <GainOrLossAmt>-123269</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-123269</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>2680</CostOrOtherBasisAmt>
          <GainOrLossAmt>-2680</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-2680</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>448</CostOrOtherBasisAmt>
          <GainOrLossAmt>-448</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-448</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>25</CostOrOtherBasisAmt>
          <GainOrLossAmt>-25</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-25</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>77</CostOrOtherBasisAmt>
          <GainOrLossAmt>-77</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-77</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>7</CostOrOtherBasisAmt>
          <GainOrLossAmt>-7</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-7</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>51</CostOrOtherBasisAmt>
          <GainOrLossAmt>-51</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-51</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>8114</CostOrOtherBasisAmt>
          <GainOrLossAmt>-8114</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-8114</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>3</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>44294</CostOrOtherBasisAmt>
          <GainOrLossAmt>-44294</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-44294</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG GROWTH III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>210548</GrossSalesPriceAmt>
          <GainOrLossAmt>210548</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>210548</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>2040335</GrossSalesPriceAmt>
          <GainOrLossAmt>2040335</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2040335</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SCF LIQUID PORTFOLIO</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>1783318</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1783318</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1783318</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE SMID</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>192969</CostOrOtherBasisAmt>
          <GainOrLossAmt>-192969</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-192969</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>245581</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>343630</CostOrOtherBasisAmt>
          <GainOrLossAmt>-98049</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-98049</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>TAURUS RESOURCES</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>40318331</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>24689818</CostOrOtherBasisAmt>
          <GainOrLossAmt>15628513</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15628513</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BITCOIN</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>7282986</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>4532554</CostOrOtherBasisAmt>
          <GainOrLossAmt>2750432</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2750432</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>K-1 ADJUSTMENTS, NET OF UBI AND RELATED AMOUNTS ABOVE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GainOrLossAmt>-225928033</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-225928033</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapitalGainNetIncomeAmt>270254392</CapitalGainNetIncomeAmt>
      </CapGainsLossTxInvstIncmDetail>
      <ExciseTaxBasedOnInvstIncmGrp>
        <InvestmentIncomeExciseTaxAmt>4897298</InvestmentIncomeExciseTaxAmt>
        <TaxUnderSection511Amt>0</TaxUnderSection511Amt>
        <SubtotalAmt>4897298</SubtotalAmt>
        <SubtitleATaxAmt>0</SubtitleATaxAmt>
        <TaxBasedOnInvestmentIncomeAmt>4897298</TaxBasedOnInvestmentIncomeAmt>
        <EstimatedPlusOvpmtIncmTxAmt>7900234</EstimatedPlusOvpmtIncmTxAmt>
        <ExemptFrgnOrgTaxWthldAtSrceAmt>0</ExemptFrgnOrgTaxWthldAtSrceAmt>
        <ExtsnRequestIncomeTaxPaidAmt>1000000</ExtsnRequestIncomeTaxPaidAmt>
        <BackupWithholdingWithheldAmt>0</BackupWithholdingWithheldAmt>
        <TotalPaymentsAndCreditsAmt>8900234</TotalPaymentsAndCreditsAmt>
        <Form2220AttachedInd referenceDocumentId="RetDoc1192000001">X</Form2220AttachedInd>
        <EsPenaltyAmt>0</EsPenaltyAmt>
        <OverpaymentAmt>4002936</OverpaymentAmt>
        <AppliedToESTaxAmt>4002936</AppliedToESTaxAmt>
        <RefundAmt>0</RefundAmt>
      </ExciseTaxBasedOnInvstIncmGrp>
      <StatementsRegardingActyGrp>
        <LegislativePoliticalActyInd>0</LegislativePoliticalActyInd>
        <MoreThan100SpentInd>0</MoreThan100SpentInd>
        <Form1120POLFiledInd>0</Form1120POLFiledInd>
        <Section4955OrganizationTaxAmt>0</Section4955OrganizationTaxAmt>
        <Section4955ManagersTaxAmt>0</Section4955ManagersTaxAmt>
        <TaxReimbursedAmt>0</TaxReimbursedAmt>
        <ActivitiesNotPreviouslyRptInd>0</ActivitiesNotPreviouslyRptInd>
        <ChangesToArticlesOrBylawsInd>0</ChangesToArticlesOrBylawsInd>
        <UnrelatedBusIncmOverLimitInd>1</UnrelatedBusIncmOverLimitInd>
        <Form990TFiledInd>1</Form990TFiledInd>
        <OrganizationDissolvedEtcInd>0</OrganizationDissolvedEtcInd>
        <Section508eRqrSatisfiedInd>1</Section508eRqrSatisfiedInd>
        <AtLeast5000InAssetsInd>1</AtLeast5000InAssetsInd>
        <OrgReportOrRegisterStateCd>NY</OrgReportOrRegisterStateCd>
        <Form990PFFiledWithAttyGenInd>1</Form990PFFiledWithAttyGenInd>
        <PrivateOperatingFoundationInd>0</PrivateOperatingFoundationInd>
        <NewSubstantialContributorsInd>0</NewSubstantialContributorsInd>
        <OwnControlledEntityInd referenceDocumentId="RetDoc2204900001 RetDoc2205000001">1</OwnControlledEntityInd>
        <DonorAdvisedFundInd>0</DonorAdvisedFundInd>
        <ComplyWithPublicInspRqrInd>1</ComplyWithPublicInspRqrInd>
        <WebsiteAddressTxt>HELMSLEYTRUST.ORG</WebsiteAddressTxt>
        <PersonsWithBooksName>
          <BusinessNameLine1Txt>NICHOLAS J SCHIAVO CFO</BusinessNameLine1Txt>
        </PersonsWithBooksName>
        <PhoneNum>2126793600</PhoneNum>
        <LocationOfBooksUSAddress>
          <AddressLine1Txt>230 PARK AVENUE SUITE 659</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10169</ZIPCd>
        </LocationOfBooksUSAddress>
        <ForeignAccountsQuestionInd>1</ForeignAccountsQuestionInd>
        <ForeignCountryCd>AS</ForeignCountryCd>
        <ForeignCountryCd>AU</ForeignCountryCd>
        <ForeignCountryCd>BE</ForeignCountryCd>
        <ForeignCountryCd>CA</ForeignCountryCd>
        <ForeignCountryCd>DA</ForeignCountryCd>
        <ForeignCountryCd>FI</ForeignCountryCd>
        <ForeignCountryCd>FR</ForeignCountryCd>
        <ForeignCountryCd>GM</ForeignCountryCd>
        <ForeignCountryCd>HK</ForeignCountryCd>
        <ForeignCountryCd>ID</ForeignCountryCd>
        <ForeignCountryCd>EI</ForeignCountryCd>
        <ForeignCountryCd>IS</ForeignCountryCd>
        <ForeignCountryCd>IT</ForeignCountryCd>
        <ForeignCountryCd>JA</ForeignCountryCd>
        <ForeignCountryCd>NL</ForeignCountryCd>
        <ForeignCountryCd>NZ</ForeignCountryCd>
        <ForeignCountryCd>NO</ForeignCountryCd>
        <ForeignCountryCd>PO</ForeignCountryCd>
        <ForeignCountryCd>SN</ForeignCountryCd>
        <ForeignCountryCd>KS</ForeignCountryCd>
        <ForeignCountryCd>SP</ForeignCountryCd>
        <ForeignCountryCd>SW</ForeignCountryCd>
        <ForeignCountryCd>SZ</ForeignCountryCd>
        <ForeignCountryCd>TW</ForeignCountryCd>
        <ForeignCountryCd>UK</ForeignCountryCd>
      </StatementsRegardingActyGrp>
      <StatementsRegardingActy4720Grp>
        <SaleOrExchDisqualifiedPrsnInd>1</SaleOrExchDisqualifiedPrsnInd>
        <BrrwOrLendDisqualifiedPrsnInd>0</BrrwOrLendDisqualifiedPrsnInd>
        <FurnGoodsDisqualifiedPrsnInd>1</FurnGoodsDisqualifiedPrsnInd>
        <PayCompDisqualifiedPrsnInd>1</PayCompDisqualifiedPrsnInd>
        <TransferAstDisqualifiedPrsnInd>0</TransferAstDisqualifiedPrsnInd>
        <PaymentToGovernmentOfficialInd>0</PaymentToGovernmentOfficialInd>
        <ActsFailToQlfyAsExceptionsInd>0</ActsFailToQlfyAsExceptionsInd>
        <UncorrectedPriorActsInd>0</UncorrectedPriorActsInd>
        <UndistributedIncomePYInd>0</UndistributedIncomePYInd>
        <BusinessHoldingsInd>1</BusinessHoldingsInd>
        <ExcessBusinessHoldingsInd>0</ExcessBusinessHoldingsInd>
        <JeopardyInvestmentsInd>0</JeopardyInvestmentsInd>
        <UncorrectedPYJeopardyInvstInd>0</UncorrectedPYJeopardyInvstInd>
        <InfluenceLegislationInd>0</InfluenceLegislationInd>
        <InfluenceElectionInd>0</InfluenceElectionInd>
        <GrantsToIndividualsInd>0</GrantsToIndividualsInd>
        <GrantsToOrganizationsInd>1</GrantsToOrganizationsInd>
        <NoncharitablePurposeInd>0</NoncharitablePurposeInd>
        <TransactionsFailToQlfyAsExcInd>0</TransactionsFailToQlfyAsExcInd>
        <MaintainedExpenditureRspnsInd referenceDocumentId="RetDoc2118100001">1</MaintainedExpenditureRspnsInd>
        <RcvFndsToPayPrsnlBnftCntrctInd>0</RcvFndsToPayPrsnlBnftCntrctInd>
        <PayPremiumsPrsnlBnftCntrctInd>0</PayPremiumsPrsnlBnftCntrctInd>
        <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
        <SubjToTaxRmnrtnExPrchtPymtInd>0</SubjToTaxRmnrtnExPrchtPymtInd>
      </StatementsRegardingActy4720Grp>
      <OfficerDirTrstKeyEmplInfoGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>SANDOR FRANKEL</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>25.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>150000</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>DAVID PANZIRER</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>35.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>150000</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>WALTER PANZIRER</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>32.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>150000</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>SARAH E PAUL</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>CHIEF EXECUTIVE OFFICER</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>1030857</CompensationAmt>
          <EmployeeBenefitProgramAmt>238318</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>JACQUELINE F BAUSCH</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>GENERAL COUNSEL</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>652750</CompensationAmt>
          <EmployeeBenefitProgramAmt>102800</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>JOSHUA W FENTON</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>CHIEF INVESTMENT OFFICER</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>1017577</CompensationAmt>
          <EmployeeBenefitProgramAmt>237966</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>NICHOLAS J SCHIAVO</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>CHIEF FINANCIAL OFFICER</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>486040</CompensationAmt>
          <EmployeeBenefitProgramAmt>123033</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>AL Y KIM</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIRECTOR OF INVESTME</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>769227</CompensationAmt>
          <EmployeeBenefitsAmt>177456</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>MEENAKSHI C LAKSHMAN</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIR. OF STRATEGY &amp; R</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>764742</CompensationAmt>
          <EmployeeBenefitsAmt>177456</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>CHRISTOPHER J RAPCEWICZ</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIR. OF RISK MNGMT.</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>760560</CompensationAmt>
          <EmployeeBenefitsAmt>156747</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>BRIAN B CHUN</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIRECTOR OF INVESTME</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>550358</CompensationAmt>
          <EmployeeBenefitsAmt>110848</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>MAUREEN E RAYHILL</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIRECTOR OF HUMAN RE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>505841</CompensationAmt>
          <EmployeeBenefitsAmt>102226</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <OtherEmployeePaidOver50kCnt>109</OtherEmployeePaidOver50kCnt>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>NEWMARKET IIFC</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>1325 NORTH BEACH STREET SUITE 201</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>19125</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>8414015</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>HIG GROWTH II</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>600 5TH AVE 24TH FL</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10020</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>2620945</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>IFP GLOBAL FRANCHISE</BusinessNameLine1Txt>
          </BusinessName>
          <ForeignAddress>
            <AddressLine1Txt>LEVEL 1 10 PORTMAN SQUARE</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
            <ForeignPostalCd>W1H 6AZ</ForeignPostalCd>
          </ForeignAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>1828023</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>COLLER VII</BusinessNameLine1Txt>
          </BusinessName>
          <ForeignAddress>
            <AddressLine1Txt>116 PARK STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
            <ForeignPostalCd>W1K 6AZ</ForeignPostalCd>
          </ForeignAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>1618408</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>HIGHCLERE INTERNATIONAL INVESTORS</BusinessNameLine1Txt>
          </BusinessName>
          <ForeignAddress>
            <AddressLine1Txt>2 MANCHESTER SQUARE</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </ForeignAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>1530277</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <ContractorPaidOver50kCnt>38</ContractorPaidOver50kCnt>
      </OfficerDirTrstKeyEmplInfoGrp>
      <SummaryOfDirectChrtblActyGrp>
        <Description1Txt>FOR COMMUNICATIONS DESIGNED TO SUPPORT AND AMPLIFY THE CHARITABLE WORK OF OUR GRANTEES, THROUGH STRATEGIC COMMUNICATIONS PLANNING, VIDEO PRODUCTION, AND DESIGN, SPECIFICALLY IN FURTHERANCE OF THE FOUNDATION'S MISSION OF PROMOTING HEALTH AND IMPROVING PEOPLE'S LIVES.</Description1Txt>
        <Expenses1Amt>1390656</Expenses1Amt>
        <Description2Txt>FOR TECHNICAL SUPPORT TO GRANTEES, INCLUDING PROVIDING RESEARCH DATA, TO HELP MEET THEIR CHARITABLE GOALS.</Description2Txt>
        <Expenses2Amt>93051</Expenses2Amt>
        <Description3Txt>FOR CONVENING OF GRANTEES AND RESEARCHERS, INCLUDING CONFERENCE SPONSORSHIP AND SUPPORT, TO PROMOTE SHARED LEARNING AND THE IDENTIFICATION OF NEW PROJECTS TO FURTHER THE FOUNDATION'S CHARITABLE MISSION.</Description3Txt>
        <Expenses3Amt>312168</Expenses3Amt>
      </SummaryOfDirectChrtblActyGrp>
      <SumOfProgramRelatedInvstGrp>
        <Description1Txt>THETIS PHARMACEUTICALS, LLC - DEVELOPMENT OF A NOVEL RESOLVIN E1 THERAPY FOR TREATMENT OF CROHN'S DISEASE</Description1Txt>
        <Expenses1Amt>4400000</Expenses1Amt>
        <Description2Txt>TIXIMED, INC. - DEVELOPING A DRUG TO PROTECT BETA CELLS DURING TYPE 1 DIABETES DEVELOPMENT</Description2Txt>
        <Expenses2Amt>2650000</Expenses2Amt>
        <AllOtherProgramRltdInvstTotAmt referenceDocumentId="RetDoc2063500001">1520000</AllOtherProgramRltdInvstTotAmt>
        <TotalAmt>8570000</TotalAmt>
      </SumOfProgramRelatedInvstGrp>
      <MinimumInvestmentReturnGrp>
        <AverageMonthlyFMVOfSecAmt>6991393403</AverageMonthlyFMVOfSecAmt>
        <AverageMonthlyCashBalancesAmt>160961317</AverageMonthlyCashBalancesAmt>
        <FMVAllOtherNoncharitableAstAmt>769022</FMVAllOtherNoncharitableAstAmt>
        <TotalFMVOfUnusedAssetsAmt>7153123742</TotalFMVOfUnusedAssetsAmt>
        <ReductionClaimedAmt>0</ReductionClaimedAmt>
        <AcquisitionIndebtednessAmt>0</AcquisitionIndebtednessAmt>
        <AdjustedTotalFMVOfUnusedAstAmt>7153123742</AdjustedTotalFMVOfUnusedAstAmt>
        <CashDeemedCharitableAmt>107296856</CashDeemedCharitableAmt>
        <NetVlNoncharitableAssetsAmt>7045826886</NetVlNoncharitableAssetsAmt>
        <MinimumInvestmentReturnAmt>352291344</MinimumInvestmentReturnAmt>
      </MinimumInvestmentReturnGrp>
      <DistributableAmountGrp>
        <MinimumInvestmentReturnAmt>352291344</MinimumInvestmentReturnAmt>
        <TaxBasedOnInvestmentIncomeAmt>4897298</TaxBasedOnInvestmentIncomeAmt>
        <IncomeTaxAmt>471679</IncomeTaxAmt>
        <TotalTaxAmt>5368977</TotalTaxAmt>
        <DistributableBeforeAdjAmt>346922367</DistributableBeforeAdjAmt>
        <RecoveriesQualfiedDistriAmt>7276276</RecoveriesQualfiedDistriAmt>
        <DistributableBeforeDedAmt>354198643</DistributableBeforeDedAmt>
        <DeductionFromDistributableAmt>0</DeductionFromDistributableAmt>
        <DistributableAsAdjustedAmt>354198643</DistributableAsAdjustedAmt>
      </DistributableAmountGrp>
      <PFQualifyingDistributionsGrp>
        <ExpensesAndContributionsAmt>477560098</ExpensesAndContributionsAmt>
        <ProgramRelatedInvstTotalAmt>8570000</ProgramRelatedInvstTotalAmt>
        <CharitableAssetsAcquisPaidAmt>70375</CharitableAssetsAcquisPaidAmt>
        <QualifyingDistributionsAmt>486200473</QualifyingDistributionsAmt>
      </PFQualifyingDistributionsGrp>
      <UndistributedIncomeGrp>
        <DistributableAsAdjustedAmt>354198643</DistributableAsAdjustedAmt>
        <UndistributedIncomePYAmt>0</UndistributedIncomePYAmt>
        <TotalForPriorYearsAmt>0</TotalForPriorYearsAmt>
        <ExcessDistributionCyovYr1Amt>129248898</ExcessDistributionCyovYr1Amt>
        <TotalExcessDistributionCyovAmt>129248898</TotalExcessDistributionCyovAmt>
        <QualifyingDistributionsAmt>486200473</QualifyingDistributionsAmt>
        <AppliedToYear1Amt>0</AppliedToYear1Amt>
        <AppliedToPriorYearsAmt>0</AppliedToPriorYearsAmt>
        <TreatedAsDistriFromCorpusAmt>0</TreatedAsDistriFromCorpusAmt>
        <AppliedToCurrentYearAmt>354198643</AppliedToCurrentYearAmt>
        <RemainingDistriFromCorpusAmt>132001830</RemainingDistriFromCorpusAmt>
        <ExcessDistriCyovAppCYCorpusAmt>0</ExcessDistriCyovAppCYCorpusAmt>
        <ExcessDistributionCyovAppCYAmt>0</ExcessDistributionCyovAppCYAmt>
        <TotalCorpusAmt>261250728</TotalCorpusAmt>
        <PriorYearUndistributedIncmAmt>0</PriorYearUndistributedIncmAmt>
        <PriorYearDeficiencyOrTaxAmt>0</PriorYearDeficiencyOrTaxAmt>
        <Taxable1Amt>0</Taxable1Amt>
        <Taxable2Amt>0</Taxable2Amt>
        <UndistributedIncomeCYAmt>0</UndistributedIncomeCYAmt>
        <CorpusDistri170b1EOr4942g3Amt>0</CorpusDistri170b1EOr4942g3Amt>
        <ExcessDistriCyovFromYr5Amt>0</ExcessDistriCyovFromYr5Amt>
        <ExcessDistriCyovToNextYrAmt>261250728</ExcessDistriCyovToNextYrAmt>
        <ExcessFromYear1Amt>129248898</ExcessFromYear1Amt>
        <ExcessFromCurrentYearAmt>132001830</ExcessFromCurrentYearAmt>
      </UndistributedIncomeGrp>
      <SupplementaryInformationGrp>
        <OnlyContriToPreselectedInd>X</OnlyContriToPreselectedInd>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>A GLIMMER OF HOPE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>11101 LOS COMANCHEROS RD</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>78717</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PF</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY</GrantOrContributionPurposeTxt>
          <Amt>1446574</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ACTION4DIABETES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>9 PARKFIELD ROAD</AddressLine1Txt>
            <CityNm>TAUNTON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PHILIPPINES T1D TASK FORCE</GrantOrContributionPurposeTxt>
          <Amt>222500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ACUMEN AMERICA LLC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>40 WORTH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10013</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPLEMENTAL SUPPORT TO ADDRESS SOCIAL DETERMINANTS OF HEALTH FOR PEOPLE WITH INSULIN REQUIRING DIABETES</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ADI NEGEV-NAHALAT ERAN RA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>POB 331</AddressLine1Txt>
            <CityNm>OFAKIM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REHABILITATION EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>244998</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AFRICAN MISSION HEALTHCARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 NORTH WOODLAND BOULEVARD</AddressLine1Txt>
            <CityNm>DELAND</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>32720</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ST. FRANCIS HOSPITAL MATERNITY CENTER</GrantOrContributionPurposeTxt>
          <Amt>191802</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALBERT EINSTEIN COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 MORRIS PARK AVENUE</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>104611975</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROMOTE DIABETES TECHNOLOGY USE IN YOUNG ADULTS FROM UNDERREPRESENTED MINORITY GROUPS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>173613</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALIMENTIV INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NEXT GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>259951</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALIMENTIV INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALIDATION OF THE PRO SYMPTOMS AND IMPACTS QUESTIONNAIRE FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>469915</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALLIANCE OF COMMUNITY HEALTH PLANS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1825 EYE STREET NW 401</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATING WITH HEALTH PLANS TO OVERCOME BARRIERS TO COVERAGE AND UTILIZATION OF CONTINUOUS GLUCOSE MONITORING : LAYING THE FOUNDATION</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALLIANCE OF COMMUNITY HEALTH PLANS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1825 EYE STREET NW 401</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATING WITH HEALTH PLANS TO OVERCOME BARRIERS TO COVERAGE AND UTILIZATION OF CONTINUOUS GLUCOSE MONITORING : LAYING THE FOUNDATION</GrantOrContributionPurposeTxt>
          <Amt>539349</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALTRU HEALTH SYSTEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 6002</AddressLine1Txt>
            <CityNm>GRAND FORKS</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58206</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALTRU HEALTH SYSTEM ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>4214824</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALVIN AILEY DANCE FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>405 W 55TH ST</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10019</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN CAMPING ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5000 STATE ROAD 67 NORTH</AddressLine1Txt>
            <CityNm>MARTINSVILLE</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>46151</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACA PROFESSIONAL DEVELOPMENT 2024-2027</GrantOrContributionPurposeTxt>
          <Amt>55330</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN COLLEGE OF DIABETOLOGY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 87633</AddressLine1Txt>
            <CityNm>FAYETTEVILLE</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>28304</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVE THE DIABETES TRAINING OPPORTUNITIES FOR PCPS</GrantOrContributionPurposeTxt>
          <Amt>1200436</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2025-2027 TYPE 1 DIABETES CAMP INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>480260</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2022-2024 TYPE 1 DIABETES CAMP INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>399368</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING AND MENTORSHIP PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>350108</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING AND MENTORSHIP PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>455274</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN GASTROENTEROLOGICAL ASSOCIATION INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4930 DEL RAY AVE</AddressLine1Txt>
            <CityNm>BETHESDA</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>20814</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AMPLIFYING LEARNING FROM THE CEDARS-SINAI ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM BEYOND MALNUTRITION</GrantOrContributionPurposeTxt>
          <Amt>64189</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POST-ACUTE STROKE CARE IMPLEMENTING QUALITY STANDARDS IN MONTANA, NEBRASKA AND NORTH DAKOTA</GrantOrContributionPurposeTxt>
          <Amt>379458</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEARTCORPS AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>871217</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AMERICAN HEART ASSOCIATION CENTER FOR TELEHEALTH</GrantOrContributionPurposeTxt>
          <Amt>6966024</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING THE SYSTEM OF STROKE CARE IN MINNESOTA</GrantOrContributionPurposeTxt>
          <Amt>908680</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION LIFELINE STROKE SOUTH DAKOTA</GrantOrContributionPurposeTxt>
          <Amt>957913</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION LIFELINE STROKE HAWAII</GrantOrContributionPurposeTxt>
          <Amt>1606124</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION LIFELINE STROKE IOWA</GrantOrContributionPurposeTxt>
          <Amt>2521277</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN PHARMACISTS ASSOCIATION FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2215 CONSTITUTION AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROJECT IMPACT CGM EXPANDING ACCESS TO CGM THROUGH COMMUNITY PHARMACIES</GrantOrContributionPurposeTxt>
          <Amt>1335393</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN PHARMACISTS ASSOCIATION FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2215 CONSTITUTION AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROJECT IMPACT CGM EXPANDING ACCESS TO CGM THROUGH COMMUNITY PHARMACIES</GrantOrContributionPurposeTxt>
          <Amt>167500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN SAMOA DEPT OF HEALTH FOR AMERICAN SAMOA COMMUNITY HEALTH CTR</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE FAGAALU ROAD</AddressLine1Txt>
            <CityNm>PAGO PAGO</CityNm>
            <StateAbbreviationCd>AS</StateAbbreviationCd>
            <ZIPCd>96799</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMAGING EQUIPMENT AT AMERICAN SAMOA COMMUNITY HEALTH CENTERS</GrantOrContributionPurposeTxt>
          <Amt>1335622</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN TELEMEDICINE ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>601 13TH ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN TELEMEDICINE ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>601 13TH ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LEVEL 5 MEMBERSHIP</GrantOrContributionPurposeTxt>
          <Amt>25500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICANS FOR BEN-GURION UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1001 AVENUE OF THE AMERICAS 19TH</AddressLine1Txt>
            <AddressLine2Txt>FLOOR</AddressLine2Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>20000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMICI DI ADWA ENTE DEL TERZO SETTORE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>VIA GIACOMO MATTEOTTI 8</AddressLine1Txt>
            <CityNm>CENTO</CityNm>
            <CountryCd>IT</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A HOSPITAL FOR ADWA, ETHIOPIA IN THE TIGRAY REGION</GrantOrContributionPurposeTxt>
          <Amt>1398329</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMSTERDAM UMC RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A PROSPECTIVE RANDOMIZED STUDY OF TREATMENT SELECTION BASED ON EPIGENETIC MARKERS IN CROHNS DISEASE OMICROHN</GrantOrContributionPurposeTxt>
          <Amt>1532103</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMSTERDAM UMC RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE</GrantOrContributionPurposeTxt>
          <Amt>225500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMSTERDAM UMC RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE</GrantOrContributionPurposeTxt>
          <Amt>306900</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ANN &amp; ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 EAST CHICAGO AVENUE BOX 205</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60611</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D</GrantOrContributionPurposeTxt>
          <Amt>2325006</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ANTHOS HOME INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>238 SEELEY ST</AddressLine1Txt>
            <CityNm>BROOKLYN</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11218</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ANTHOS HOME INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>238 SEELEY ST</AddressLine1Txt>
            <CityNm>BROOKLYN</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11218</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASHLEY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>612 CENTER AVE N</AddressLine1Txt>
            <CityNm>ASHLEY</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>584130450</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ASHLEY MEDICAL CENTER (ND) ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>76961</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 SOUTH WACKER DRIVE SUITE 600</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60606</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DANATECH DIABETES TECHNOLOGY PLATFORM EXPANSION &amp; MAINTENANCE</GrantOrContributionPurposeTxt>
          <Amt>1030062</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 SOUTH WACKER DRIVE SUITE 600</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60606</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF THE DANATECH PLATFORM</GrantOrContributionPurposeTxt>
          <Amt>432057</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 SOUTH WACKER DRIVE SUITE 600</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60606</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF THE DANATECH PLATFORM</GrantOrContributionPurposeTxt>
          <Amt>423489</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION SANTE DIABETE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>5 RUE FEDERICO GARCIA LORCA</AddressLine1Txt>
            <CityNm>GRENOBLE</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS</GrantOrContributionPurposeTxt>
          <Amt>587221</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>55 VICTORIA PARADE</AddressLine1Txt>
            <CityNm>FITZROY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE THE MIRO (MICROBIOTA RESTORATION) STUDY.</GrantOrContributionPurposeTxt>
          <Amt>315421</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>55 VICTORIA PARADE</AddressLine1Txt>
            <CityNm>FITZROY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE THE MIRO (MICROBIOTA RESTORATION) STUDY.</GrantOrContributionPurposeTxt>
          <Amt>209377</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BALLAD RESEARCH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3525 JOHN HOPKINS COURT</AddressLine1Txt>
            <CityNm>SAN DIEGO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CD127-HIGH T-CELL POPULATIONS IN AUTOANTIBODY POSITIVE CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>315380</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAPTIST MEDICAL CENTRE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BAPTIST MEDICAL CENTRE ROAD</AddressLine1Txt>
            <CityNm>NALERIGU</CityNm>
            <CountryCd>GH</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ELEVATING MATERNAL AND PEDIATRIC HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>4505896</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAPTIST MEDICAL CENTRE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BAPTIST MEDICAL CENTRE ROAD</AddressLine1Txt>
            <CityNm>NALERIGU</CityNm>
            <CountryCd>GH</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CT SCANNER FOR BAPTIST MEDICAL CENTRE</GrantOrContributionPurposeTxt>
          <Amt>848730</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAR ILAN UNIVERSITY IN ISRAEL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MAX VE-ANNA WEBB ST</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE LEONA M. AND HARRY B. HELMSLEY ENERGY PROTOTYPE LAB AT BAR-ILAN UNIVERSITY</GrantOrContributionPurposeTxt>
          <Amt>3348125</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BARBARA'S HOUSE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>100 MELROSE AVENUE</AddressLine1Txt>
            <CityNm>GREENWICH</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06830</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>45000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAYLOR COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE BAYLOR PLAZA</AddressLine1Txt>
            <CityNm>HOUSTON</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREDICTIVE ANALYTICS AND TARGETED INTERVENTIONS SHIFTING THE PARADIGM FROM REACTIVE TO PROACTIVE DIABETES CARE</GrantOrContributionPurposeTxt>
          <Amt>265400</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 NINTH AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981012795</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MECHANISMS OF AUTOANTIBODY REVERSION IN AT-RISK SUBJECTS</GrantOrContributionPurposeTxt>
          <Amt>379135</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEN-GURION UNIVERSITY OF THE NEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEN-GURION BLVD 1</AddressLine1Txt>
            <CityNm>BEER SHEVA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM COBMINDEX GOES FORWARD- A SMARTPHONE APPLICATION FOR ADDED PSYCHOLOGICAL WELLBEING IN CD.</GrantOrContributionPurposeTxt>
          <Amt>765436</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEN-GURION UNIVERSITY OF THE NEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEN-GURION BLVD 1</AddressLine1Txt>
            <CityNm>BEER SHEVA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONSTRUCTION OF THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST COMPUTER SCIENCE BUILDING</GrantOrContributionPurposeTxt>
          <Amt>5785714</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEYOND TYPE 1</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 CONCAR DRIVE OFFICE 03-155</AddressLine1Txt>
            <CityNm>SAN MATEO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94402</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>555000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEYOND TYPE 1</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 CONCAR DRIVE OFFICE 03-155</AddressLine1Txt>
            <CityNm>SAN MATEO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94402</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>600000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEYOND TYPE 1</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 CONCAR DRIVE OFFICE 03-155</AddressLine1Txt>
            <CityNm>SAN MATEO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94402</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>600000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BILLINGS CLINIC SURGICAL INTENSIVE CARE UNIT</GrantOrContributionPurposeTxt>
          <Amt>2000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BILLINGS CLINIC SURGICAL INTENSIVE CARE UNIT</GrantOrContributionPurposeTxt>
          <Amt>5000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ECMO SERVICES AT BILLINGS CLINIC</GrantOrContributionPurposeTxt>
          <Amt>449629</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BILLINGS CLINIC TRANSFER CENTER</GrantOrContributionPurposeTxt>
          <Amt>2215173</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BIPARTISAN POLICY CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1225 I ST NW 1000</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING RURAL HEALTH CARE DELIVERY AND SERVICES</GrantOrContributionPurposeTxt>
          <Amt>658783</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1209 ORANGE STREET</AddressLine1Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF BLUE CIRCLE HEALTH</GrantOrContributionPurposeTxt>
          <Amt>3975887</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1209 ORANGE STREET</AddressLine1Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF BLUE CIRCLE HEALTH</GrantOrContributionPurposeTxt>
          <Amt>4470843</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1209 ORANGE STREET</AddressLine1Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF BLUE CIRCLE HEALTH</GrantOrContributionPurposeTxt>
          <Amt>4470844</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BNAI ZION MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>47 GOLOMB ST</AddressLine1Txt>
            <CityNm>HAIFA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF THE HELMSLEY CARDIOVASCULAR CARE UNIT</GrantOrContributionPurposeTxt>
          <Amt>2764483</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2601 ENTERPRISE ROAD</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89512</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CARDIORESPIRATORY CARE SCIENCE DEGREE PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>137345</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2601 ENTERPRISE ROAD</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89512</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRASOUND TRAINING INITIATIVE IN NEVADA</GrantOrContributionPurposeTxt>
          <Amt>197208</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF PERSONALIZED DECISION SUPPORT TOOL USING NETIOB TO HELP MANAGE EXERCISE FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>758218</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DETERMINING THE THERAPEUTIC POTENTIAL OF STATINS ON STRICTURING CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>667666</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A MOLECULAR SWITCH BASED CONTINUOUS INSULIN SENSOR</GrantOrContributionPurposeTxt>
          <Amt>1306247</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABDOCS NATIONAL K12 SUPPLEMENT</GrantOrContributionPurposeTxt>
          <Amt>201490</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABETESWISE FOR EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>835639</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON MEDICAL CENTER CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE BOSTON MEDICAL CENTER PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02118</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPLEMENTAL FUNDING FOR AN EFFECTIVENESS TRIAL TO SUPPORT ADOPTION OF AID IN UNDERSERVED ADULTS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>128527</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON SYMPHONY ORCHESTRA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>301 MASSACHUSETTS AVENUE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>12500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BREAKING GROUND HOUSING DEVELOPMENT FUND CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 EIGHTH AVENUE 5TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING AND EVALUATING THE HEALTH EFFECTS OF ACCELERATED PLACEMENTS INTO PERMANENT SUPPORTIVE HOUSING</GrantOrContributionPurposeTxt>
          <Amt>567155</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BREAKTHROUGH T1D</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CO-FUNDED DEVELOPMENT OF A 3-B-HYDROXYBUTYRATE BINDING PROTEIN BASED CONTINUOUS KETONE MONITORING MICROSENSOR</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BREAKTHROUGH T1D</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CO-FUNDED DEVELOPMENT OF A MICRONEEDLE SENSOR FOR SIMULTANEOUS CONTINUOUS MONITORING OF KETONES AND GLUCOSE</GrantOrContributionPurposeTxt>
          <Amt>133332</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BREAKTHROUGH T1D</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY AND JDRF CO-FUNDED WORKSHOPS</GrantOrContributionPurposeTxt>
          <Amt>93442</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIDGES TO PROSPERITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1031 33RD STREET</AddressLine1Txt>
            <CityNm>DENVER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMATIVE CONNECTIVITY IN RURAL ZAMBIA</GrantOrContributionPurposeTxt>
          <Amt>2306101</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CANDID</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>32 OLD SLIP 24TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>28749</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARDIFF UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>30-36 NEWPORT RD</AddressLine1Txt>
            <CityNm>WALES</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T1D-PLUS AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D</GrantOrContributionPurposeTxt>
          <Amt>211718</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARE-FOR-RARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LINDWURMSTRASSE 4</AddressLine1Txt>
            <CityNm>MUNICH</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES MUNICH STUDIES</GrantOrContributionPurposeTxt>
          <Amt>667252</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELPING MOTHERS AND NEWBORNS SURVIVE AND THRIVE</GrantOrContributionPurposeTxt>
          <Amt>1337724</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING COMMUNITY RECOVERY AND RESILIENCE</GrantOrContributionPurposeTxt>
          <Amt>1808630</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CAVALIER COUNTY MEMORIAL HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>909 2ND SREET</AddressLine1Txt>
            <CityNm>LANGDON</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58249</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORTH DAKOTA ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>408100</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES CEDARS-SINAI</GrantOrContributionPurposeTxt>
          <Amt>115500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY</GrantOrContributionPurposeTxt>
          <Amt>211815</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY</GrantOrContributionPurposeTxt>
          <Amt>219514</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM BEYOND MALNUTRITION</GrantOrContributionPurposeTxt>
          <Amt>519768</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM BEYOND MALNUTRITION</GrantOrContributionPurposeTxt>
          <Amt>733694</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTER FOR HEALTH CARE STRATEGIES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 AMERICAN METRO BOULEVARD SUITE</AddressLine1Txt>
            <AddressLine2Txt>125</AddressLine2Txt>
            <CityNm>HAMILTON</CityNm>
            <StateAbbreviationCd>NJ</StateAbbreviationCd>
            <ZIPCd>08619</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFYING OPPORTUNITIES TO SUPPORT T1D AUTOANTIBODY SCREENING IN MEDICAID PROGRAMS AND HEALTH CARE SYSTEMS THAT SERVE MEDICAID BENEFICIARIES</GrantOrContributionPurposeTxt>
          <Amt>149672</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTER FOR HEALTH CARE STRATEGIES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 AMERICAN METRO BOULEVARD SUITE</AddressLine1Txt>
            <AddressLine2Txt>125</AddressLine2Txt>
            <CityNm>HAMILTON</CityNm>
            <StateAbbreviationCd>NJ</StateAbbreviationCd>
            <ZIPCd>08619</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM MEDICAID ACCESS ACCELERATOR - TARGETED RESOURCES AND TECHNICAL ASSISTANCE TO IMPROVE CARE FOR PEOPLE LIVING WITH DIABETES WHO USE INSULIN</GrantOrContributionPurposeTxt>
          <Amt>1002514</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTER FOR HEALTH CARE STRATEGIES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 AMERICAN METRO BOULEVARD SUITE</AddressLine1Txt>
            <AddressLine2Txt>125</AddressLine2Txt>
            <CityNm>HAMILTON</CityNm>
            <StateAbbreviationCd>NJ</StateAbbreviationCd>
            <ZIPCd>08619</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ACCESS TO AID DEVICES IN MEDICAID</GrantOrContributionPurposeTxt>
          <Amt>141530</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTER FOR URBAN COMMUNITY SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>198 EAST 121ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10035</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRE HOSPITALIER REGIONAL DE NANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>29 AVENUE MAL DE LATTRE TASSIGNY</AddressLine1Txt>
            <CityNm>NANCY</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE THE NEMO PROJECT</GrantOrContributionPurposeTxt>
          <Amt>94386</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHANCELLOR MASTERS &amp; SCHOLARS OF THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLINGTON SQUARE</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING THE SIGNALING CIRCUITS AND REGULONS MEDIATING CROHNS FIBROSIS.</GrantOrContributionPurposeTxt>
          <Amt>612471</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHANCELLOR MASTERS &amp; SCHOLARS OF THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLINGTON SQUARE</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE IN VEOIBD</GrantOrContributionPurposeTxt>
          <Amt>244860</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHI HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>12809 WEST DODGE ROAD</AddressLine1Txt>
            <CityNm>OMAHA</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68154</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY</GrantOrContributionPurposeTxt>
          <Amt>359722</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHI HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>12809 WEST DODGE ROAD</AddressLine1Txt>
            <CityNm>OMAHA</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68154</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY</GrantOrContributionPurposeTxt>
          <Amt>458920</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHI HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>12809 WEST DODGE ROAD</AddressLine1Txt>
            <CityNm>OMAHA</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68154</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHI HEALTH ND ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>903993</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 414413</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES BOSTON STUDIES</GrantOrContributionPurposeTxt>
          <Amt>1470081</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 414413</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADVANCING THE DEVELOPMENT OF A NOVEL IMPLANTABLE GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>1296628</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 414413</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULIN (GRI)</GrantOrContributionPurposeTxt>
          <Amt>732284</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4650 SUNSET BOULEVARD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90027</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BEYOND COYOT1 EXPANSION OF PATIENT-CENTERED VIRTUAL CARE</GrantOrContributionPurposeTxt>
          <Amt>153056</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALIDATION OF A PERIPHERAL BLOOD BIOMARKER SIGNATURE FOR ANTI-TNF RESPONSE IN PATIENTS WITH CROHNS DISEASE (ATPBIOS)</GrantOrContributionPurposeTxt>
          <Amt>583113</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ARTIFICIAL INTELLIGENCE PREDICTION OF MEANINGFUL OUTCOMES IN NEWLY DIAGNOSED SMALL BOWEL CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1093319</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL</GrantOrContributionPurposeTxt>
          <Amt>963282</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ROLE OF PPAR-ALPHA IN PROMOTING BRUSH BORDER MATURITY OF INTESTINAL ENTEROCYTES</GrantOrContributionPurposeTxt>
          <Amt>439601</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>725157</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL OF PHILADELPHIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2716 SOUTH STREET</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191462305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LEVERAGING HLA PROTECTION AND HUMORAL IMMUNITY TO DEVELOP MICROBIAL THERAPEUTICS THAT PREVENT T1D</GrantOrContributionPurposeTxt>
          <Amt>107168</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHRISTIAN UNITY HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>164 WEST 13TH STREET</AddressLine1Txt>
            <CityNm>GRAFTON</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58237</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORTH DAKOTA ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>646571</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY FUTURES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>80 8TH AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10011</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC GREENSPACE POLICY REPORTS FOCUSED ON PROMOTING RECREATION, AND IMPROVING ACCESS TO GREENSPACE</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY PARKS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>830 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CATALYST SUSTAINABILITY THE IMPORTANCE OF COMMUNITY ENGAGEMENT IN PARKS</GrantOrContributionPurposeTxt>
          <Amt>161100</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY PARKS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>830 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING NYCS URBAN FOREST PLAN PUBLIC PARK LANDS</GrantOrContributionPurposeTxt>
          <Amt>466100</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY PARKS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>830 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC GREEN FUND</GrantOrContributionPurposeTxt>
          <Amt>750000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM BIOMARKER-BASED MULTIDISCIPLINARY TEAM APPROACH TO IMPROVE EARLY CROHN'S DISEASE OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>463512</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>700000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>2658835</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>2541165</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>1472591</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM MANAGEMENT</GrantOrContributionPurposeTxt>
          <Amt>145605</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CT LINEAR ACCELERATOR FOR RABIN CANCER CENTER</GrantOrContributionPurposeTxt>
          <Amt>2050000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLINTON HEALTH ACCESS INITIATIVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>383 DORCHESTER AVENUE SUITE 400</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02127</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REACH EXPANDING ACCESS TO PRIMARY CARE FOR DIABETES AND HYPERTENSION (2024-2027)</GrantOrContributionPurposeTxt>
          <Amt>1652598</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLINTON HEALTH ACCESS INITIATIVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>383 DORCHESTER AVENUE SUITE 400</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02127</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING MEDICAL OXYGEN PRODUCTION AND UTILIZATION</GrantOrContributionPurposeTxt>
          <Amt>2811261</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COMMUNITY HEALTH SERVICE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2310 4TH AVE N</AddressLine1Txt>
            <CityNm>MOORHEAD</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56560</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMMUNITY HEALTH SERVICE INC ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>132287</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CONVERGENT IMPACT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3223 ARAPAHOE AVE</AddressLine1Txt>
            <CityNm>BOULDER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80303</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORNELL UNIVERSITY FOR THE JOAN &amp; SANFORD I WEILL MEDICAL COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 YORK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100654805</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING THE MYCOBIOME IN PATIENTS WITH CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>863618</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORPORATION FOR SUPPORTIVE HOUSING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COUNCIL FOR ECONOMIC EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>122 EAST 42ND STREET</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10168</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COUNCIL ON FOUNDATIONS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1255 23RD ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR ONE YEAR MEMBERSHIP</GrantOrContributionPurposeTxt>
          <Amt>34000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COUNCIL ON THE ENVIRONMENT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>100 GOLD ST SUITE 3300</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>15000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COZAD HOSPITAL DISTRICT NO 2</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 EAST 12TH STREET</AddressLine1Txt>
            <CityNm>COZAD</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69130</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY AT COZAD COMMUNITY HEALTH SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>35283</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CRITICAL PATH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1840 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>TUCSON</CityNm>
            <StateAbbreviationCd>AZ</StateAbbreviationCd>
            <ZIPCd>85718</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSLATIONAL THERAPEUTICS ACCELERATOR DEVELOPING KINASE INHIBITORS OF THE UNFOLDED PROTEIN RESPONSE TO TREAT T1D</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CRITICAL PATH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1840 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>TUCSON</CityNm>
            <StateAbbreviationCd>AZ</StateAbbreviationCd>
            <ZIPCd>85718</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T1D CONSORTIUM 2.0</GrantOrContributionPurposeTxt>
          <Amt>266741</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SPONSORSHIP FOR THE 2025 CROHNS &amp; COLITIS CONGRESS PRESENTED BY THE CROHNS &amp; COLITIS FOUNDATION AND THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION</GrantOrContributionPurposeTxt>
          <Amt>235000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACHIEVING REMISSION IN IBD OPTIMIZING TREAT-TO-TARGET IN CLINICAL PRACTICE</GrantOrContributionPurposeTxt>
          <Amt>1632470</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>APPLICATION OF MACHINE LEARNING TO PRECISION NUTRITION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>342493</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERNATIONAL CONSORTIUM ON MEDICAL NUTRITION IN IBD</GrantOrContributionPurposeTxt>
          <Amt>310748</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING ENROLLMENT IN IBD CLINICAL TRIALS</GrantOrContributionPurposeTxt>
          <Amt>744245</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IBD VENTURES ACADEMIC INCUBATOR</GrantOrContributionPurposeTxt>
          <Amt>1180400</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF NATIONWIDE TELEMEDICINE NETWORK TO MITIGATE GEOGRAPHIC DISPARITIES IN ACCESS TO HEALTHCARE FOR CD PATIENTS LIVING IN CANADA</GrantOrContributionPurposeTxt>
          <Amt>374912</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTING A MULTIMODAL RCT INTERVENTION TO IMPROVE THE TRANSITION OF PATIENTS WITH CROHNS DISEASE FROM PEDIATRIC TO ADULT CARE</GrantOrContributionPurposeTxt>
          <Amt>297612</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS UK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 BISHOPS SQUARE</AddressLine1Txt>
            <CityNm>HATFIELD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF A LOWER GI DIAGNOSTIC PATHWAY IN PRIMARY HEALTHCARE AND DEVELOPMENT AND DISSEMINATION OF A LOWER GI PATIENT TOOLKIT</GrantOrContributionPurposeTxt>
          <Amt>467726</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S COLITIS CURE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>100 HARRIS STREET</AddressLine1Txt>
            <CityNm>PYRMONT NSW</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENHANCING INFLAMMATORY BOWEL DISEASE CARE CONSUMER-CENTRIC PORTAL FOR BETTER COMMUNICATION &amp; REDUCED NAVIGATION STRESS</GrantOrContributionPurposeTxt>
          <Amt>871250</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DARTMOUTH- HITCHCOCK CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE MEDICAL CENTER DRIVE</AddressLine1Txt>
            <CityNm>LEBANON</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03756</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING FOR DARTMOUTH-HITCHCOCK'S VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>706219</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DEUTSCHE WELTHUNGERHILFE EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>FRIEDRICH-EBERT-STRABE 1</AddressLine1Txt>
            <CityNm>BONN BAD GODESBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOLISTICALLY ADDRESSING AGROBUSINESS</GrantOrContributionPurposeTxt>
          <Amt>1898076</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DIABETES AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>19-23 MOORE STREET GROUND FLOOR</AddressLine1Txt>
            <CityNm>TURNER</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVEMENTS IN OUTCOMES FOR YOUNG PEOPLE WITH DIABETES THROUGH GEOGRAPHIC EXPANSION AND COUNTRY-SPECIFIC DATA-DRIVEN INITIATIVES</GrantOrContributionPurposeTxt>
          <Amt>1855504</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DUKE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2200 WEST MAIN STREET SUITE 1000</AddressLine1Txt>
            <CityNm>DURHAM</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>27705</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL ASSAYS FOR PROGLUCAGON PEPTIDES TO UNDERSTAND ALPHA CELL FUNCTION IN HEALTH AND DIABETES</GrantOrContributionPurposeTxt>
          <Amt>275861</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DUNDY COUNTY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1313 N CHEYENNE ST</AddressLine1Txt>
            <CityNm>BENKELMAN</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69021</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>11725</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>EMERGING PRACTITIONERS IN PHILANTHROPY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>201 N UNION ST STE 110</AddressLine1Txt>
            <CityNm>ALEXANDRIA</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22314</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR 2024 MEMBERSHIP</GrantOrContributionPurposeTxt>
          <Amt>11250</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>EMORY UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1599 CLIFTON ROAD NE</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303224250</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>302430</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ENGINEERING MINISTRIES INTERNATIONAL USA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7025 CAMPUS DRIVE</AddressLine1Txt>
            <CityNm>COLORADO SPRINGS</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80920</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATING RURAL HEALTH CARE FACILITIES</GrantOrContributionPurposeTxt>
          <Amt>89417</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ENGINEERING MINISTRIES INTERNATIONAL USA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7025 CAMPUS DRIVE</AddressLine1Txt>
            <CityNm>COLORADO SPRINGS</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80920</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MINGA MISSION HOSPITAL DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>1433145</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ESSENTIA HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>502 E 2ND ST</AddressLine1Txt>
            <CityNm>DULUTH</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55805</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ESSENTIA HEALTH ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>2065413</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FAIRVIEW HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2450 RIVERSIDE AVE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55454</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE</GrantOrContributionPurposeTxt>
          <Amt>3176500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FAMILY HEALTHCARE CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>301 NP AVE N</AddressLine1Txt>
            <CityNm>FARGO</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FAMILY HEALTHCARE CENTER ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>172160</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FEDERAL INSTITUTE OF TECHNOLOGY ZURICH ETHZ</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RAMISTRASSE 101</AddressLine1Txt>
            <CityNm>ZURICH</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SPATIAL BIOLOGY OF CROHNS COLITIS</GrantOrContributionPurposeTxt>
          <Amt>421278</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FJC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 WEST 39TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE WELLNESS CLASSROOM, A PROJECT OF FJC - A FOUNDATION OF PHILANTHROPIC FUNDS</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FOR INSPIRATION AND RECOGNITION OF SCIENCE AND TECHNOLOGY (FIRST)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 BEDFORD STREET</AddressLine1Txt>
            <CityNm>MANCHESTER</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FIRST SENIOR MENTOR PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CHEMIN DU POMMIER 40</AddressLine1Txt>
            <CityNm>LE GRANDSACONNEX</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACESS TO CGMS FOR EQUITY IN DIABETES MANAGEMENT - THE ACCEDE PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1118735</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FOUNTAIN HOUSE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>425 WEST 47TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FRIENDS OF RYE TOWN PARK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 345</AddressLine1Txt>
            <CityNm>RYE</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10580</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>7000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FUNDACIO DE RECERCA CLINIC BARCELONA INSTITUT D'INVESTIGACIONS BIOMED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>ROSSELLO 149</AddressLine1Txt>
            <CityNm>BARCELONA</CityNm>
            <CountryCd>SP</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY DETECTION OF PERIANAL FISTULIZING DISEASE- PATHOPHYSIOLOGY AND IMAGING</GrantOrContributionPurposeTxt>
          <Amt>576960</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GALILEE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEN ZVI BLVD POB 21</AddressLine1Txt>
            <CityNm>NAHARIYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>2200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GALILEE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEN ZVI BLVD POB 21</AddressLine1Txt>
            <CityNm>NAHARIYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RENOVATION OF ONE FLOOR OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>750000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GATES PHILANTHROPY PARTNERS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 60555</AddressLine1Txt>
            <CityNm>CITY OF INDUSTRY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91716</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POLIO ERADICATION FUND SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GAY AND LESBIAN COMMUNITY CENTER OF SOUTHERN NEVADA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 S MARYLAND PARKWAY</AddressLine1Txt>
            <CityNm>LAS VEGAS</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPITAL SUPPORT FOR THE CENTER</GrantOrContributionPurposeTxt>
          <Amt>2267929</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GENETIC ALLIANCE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>25904 WOODFIELD ROAD</AddressLine1Txt>
            <CityNm>DAMASCUS</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>20872</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IHOPE GENETIC HEALTH</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLCOME GENOME CAMPUS</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCIBD-RESPONSE MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>187672</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLCOME GENOME CAMPUS</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCIBD-RESPONSE MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>402672</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEORGETOWN UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>37TH O STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20057</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADVANCING ACCESS TO HIGH QUALITY, AFFORDABLE DIABETES CARE THROUGH PRIVATE HEALTH INSURANCE REGULATION</GrantOrContributionPurposeTxt>
          <Amt>432998</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEORGIA TECH RESEARCH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 10TH STREET NW</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303320420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>485616</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEOSCIENCE AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 JERRABOMBERRA AVE</AddressLine1Txt>
            <CityNm>SYMONSTON</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGITAL EARTH AFRICA - SUSTAINABLE UPTAKE AND IMPACT</GrantOrContributionPurposeTxt>
          <Amt>1195336</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GOOD SAMARITAN HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>800 S MAIN AVE</AddressLine1Txt>
            <CityNm>RUGBY</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58368</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEART OF AMERICA MEDICAL CENTER ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>468841</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GRANTMAKERS FOR EFFECTIVE ORGANIZATIONS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1310 L STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>18920</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GRANTMAKERS IN HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 CONNECTICUT AVENUE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR 2024</GrantOrContributionPurposeTxt>
          <Amt>24640</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HADASSAH MEDICAL ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>POB 12000</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RECRUITMENT OF TOP MEDICAL TALENT FOR THE NEW HADASSAH-HELMSLEY MEDICAL CENTER, NETIVOT</GrantOrContributionPurposeTxt>
          <Amt>950450</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HADASSAH MEDICAL ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>POB 12000</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EQUIPPING THE NEW HADASSAH - HELMSLEY MEDICAL CENTER, NETIVOT</GrantOrContributionPurposeTxt>
          <Amt>5265160</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HAWAI'I HEALTH SYSTEMS CORP KAUA'I REGION FOR VETERANS MEMORIAL HOSP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4643 WAIMEA CANYON DRIVE</AddressLine1Txt>
            <CityNm>WAIMEA</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96796</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MEDICAL SIMULATION AT KAUA'I VETERANS MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>381278</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HAZEN MEMORIAL HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>510 8TH AVE NE</AddressLine1Txt>
            <CityNm>HAZEN</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58545</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SAKAKAWEA MEDICAL CENTER (ND) ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>88179</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEALING HANDS OF JOY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4747 HEDGEMORE DR</AddressLine1Txt>
            <CityNm>CHARLOTTE</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>28209</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ELIMINATION OF OBSTETRIC FISTULA</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEALTH RESEARCH ALLIANCE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 146</AddressLine1Txt>
            <CityNm>RALEIGH</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>27612</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>22150</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEBREW UNIVERSITY OF JERUSALEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BOYAR BUILDING 5TH FLOOR</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>221500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>1184939</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>1310183</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>1927629</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1282899</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>794714</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH AND AUTOIMMUNITY OUTCOMES IN CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>162877</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>1913981</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>800000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>1833580</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT</GrantOrContributionPurposeTxt>
          <Amt>3157</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT</GrantOrContributionPurposeTxt>
          <Amt>46760</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>988211</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>920486</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EUROPEAN PRE-T1D REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>158504</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOSAMPLE RFP</GrantOrContributionPurposeTxt>
          <Amt>229162</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HENRY J KAISER FAMILY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>185 BERRY STREET NO 2000</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>KFF HEALTH NEWS RURAL HEALTH DESK</GrantOrContributionPurposeTxt>
          <Amt>1521095</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HERLEV OG GENTOFTE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERLEV RINGVEJ 75 OPG115</AddressLine1Txt>
            <CityNm>HERLEV</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERACTION BETWEEN AMINO ACIDS AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE IN PANCREATIC ALPHA CELLS</GrantOrContributionPurposeTxt>
          <Amt>135722</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HIGH QUALITY MEDICAL EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4117 PENFIELD CT S</AddressLine1Txt>
            <CityNm>AFTON</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR NORTH DAKOTA RURAL PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>1384586</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HIGH QUALITY MEDICAL EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4117 PENFIELD CT S</AddressLine1Txt>
            <CityNm>AFTON</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>2112639</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HILLEL THE FOUNDATION FOR JEWISH CAMPUS LIFE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>180 S GARNER STREET</AddressLine1Txt>
            <CityNm>STATE COLLEGE</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>16804</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HILLEL YAFFE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HA-SHALOM ST</AddressLine1Txt>
            <CityNm>HADERA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EYE INSTITUTE AND AMBULATORY SURGERY CENTER</GrantOrContributionPurposeTxt>
          <Amt>3158400</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HILLEL YAFFE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HA-SHALOM ST</AddressLine1Txt>
            <CityNm>HADERA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONSTRUCTION OF PET-CT INSTITUTE</GrantOrContributionPurposeTxt>
          <Amt>3536258</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HOLON INSTITUTE OF TECHNOLOGY - HIT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>52 GOLOMB ST</AddressLine1Txt>
            <CityNm>HOLON</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MEDICAL TECHNOLOGIES BUILDING AT THE HOLON INSTITUTE OF TECHNOLOGY (HIT)</GrantOrContributionPurposeTxt>
          <Amt>681350</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HUMAN CELL ATLAS INCORPORATED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN ST</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2024 HUMAN CELL ATLAS GENERAL MEETING</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HUMBOLDT COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1000 N 15TH ST</AddressLine1Txt>
            <CityNm>HUMBOLDT</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50548</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT HUMBOLDT COUNTY MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>39438</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES MOUNT SINAI STUDIES</GrantOrContributionPurposeTxt>
          <Amt>220000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE WOMEN WITH INFLAMMATORY BOWEL DISEASE AND MOTHERHOOD (WISDOM) REGISTRY A PROSPECTIVE STUDY OF FEMALE FERTILITY IN IBD</GrantOrContributionPurposeTxt>
          <Amt>574537</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROMOTE BIRTH EQUITY THROUGH COMMUNITY-BASED DOULA CARE, HOMELESS AND JUSTICE-INVOLVED PREGNANT PERSONS.</GrantOrContributionPurposeTxt>
          <Amt>779716</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATION THERAPY OF RESILIENCE INTERVENTION WITH BIOLOGICS IN CROHNS DISEASE [CATHARSIS TRIAL]</GrantOrContributionPurposeTxt>
          <Amt>523716</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SPATIAL MAPPING OF FIBROMUSCULAR CROHNS DISEASE FROM GENETIC TO SENESCENT SIGNALS</GrantOrContributionPurposeTxt>
          <Amt>920802</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY LIFE EXPOSOME BIOMARKERS AND CROHN'S DISEASE RISK THE EARLY-CD PROJECT</GrantOrContributionPurposeTxt>
          <Amt>618257</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE USE OF GLP-1R AGONISTS TO PROMOTE EPITHELIAL HEALING IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>993497</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING THE PRE-DISEASE PHASE OF CROHNS DISEASE PREDICT AND PREVENT</GrantOrContributionPurposeTxt>
          <Amt>2303337</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF NOVEL LRRK2 INHIBITORS TO TREAT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>583881</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IDA COUNTY IOWA COMMUNITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>701 EAST SECOND STREET</AddressLine1Txt>
            <CityNm>IDA GROVE</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51445</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT HORN MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>44685</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IMPACT-SE INST FOR MONITORING PEACE &amp; CULTURAL TOLERANCE IN SCHOOL ED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2 JABOTINSKY ST</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMING EDUCATION FOR PEACE A NATIONWIDE AWARENESS CAMPAIGN ON INCITEMENT IN PALESTINIAN/UNRWA TEXTBOOKS.</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IMPROVECARENOW INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4 CARMICHAEL ST UNIT 111</AddressLine1Txt>
            <CityNm>ESSEX JUNCTION</CityNm>
            <StateAbbreviationCd>VT</StateAbbreviationCd>
            <ZIPCd>05452</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTING THE COMBINE TRIAL RESULTS IN THE IMPROVECARENOW (ICN) LEARNING HEALTH NETWORK</GrantOrContributionPurposeTxt>
          <Amt>931101</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INNODIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERESTRAAT 49</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INNODIA NONPROFIT LAUNCH</GrantOrContributionPurposeTxt>
          <Amt>7905</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>79723</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>95213</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>86 RUE REGNAULT</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FROM BENIGN ISLET AUTOIMMUNITY TO TYPE 1 DIABETES HLA-A- VS. HLA-B-RESTRICTED CD8 T-CELL BIOMARKERS OF PROGRESSION</GrantOrContributionPurposeTxt>
          <Amt>362460</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUTE FOR COMMUNITY LIVING INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 BROAD STREET</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUTE FOR COMMUNITY LIVING INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 BROAD STREET</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING A THREE-YEAR IMT/ACT STEP-DOWN PROJECT</GrantOrContributionPurposeTxt>
          <Amt>749790</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSULIN FOR LIFE USA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2555 SW 76TH STREET 130</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>32608</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING ORGANIZATIONAL CAPACITY</GrantOrContributionPurposeTxt>
          <Amt>60700</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL ALLIANCE FOR DIABETES ACTION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 STATE STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEED FUNDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>893663</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION GLOBALLY (IBUS EIUS ED)</GrantOrContributionPurposeTxt>
          <Amt>645000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF AN INTESTINAL ULTRASOUND SCORE TO EVALUATE INFLAMMATION AND TREATMENT RESPONSE IN CROHNS DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>1168344</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POINT-OF-CARE INTESTINAL ULTRASOUND TRAINING IN THE UNITED STATES INTRODUCTION TO INTESTINAL ULTRASONOGRAPHY</GrantOrContributionPurposeTxt>
          <Amt>169420</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE EXTENT STUDY (CALCULATING THE LEMANN INDEX USING INTESTINAL ULTRASOUND)</GrantOrContributionPurposeTxt>
          <Amt>488553</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL WATER MANAGEMENT INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>127 SUNIL MAWATHA</AddressLine1Txt>
            <CityNm>BATTARAMULLA</CityNm>
            <CountryCd>CE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGITAL INNOVATIONS FOR A WATER SECURE AFRICA</GrantOrContributionPurposeTxt>
          <Amt>2449440</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INT'L BANK FOR RECONSTRUCTION &amp; DEV AND INT'L DEVELOPMENT ASSOC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1818 H STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20433</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH SYSTEM TRANSFORMATION AND RESILIENCE MULTI-DONOR TRUST FUND - NONCOMMUNICABLE DISEASE PARTNERSHIP GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>2500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ISRAEL ANTIQUITIES AUTHORITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>27 SULTAN SULEIMAN STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REVIVAL EXHIBITION AT BEN GURION AIRPORT</GrantOrContributionPurposeTxt>
          <Amt>350000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ISRAEL CENTER ON ADDICTION RA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2 HATZORAN ST</AddressLine1Txt>
            <CityNm>NETANYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ICA'S EMERGENCY MENTAL HEALTH SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>55000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JACOBSON MEMORIAL HOSPITAL CARE CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>601 EAST ST N</AddressLine1Txt>
            <CityNm>ELGIN</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58533</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JACOBSON MEMORIAL HOSPITAL ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>77620</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TECHNOSPHERE INSULIN VERSUS RAPID ACTING ANALOGUE INSULIN ON EXERCISE-INDUCED HYPOGLYCEMIA IN ADULTS WITH T1D USING AUTOMATED INSULIN DELIVERY</GrantOrContributionPurposeTxt>
          <Amt>1025846</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VIRTUAL DIABETES SPECIALTY CLINIC (VDISC) - A STUDY EVALUATING REMOTE INITIATION OF CONTINUOUS GLUCOSE MONITORING</GrantOrContributionPurposeTxt>
          <Amt>194126</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>180800</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>47712</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM FOR THE EARLY DETECTION AND MANAGEMENT OF DYSGLYCEMIA IN PREGNANCY (IMAGINE)</GrantOrContributionPurposeTxt>
          <Amt>1337806</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>80-84 CHANDOS STREET</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDIA FOLLOW UP 2023-2025 SAMPLES ANALYSIS RFA</GrantOrContributionPurposeTxt>
          <Amt>929309</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>80-84 CHANDOS STREET</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDIA FOLLOW UP 2023-2025 SAMPLES ANALYSIS RFA</GrantOrContributionPurposeTxt>
          <Amt>816628</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JERUSALEM COLLEGE OF TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>21 HAVAAD HALEUMI ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY SUPPORT FOR STUDENTS AT THE JERUSALEM COLLEGE OF TECHNOLOGY.</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JERUSALEM FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>420 LEXINGTON AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10170</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING A NEW HOME FOR TSAD KADIMA</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JEWISH BOARD OF FAMILY &amp; CHILDREN'S SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>463 7TH AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 NORTH BROADWAY MRB 117</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF AN APTAMER-BASED BIOSENSOR FOR CONTINUOUS INSULIN MONITORING</GrantOrContributionPurposeTxt>
          <Amt>742901</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 NORTH BROADWAY MRB 117</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERED CYTOKINE/ANTIBODY FUSION PROTEIN TO TREAT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>750000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOSLIN DIABETES CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE JOSLIN PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02215</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES</GrantOrContributionPurposeTxt>
          <Amt>569990</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>K9S FOR WARRIORS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>114 CAMP K9 ROAD</AddressLine1Txt>
            <CityNm>PONTE VEDRA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>32081</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT/WARRIOR SERVICE DOG PAIRING PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>7500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KAISER FOUNDATION HEALTH PLAN OF GEORGIA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1375 PEACHTREE STREET NE</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>30309</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF THE T1DES PILOT TO A PUBLIC HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>41911</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KAPIOLANI HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 MERCHANT ST</AddressLine1Txt>
            <CityNm>HONOLULU</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96813</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MARTHA B. SMITH CANCER &amp; INFUSION CENTER AT KAPIOLANI MEDICAL CENTER FOR WOMEN &amp; CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>5000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING CHRONIC INFLAMMATION AND TISSUE REMODELLING IN CROHN'S DISEASE WITH ENGINEERED T CELLS</GrantOrContributionPurposeTxt>
          <Amt>426571</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMBODY EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY</GrantOrContributionPurposeTxt>
          <Amt>221407</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FAT AS A VILLAIN IN CROHN'S DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>1456556</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDS 2024 BRUGES</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDENT1FI</GrantOrContributionPurposeTxt>
          <Amt>1644973</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RESOLVING HARMFUL ACCUMULATION OF INNATE LYMPHOID CELLS DURING CROHNS DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>384292</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6) SUBJECTS</GrantOrContributionPurposeTxt>
          <Amt>8567</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY)</GrantOrContributionPurposeTxt>
          <Amt>221552</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KYLER CARES FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8070 CROWDER BOULEVARD SUITE B</AddressLine1Txt>
            <CityNm>NEW ORLEANS</CityNm>
            <StateAbbreviationCd>LA</StateAbbreviationCd>
            <ZIPCd>70126</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>339900</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KYLER CARES FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8070 CROWDER BOULEVARD SUITE B</AddressLine1Txt>
            <CityNm>NEW ORLEANS</CityNm>
            <StateAbbreviationCd>LA</StateAbbreviationCd>
            <ZIPCd>70126</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>339900</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LANDER COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>535 SOUTH HUMBOLDT STREET</AddressLine1Txt>
            <CityNm>BATTLE MOUNTAIN</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>898201988</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BATTLE MOUNTAIN GENERAL HOSPITAL HOSPITAL EQUIPMENT REVITALIZATION</GrantOrContributionPurposeTxt>
          <Amt>1035000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LINTON HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>111 ELM AVE WEST</AddressLine1Txt>
            <CityNm>LINTON</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58552</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LINTON HOSPITAL (ND) ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>76961</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LIVING WATER INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4001 GREENBRIAR DRIVE</AddressLine1Txt>
            <CityNm>STAFFORD</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77477</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING INTEGRATED WASH SERVICES</GrantOrContributionPurposeTxt>
          <Amt>2574349</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LUTHERAN CHARITY ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2422 20TH STREET SW</AddressLine1Txt>
            <CityNm>JAMESTOWN</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58401</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JAMESTOWN REGIONAL MEDICAL CENTER ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>693723</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MARY C WHEELER SCHOOL INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>216 HOPE STREET</AddressLine1Txt>
            <CityNm>PROVIDENCE</CityNm>
            <StateAbbreviationCd>RI</StateAbbreviationCd>
            <ZIPCd>02906</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>12500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING PROGRESS AND PROMOTING QUALITY T1D CARE FOR THE POOREST BILLION THROUGH THE GLOBAL PEN-PLUS PARTNERSHIP</GrantOrContributionPurposeTxt>
          <Amt>6753638</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REAL-TIME POST-OP TOUCHLESS, REMOTE MONITORING IN CROHNS DISEASE THE SAPPHIRE TRIAL</GrantOrContributionPurposeTxt>
          <Amt>2905515</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>U.S. PREVENTIVE TYPE 1 DIABETES COALITION</GrantOrContributionPurposeTxt>
          <Amt>543037</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALIDATION OF WIRELESS THERMAL AND MICROSCOPIC IMAGING TECHNOLOGY FOR QUANTIFYING INFLAMMATION AND FIBROSIS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1352242</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MICROBES, MOLECULES, AND CHEMISTRY DYSBIOSIS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1722621</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS INSTITUTE OF TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>77 MASSACHUSETTS AVENUE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02139</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPUTATIONAL MODELING TO IMPROVE GLUCOSE-RESPONSIVE GLUCAGON DESIGNS</GrantOrContributionPurposeTxt>
          <Amt>348553</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>151705</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>157469</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MILITARY SCIENCES MEDICAL TRAINING 2024-2026</GrantOrContributionPurposeTxt>
          <Amt>160940</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MCKENZIE COUNTY HEALTHCARE SYSTEMS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>709 4TH AVE NE</AddressLine1Txt>
            <CityNm>WATFORD CITY</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58854</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MCKENZIE HEALTH ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>46052</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MCKENZIE COUNTY HEALTHCARE SYSTEMS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>709 4TH AVE NE</AddressLine1Txt>
            <CityNm>WATFORD CITY</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58854</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MCKENZIE HEALTH ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>757493</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEDICAL UNIVERSITY OF SOUTH CAROLINA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>179 ASHLEY AVENUE</AddressLine1Txt>
            <CityNm>CHARLESTON</CityNm>
            <StateAbbreviationCd>SC</StateAbbreviationCd>
            <ZIPCd>29425</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>28108</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEDICINES FOR HUMANITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>800 HINGHAM STREET</AddressLine1Txt>
            <CityNm>ROCKLAND</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02370</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MAI MBELEKI II EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>322909</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MERCY HOSPITAL OF DEVILS LAKE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1031 7TH STREET NE</AddressLine1Txt>
            <CityNm>DEVILS LAKE</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58301</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHI ST. ALEXIUS HEALTH DEVILS LAKE ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>743309</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MERCY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1301 15TH AVENUE WEST</AddressLine1Txt>
            <CityNm>WILLISTON</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHI ST. ALEXIUS HEALTH WILLISTON ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>619183</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MICHIGAN STATE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>426 AUDITORIUM ROAD ROOM 2</AddressLine1Txt>
            <CityNm>EAST LANSING</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>488242601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A C-PEPTIDE COMPLEX FOR IMPROVED GLUCOSE METABOLISM IN PEOPLE WITH TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1215611</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MIDDLE EAST MEDIA AND RESEARCH INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 27837</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE INTERCONNECTED IRAN -RUSSIA-CHINA AXIS</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MILLE LACS HEALTH SYSTEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 ELM STREET NORTH</AddressLine1Txt>
            <CityNm>ONAMIA</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56359</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-PHARMACY AT MILLE LACS HEALTH SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>17020</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MINERAL COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 SOUTH A STREET</AddressLine1Txt>
            <CityNm>HAWTHORNE</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89415</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USDA COMMUNITY FACILITY DIRECT LOAN PROGRAM APPLICATION</GrantOrContributionPurposeTxt>
          <Amt>364679</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MINNESOTA RURAL HEALTH ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>27011 460TH AVE</AddressLine1Txt>
            <CityNm>HENNING</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56551</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL MINNESOTA</GrantOrContributionPurposeTxt>
          <Amt>318700</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MINNESOTA STATE COLLEGES AND UNIVERSITIES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>30 E 7TH STREET</AddressLine1Txt>
            <CityNm>ST PAUL</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING RURAL SONOGRAPHY EXPERTISE IN MINNESOTA</GrantOrContributionPurposeTxt>
          <Amt>217428</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MOUNTRAIL COUNTY MEDICAL CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 6TH ST SE</AddressLine1Txt>
            <CityNm>STANLEY</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58784</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORTH DAKOTA ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>238556</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL ASSOCIATION OF SCHOOL NURSES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 WAYNE AVE</AddressLine1Txt>
            <CityNm>SILVER SPRING</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>20910</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROVIDING COORDINATED CARE AND CAPTURING OUTCOMES FOR STUDENTS WITH T1D SCHOOL NURSE-LED PILOT PROJECT</GrantOrContributionPurposeTxt>
          <Amt>763279</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL COMMITTEE FOR QUALITY ASSURANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 13TH ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NCQA DIABETES RECOGNITION PROGRAM REFRESH &amp; DIABETES MEASURE DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>753478</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL COMMITTEE FOR QUALITY ASSURANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 13TH ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NCQA DIABETES RECOGNITION PROGRAM REFRESH &amp; DIABETES MEASURE DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>621487</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL MULTIPLE SCLEROSIS SOCIETY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATURAL AREAS CONSERVANCY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1234 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACTIVATING AND SUSTAINING NYC NATURE TRAIL NETWORK (PHASE 3)</GrantOrContributionPurposeTxt>
          <Amt>363328</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATURAL AREAS CONSERVANCY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1234 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING NYC'S URBAN FOREST PLAN NATURAL AREAS</GrantOrContributionPurposeTxt>
          <Amt>193132</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NCD ALLIANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>31-33 AVENUE GIUSEPPE MOTTA</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT - NCD ALLIANCE SUPPORTERS GROUP</GrantOrContributionPurposeTxt>
          <Amt>42500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NELSON COUNTY HEALTH SYSTEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 NORTH MAIN STREET</AddressLine1Txt>
            <CityNm>MCVILLE</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58254</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NELSON COUNTY HEALTH SYSTEM ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>153546</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4126 TECHNOLOGY WAY</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89706</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEVADA VIRTUAL CRISIS CARE</GrantOrContributionPurposeTxt>
          <Amt>1239092</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA HEALTH CENTERS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3325 RESEARCH WAY</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89706</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>QUALITY ULTRASOUND SERVICES AND TRAINING PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>14249</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA RURAL HOSPITAL PARTNERS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4600 KIETZKE LANE</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89502</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL NEVADA HOSPITALS</GrantOrContributionPurposeTxt>
          <Amt>27500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW DESTINY HOUSING CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>12 W 37TH STREET 7TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING AFTERCARE INTERVENTION TO IMPROVE HOUSING AND HEALTH STABILITY FOR FORMERLY HOMELESS DOMESTIC VIOLENCE SURVIVORS</GrantOrContributionPurposeTxt>
          <Amt>183350</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW VENTURE FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1828 L STREET NW SUITE 300-A</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES CAMPS PROJECT (2025-2028)</GrantOrContributionPurposeTxt>
          <Amt>1889319</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW VENTURE FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1828 L STREET NW SUITE 300-A</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES CAMPS PROJECT (2025-2028)</GrantOrContributionPurposeTxt>
          <Amt>374930</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK CITY BALLET INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>20 LINCOLN CENTER PLAZA</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10023</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>15000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK CITY HEALTH AND HOSPITALS CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>50 WATER STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPRESSCARE TELE-BEHAVIORAL HEALTH SERVICE LAUNCH AND TAILORED SERVICE STRATEGIES FOR HIGH NEEDS PATIENTS IN NYC</GrantOrContributionPurposeTxt>
          <Amt>614668</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK CITY HEALTH AND HOSPITALS CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>50 WATER STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROJECT ASAP BUILDING CAPACITY FOR SUPPORTIVE HOUSING FACILITATION AND BRIDGE CARE IN NYC'S PUBLIC HOSPITALS</GrantOrContributionPurposeTxt>
          <Amt>777607</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK JUNIOR TENNIS LEAGUE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>36-36 33RD STREET</AddressLine1Txt>
            <CityNm>ASTORIA</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11106</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK RESTORATION PROJECT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>254 WEST 31ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC URBAN REFORESTATION &amp; EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>193536</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>665 BROADWAY SUITE 801</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH</GrantOrContributionPurposeTxt>
          <Amt>2756847</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NORTH DAKOTA STATE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1301 12TH AVENUE N</AddressLine1Txt>
            <CityNm>FARGO</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING RURAL SONOGRAPHY EXPERTISE IN NORTH DAKOTA</GrantOrContributionPurposeTxt>
          <Amt>99500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NORTHERN WESTCHESTER HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 EAST MAIN STREET</AddressLine1Txt>
            <CityNm>MOUNT KISCO</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10549</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY DEPARTMENT RAPID ACCESS EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>400000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NORTHWOOD DEACONESS HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4 N PARK ST</AddressLine1Txt>
            <CityNm>NORTHWOOD</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58267</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORTHWOOD DEACONESS HEALTH CENTER (ND) ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>95182</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NURU INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2020 PENNSYLVANIA AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>20006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF AGRIBUSINESS</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OAKLAND UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2200 NORTH SQUIRREL ROAD</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48309</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2)</GrantOrContributionPurposeTxt>
          <Amt>1129765</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OREGON HEALTH &amp; SCIENCE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3181 SW SAM JACKSON PARK ROAD</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>972393098</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DISSEMINATION PILOT THE IMPLEMENTATION OF NOVEL INTERVENTIONS IN CHILDREN'S HEALTHCARE (NICH) IN ANOTHER HEALTHCARE SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>41318</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OREGON HEALTH &amp; SCIENCE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3181 SW SAM JACKSON PARK ROAD</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>972393098</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN MDI DECISION SUPPORT SYSTEM WITH CDCES AND BEHAVIORAL HEALTH SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1795816</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>P R HEALTH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>115 VIVIAN ST</AddressLine1Txt>
            <CityNm>PARK RIVER</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58270</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FIRST CARE HEALTH CENTER ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>93347</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PALO ALTO VETERANS INSTITUTE FOR RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3801 MIRANDA AVENUE</AddressLine1Txt>
            <CityNm>PALO ALTO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>943040038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>318978</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PANORAMA GLOBAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2101 FOURTH AVENUE SUITE 2100</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T1D COMMUNITY FUND STAGE II</GrantOrContributionPurposeTxt>
          <Amt>1469142</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PAPAHANAUMOKUAKEA MARINE DEBRIS PROJECT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>905 KALANIANAOLE HWY</AddressLine1Txt>
            <CityNm>KAILUA</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96734</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PAPAHANAUMOKUAKEA MARINE DEBRIS PROJECT CAPACITY-BUILDING</GrantOrContributionPurposeTxt>
          <Amt>256540</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PATH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>437 N 34TH STREET</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98103</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DIABETES CAREPAK PROJECT ENABLING HIGH-QUALITY DIABETES SELF-CARE</GrantOrContributionPurposeTxt>
          <Amt>871123</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PEMBINA COUNTY MEMORIAL HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>301 MOUNTAIN STREET EAST</AddressLine1Txt>
            <CityNm>CAVALIER</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58220</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORTH DAKOTA ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>312733</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PENNINGTON COUNTY HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>321 KANSAS CITY STREET</AddressLine1Txt>
            <CityNm>RAPID CITY</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PENNINGTON COUNTY CRISIS STABILIZATION UNIT</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PETALS 4 PAWS LLC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 112360</AddressLine1Txt>
            <CityNm>STAMFORD</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06911</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>7500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PHILANTHROPY NEW YORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>320 EAST 43RD STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR 2025 MEMBERSHIP</GrantOrContributionPurposeTxt>
          <Amt>63750</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PHILANTHROPY NEW YORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>320 EAST 43RD STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>39250</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PHILLIPS COUNTY HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>311 S 8TH AVENUE EAST</AddressLine1Txt>
            <CityNm>MALTA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59538</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY AND TELE-PHARMACY AT PHILLIPS COUNTY</GrantOrContributionPurposeTxt>
          <Amt>25448</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PIONEER MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>301 WEST 7TH AVE</AddressLine1Txt>
            <CityNm>BIG TIMBER</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59011</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-PHARMACY AT PIONEER MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>9988</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PRESENTATION MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>213 2ND AVE NE</AddressLine1Txt>
            <CityNm>ROLLA</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58367</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ST. KATERI ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>68957</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PROJECT CONCERN ZAMBIA LIMITED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLOT 37/1P</AddressLine1Txt>
            <CityNm>LUSAKA</CityNm>
            <CountryCd>ZA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMPOWERED CHILDREN AND ADOLESCENTS PROGRAM PLUS</GrantOrContributionPurposeTxt>
          <Amt>1004026</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PULITZER CENTER ON CRISIS REPORTING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1779 MASSACHUSETTS AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INSIGHT AND CONNECTION THROUGH JOURNALISM AND EDUCATION</GrantOrContributionPurposeTxt>
          <Amt>393053</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RAMBAM HEALTH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HAALIA HASNIA 8</AddressLine1Txt>
            <CityNm>HAIFA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANGIOGRAPHY SYSTEM FOR THE INTERVENTIONAL RADIOLOGY UNIT OF RAMBAM MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>1365000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REACH LITERACY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2101 W 41ST ST</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR SIOUX FALLS VOLUNTEER DAY</GrantOrContributionPurposeTxt>
          <Amt>15000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REACHANOTHER FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1900 NE 3RD ST STE 106-307</AddressLine1Txt>
            <CityNm>BEND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>97701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>346974</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REACHANOTHER FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1900 NE 3RD ST STE 106-307</AddressLine1Txt>
            <CityNm>BEND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>97701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>952406</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REACHANOTHER FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1900 NE 3RD ST STE 106-307</AddressLine1Txt>
            <CityNm>BEND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>97701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMING PEDIATRIC NEUROSURGERY SERVICES</GrantOrContributionPurposeTxt>
          <Amt>1441299</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MICHIGAN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>92033</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MICHIGAN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>92033</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MICHIGAN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS</GrantOrContributionPurposeTxt>
          <Amt>226169</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 OAK STREET SE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUING DEVELOPMENT OF OXYGEN SUPER-SATURATED SALINE FOR DEPLOYMENT IN MEDICAL EMERGENCIES</GrantOrContributionPurposeTxt>
          <Amt>273689</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 OAK STREET SE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES (PHASE 3)</GrantOrContributionPurposeTxt>
          <Amt>502750</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 OAK STREET SE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MINNESOTA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1296918</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF UNIVERSITY OF CALIFORNIA BERKELEY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>190 DOE</AddressLine1Txt>
            <CityNm>BERKELEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94720</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPING MICROBIOME EDITING TOOLS TO ADVANCE UNDERSTANDING OF THE MICROBIAL INFLUENCE ON CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1054179</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGION HOVEDSTADEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>KONGENS VAENGE 2</AddressLine1Txt>
            <CityNm>HILLEROD</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAN MICROCHIMERISM EXPLAIN DIFFERENCES IN PARENTAL TYPE 1 DIABETES CONFERRED RISK OF OFFSPRING TYPE 1 DIABETES?</GrantOrContributionPurposeTxt>
          <Amt>375228</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RENOWN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1155 MILL ST</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89502</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RENOWN HEALTH TO BRING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) TO NORTHERN NEVADA</GrantOrContributionPurposeTxt>
          <Amt>1091987</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RESEARCH TRIANGLE INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3040 EAST CORNWALLIS ROAD</AddressLine1Txt>
            <CityNm>DURHAM</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>277092194</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USING GENOME SEQUENCING AND GENETIC RISK SCORES TO IDENTIFY NEWBORNS WITH SERIOUS HEALTH CONDITIONS A STATEWIDE IMPLEMENTATION STUDY</GrantOrContributionPurposeTxt>
          <Amt>1110288</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RIVER'S EDGE HOSPITAL AND CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1900 N SUNRISE DRIVE</AddressLine1Txt>
            <CityNm>ST PETER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56082</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES FOR RIVER'S EDGE HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>17567</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAFE WATER NETWORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>122 EAST 42ND STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10168</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING SUSTAINABLE SAFE WATER ACCESS</GrantOrContributionPurposeTxt>
          <Amt>2064000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAGE BIONETWORKS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2901 THIRD AVE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981213014</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXTENSION OF VEOIBD DATA COORDINATION TO ACCELERATE DISCOVERY OF PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>75165</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAINT LOUIS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>221 NORTH GRAND BOULEVARD</AddressLine1Txt>
            <CityNm>SAINT LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>63103</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFY AND VALIDATE POTENTIAL THERAPEUTIC TARGETS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>608523</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SANFORD RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1305 W 18TH ST</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>571040569</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PLEDGE PHASE 3</GrantOrContributionPurposeTxt>
          <Amt>528559</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SANFORD WORLD CLINICS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1305 W 18TH ST</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROGRAM DETEKTA DETECTING TYPE 1 DIABETES AND PREVENTING DIABETIC KETOACIDOSIS (DKA)</GrantOrContributionPurposeTxt>
          <Amt>59605</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAPIR ACADEMIC COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>POST HOF ASHKELON 7915600</AddressLine1Txt>
            <CityNm>GEVIM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PLANNING FOR SAPIR ACADEMIC COLLEGE LAW SCHOOL BUILDING</GrantOrContributionPurposeTxt>
          <Amt>303000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAVE A LAB RESCUE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>165 ELLERY AVE</AddressLine1Txt>
            <CityNm>MIDDLETOWN</CityNm>
            <StateAbbreviationCd>RI</StateAbbreviationCd>
            <ZIPCd>02842</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SEATTLE CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 5731 M/S S-200</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981455005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING USE OF ENGINEERED TREGS IN T1D THERAPY (PHASE 4)</GrantOrContributionPurposeTxt>
          <Amt>609141</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM COMBINING MULTI-TIER ADMINISTRATIVE DATA FOR FACILITATING DISEASE FREE MANAGEMENT</GrantOrContributionPurposeTxt>
          <Amt>989083</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF THE HELMSLEY COMPREHENSIVE CARDIAC CARE CENTER</GrantOrContributionPurposeTxt>
          <Amt>2500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF THE HELMSLEY SURGICAL WING</GrantOrContributionPurposeTxt>
          <Amt>2500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHARE TRUST INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>310 DEDHAM ST</AddressLine1Txt>
            <CityNm>DOVER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING COMMUNITY DRIVEN COLLECTIVE ACTION</GrantOrContributionPurposeTxt>
          <Amt>1540658</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHATTERPROOF A NONPROFIT CORP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 MERRITT 7 CORPORATE PARK 1ST</AddressLine1Txt>
            <AddressLine2Txt>FLOOR</AddressLine2Txt>
            <CityNm>NORWALK</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06851</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIMULATION IN MOTION MONTANA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2021 11TH AVE SUITE 1</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIMULATION IN MOTION MONTANA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2021 11TH AVE SUITE 1</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SNV NETHERLANDS DEVELOPMENT ORGANISATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PARKSTRAAT 83</AddressLine1Txt>
            <CityNm>DEN HAAG</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING THE HEALTHY FUTURE FOR ALL MODEL</GrantOrContributionPurposeTxt>
          <Amt>1246508</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOCIAL SCIENCE RESEARCH COUNCIL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE PIERREPONT PLAZA 15TH FLOOR</AddressLine1Txt>
            <CityNm>BROOKLYN</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA2GO.NYC REVAMP AND DATA CLINIC</GrantOrContributionPurposeTxt>
          <Amt>336025</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOCIETY FOR MUCOSAL IMMUNOLOGY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>N83 W13410 LEON ROAD</AddressLine1Txt>
            <CityNm>MENOMONEE FALLS</CityNm>
            <StateAbbreviationCd>WI</StateAbbreviationCd>
            <ZIPCd>53051</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>21ST INTERNATIONAL CONGRESS OF MUCOSAL IMMUNOLOGY (ICMI 2024)</GrantOrContributionPurposeTxt>
          <Amt>15000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOCIETY FOR THE PRESERVATION OF NEW ENGLAND ANTIQUITIES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>151 ESSEX STREET</AddressLine1Txt>
            <CityNm>HAVERHILL</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01832</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOLIDARIDAD NETWORK FOUNDATION LIMITED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>163 KUDU ROAD</AddressLine1Txt>
            <CityNm>LUSAKA</CityNm>
            <CountryCd>ZA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOOVES FOR SUSTAINABILITY (H4S)</GrantOrContributionPurposeTxt>
          <Amt>468562</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTH LINCOLN HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>711 ONYX ST</AddressLine1Txt>
            <CityNm>KEMMERER</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>83101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY AT SOUTH LINCOLN MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>10791</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTHCENTRAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4501 DIPLOMACY DR</AddressLine1Txt>
            <CityNm>ANCHORAGE</CityNm>
            <StateAbbreviationCd>AK</StateAbbreviationCd>
            <ZIPCd>99508</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>818171</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTHWEST HEALTHCARE CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>802 SECOND STREET NW</AddressLine1Txt>
            <CityNm>BOWMAN</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58623</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORTH DAKOTA ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>225517</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ALOISIUS HOSPITAL INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>325 BREWSTER STREET EAST</AddressLine1Txt>
            <CityNm>HARVEY</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58341</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SMP HEALTH - ST. ALOISIUS ULTRASOUND PROJECT</GrantOrContributionPurposeTxt>
          <Amt>256572</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST LUKE HEALTH CARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>28W609 HICKORY LN</AddressLine1Txt>
            <CityNm>WEST CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60185</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOPE CENTER FOR WOMEN AND CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>3293350</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST LUKE'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>702 1ST ST SW</AddressLine1Txt>
            <CityNm>CROSBY</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58730</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ST. LUKE'S MEDICAL CENTER ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>74770</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ALEXIUS MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>900 EAST BROADWAY AVE</AddressLine1Txt>
            <CityNm>BISMARCK</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58501</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHI ST. ALEXIUS HEALTH ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>3799563</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ANDREW'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>316 OHMER STREET</AddressLine1Txt>
            <CityNm>BOTTINEAU</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58318</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ST. ANDREW'S HOSPITAL ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>74293</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST JOSEPHS HOSPITAL AND HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2500 FAIRWAY ST</AddressLine1Txt>
            <CityNm>DICKINSON</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHI ST. ALEXIUS HEALTH DICKINSON ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>632439</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST MARK'S HOSPITAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>ACTON LANE</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT FOR THE ONGOING DEVELOPMENT OF THE TOPCLASS PERIANAL CD CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>254998</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST MARK'S HOSPITAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>ACTON LANE</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLOBAL PERIANAL CROHN'S DISEASE PRIORITY SETTING PARTNERSHIP</GrantOrContributionPurposeTxt>
          <Amt>24288</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ROSE DOMINICAN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>102 E LAKE MEAD PARKWAY</AddressLine1Txt>
            <CityNm>HENDERSON</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89015</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGNITY HEALTH - ST. ROSE DOMINICAN - SIENA CAMPUS ECMO PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>124981</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>9 PRINCES ST</AddressLine1Txt>
            <CityNm>MELBOURNE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WHICH CHECKPOINTS MAINTAIN IMMUNE TOLERANCE TO BETA-CELLS IN GENETICALLY AT-RISK PEOPLE WHO DONT HAVE T1D?</GrantOrContributionPurposeTxt>
          <Amt>298224</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STATE OF NEVADA DEPARTMENT OF DIVISION OF STATE PARKS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>901 S STEWART ST SUITE 5005</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALLEY OF FIRE VISITOR CENTER</GrantOrContributionPurposeTxt>
          <Amt>3500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STATE UNIVERSITY OF IOWA FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE WEST PARK ROAD</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52242</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION-IOWA ENDOWMENT</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING ACCESS TO MEDICINE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NARITAWEG 227 SUITE A</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ACCESS TO DIABETES CARE</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING HEALTH ACTION INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OVERTOOM 60</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV</GrantOrContributionPurposeTxt>
          <Amt>1200977</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING PHARMACCESS INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AHTC TOWER C4 PAASHEUVELWEG 25</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SAFECARE A BUSINESS MODEL FOR HEALTHCARE QUALITY</GrantOrContributionPurposeTxt>
          <Amt>686565</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING THE OCEAN CLEANUP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BATAVIERENSTRAAT 15</AddressLine1Txt>
            <CityNm>ROTTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AND SCALE TECHNOLOGIES TO RID THE OCEANS OF PLASTICS</GrantOrContributionPurposeTxt>
          <Amt>5000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STIFTELSEN FOR UTBILDNING (IOIBD)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LINKPING UNIVERSITY HOSPITAL FLOOR</AddressLine1Txt>
            <AddressLine2Txt>14</AddressLine2Txt>
            <CityNm>OREBRO</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INVESTIGATIVE CAREERS IN IBD</GrantOrContributionPurposeTxt>
          <Amt>132000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SUPPORTIVE HOUSING NETWORK OF NEW YORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>247 W 37TH ST</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING ACADEMY AND COMMUNITY OF PRACTICE FOR SUPPORTIVE HOUSING PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>450000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SUSTAINABLE COASTLINES HAWAII</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3160 WAIALAE AVE</AddressLine1Txt>
            <CityNm>HONOLULU</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96816</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING SUSTAINABLE COASTLINES HAWAII BUILDING LEADERSHIP FOR LONG-TERM GROWTH AND IMPACT</GrantOrContributionPurposeTxt>
          <Amt>299213</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 FEDERAL STREET SUITE 440</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>1917417</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 FEDERAL STREET SUITE 440</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>650000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 FEDERAL STREET SUITE 440</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>2567417</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 FEDERAL STREET SUITE 440</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>633709</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TAMPERE UNIVERSITY FOUNDATION SR</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>KALEVANTIE 4 33100</AddressLine1Txt>
            <CityNm>TAMPERE</CityNm>
            <CountryCd>FI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENTEROVIRUS-INDUCED TYPE 1 DIABETES MECHANISMS AND BIOMARKERS FOR RISK</GrantOrContributionPurposeTxt>
          <Amt>227066</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TECHNISCHE UNIVERSITAET MUENCHEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>ARCISSTRABE 21</AddressLine1Txt>
            <CityNm>MUNCHEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COST-EFFECTIVENESS OF PUBLIC HEALTH SCREENING FOR PRE-SYMPTOMATIC TYPE 1 DIABETES WITH AND WITHOUT TREATMENT FOR PREVENTION OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>151947</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WEIZMANN ST 6</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IBD GENETICS RESEARCH ROLE OF PROTEASE-ACTIVATED RECEPTOR 2 (PAR2) IN INFLAMMATORY GASTROINTESTINAL DISORDERS</GrantOrContributionPurposeTxt>
          <Amt>268340</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WEIZMANN ST 6</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONSTRUCTION OF THE SHELTERED -5 FLOOR OF THE NORTH TOWER</GrantOrContributionPurposeTxt>
          <Amt>4879510</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ACADEMIC COLLEGE AT TEL-HAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL-HAI COLLEGE</AddressLine1Txt>
            <CityNm>UPPER GALILEE</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY RESEARCH AND INNOVATION WING IN THE TEL-HAI COMPUTER SCIENCE BUILDING.</GrantOrContributionPurposeTxt>
          <Amt>2600000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ACADEMIC COLLEGE AT TEL-HAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL-HAI COLLEGE</AddressLine1Txt>
            <CityNm>UPPER GALILEE</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY FELLOWSHIPS FOR SUSTAINABILITY AND HEALTH</GrantOrContributionPurposeTxt>
          <Amt>1517781</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ASSOCIATION FOR THE BETTERMENT OF ESHKOL REGION RESIDENTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>ESHKOL REGIONAL COUNCIL</AddressLine1Txt>
            <CityNm>KIBBUTZ MAGEN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BE'ERI AGRICULTURAL EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>2203283</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2012100 HALUTZ</AddressLine1Txt>
            <CityNm>RAMAT HANEGEV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RAMAT HANEGEV SENIOR CITIZEN CENTER</GrantOrContributionPurposeTxt>
          <Amt>2241803</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2012100 HALUTZ</AddressLine1Txt>
            <CityNm>RAMAT HANEGEV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RAMAT HANEGEV CENTRAL AUDITORIUM</GrantOrContributionPurposeTxt>
          <Amt>843988</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BINYAMIN FUND INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>445 CENTRAL AVENUE</AddressLine1Txt>
            <CityNm>CEDARHURST</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11516</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY GENERATORS FOR COMMUNITIES IN THE BINYAMIN REGIONAL COUNCIL</GrantOrContributionPurposeTxt>
          <Amt>350000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BIONICS INSTITUTE OF AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>384-388 ALBERT STREET</AddressLine1Txt>
            <CityNm>EAST MELBOURNE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PATIENT-SPECIFIC ADAPTIVE, ELECTRIC THERAPY FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1779261</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNCOVERING CROHN'S GENETIC RISK IN AFRICAN-AMERICAN AND HISPANIC/LATINO POPULATIONS</GrantOrContributionPurposeTxt>
          <Amt>971014</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>3497605</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CENTER FOR EFFECTIVE PHILANTHROPY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>675 MASSACHUSETTS AVENUE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02139</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR 2024</GrantOrContributionPurposeTxt>
          <Amt>54780</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TRINITY LANE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DOES THE WESTERN DIET TRIGGER CROHN'S DISEASE VIA OSMOTIC STRESS?</GrantOrContributionPurposeTxt>
          <Amt>808734</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TRINITY LANE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW INSIGHTS INTO CROHN'S DISEASE FROM STUDYING NAKED MOLE RATS</GrantOrContributionPurposeTxt>
          <Amt>1510641</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY CHARITABLE TRUST GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CD318 MEDIATED REGULATION OF ISLET AUTOANTIGEN SPECIFIC T CELL IMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>368500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENETIC PROTECTION BY HLA-DQ6 IN T1D</GrantOrContributionPurposeTxt>
          <Amt>235681</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>1321210</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE MILESTONE INITIATIVE EDUCATION INNOVATION FOR ADVANCED IBD FELLOWS IN THE USA</GrantOrContributionPurposeTxt>
          <Amt>236313</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MECHANOBIOLOGY OF THE INTESTINAL EPITHELIAL BARRIER DISRUPTION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>387615</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>869476</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE COMMUNICATIONS NETWORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1717 NORTH NAPER BLVD</AddressLine1Txt>
            <CityNm>NAPERVILLE</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60563</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR 2025-27 MEMBERSHIP</GrantOrContributionPurposeTxt>
          <Amt>30000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE END FUND INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10016</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TACKLING TRACHOMA SURGERY DISPARITIES</GrantOrContributionPurposeTxt>
          <Amt>2117400</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD</GrantOrContributionPurposeTxt>
          <Amt>137417</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD</GrantOrContributionPurposeTxt>
          <Amt>127077</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A DRUG-WIDE SCAN TO IDENTIFY REPURPOSED MEDICATIONS FOR CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>394365</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HOLE IN THE WALL GANG FUND INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>555 LONG WHARF DRIVE</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06511</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HOSPITAL FOR SICK CHILDREN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>555 UNIVERSITY AVE</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO STUDIES</GrantOrContributionPurposeTxt>
          <Amt>555480</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HOSPITAL FOR SICK CHILDREN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>555 UNIVERSITY AVE</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNE RESPONSES TO GUT MICROBES ASSOCIATED WITH T1D RISK AND PROGRESSION</GrantOrContributionPurposeTxt>
          <Amt>248621</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>EXHIBITION RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION</GrantOrContributionPurposeTxt>
          <Amt>156358</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>EXHIBITION RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNRAVELING THE IMMUNOPATHOLOGY OF PERIANAL FISTULIZING CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1032574</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE JEWISH AGENCY FOR ISRAEL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>48 KING GEORGE STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BAYIT PROJECT, COMMUNAL MULTI-FAMILY SHELTERS AT THE SHOSHANA ABSORPTION CENTER IN KIRYAT GAT</GrantOrContributionPurposeTxt>
          <Amt>750000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE JEWISH AGENCY FOR ISRAEL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>48 KING GEORGE STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE SECURITY FUND SECURING AND SAFEGUARDING JEWISH COMMUNITIES WORLDWIDE</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>YEZREEL VALLEY</AddressLine1Txt>
            <CityNm>YEZREEL VALLEY</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>OPPORTUNITY FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS PURSUING NURSING DEGREES</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>YEZREEL VALLEY</AddressLine1Txt>
            <CityNm>YEZREEL VALLEY</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NURSING SIMULATION CENTER UPGRADES</GrantOrContributionPurposeTxt>
          <Amt>751269</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE MILKEN INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1250 FOURTH STREET</AddressLine1Txt>
            <CityNm>SANTA MONICA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90401</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FASTERCURES LEADERSLINK PROGRAM EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE NATURE CONSERVANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4245 NORTH FAIRFAX DRIVE SUITE 100</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FUTURE FOREST NYC PHASE III</GrantOrContributionPurposeTxt>
          <Amt>347804</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE QUEENS MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1301 PUNCHBOWL ST</AddressLine1Txt>
            <CityNm>HONOLULU</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96813</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE QUEENS MEDICAL CENTER &amp; CLARENCE T.C. CHING ECMO PROGRAM EXCELLENCE AND VIABILITY APPRAISAL</GrantOrContributionPurposeTxt>
          <Amt>1635796</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE QUEENS MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1301 PUNCHBOWL ST</AddressLine1Txt>
            <CityNm>HONOLULU</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96813</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE QUEEN'S MEDICAL CENTER - WEST OAHU CANCER CENTER EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>5000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 400195</AddressLine1Txt>
            <CityNm>CHARLOTTESVILLE</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>229044195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RISK PREDICTION INTEGRATION OF PHYSIOLOGY WITH GENETICS</GrantOrContributionPurposeTxt>
          <Amt>115896</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>120 THEORY SUITE 200</AddressLine1Txt>
            <CityNm>IRVINE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>926971050</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A MULTI-ANALYTE SENSOR - GLUCOSE, LACTATE, OXYGEN, KETONES, INSULIN FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1108867</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10889 WILSHIRE BLVD SUITE 700</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>900951406</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE RESPONSIVE GLUCAGON (GRG) FOR THE REDUCTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>439378</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10889 WILSHIRE BLVD SUITE 700</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>900951406</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE RESPONSIVE GLUCAGON (GRG) FOR THE REDUCTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>128649</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 GILMAN DRIVE</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92093</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DRUGGABLE GPCROME IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1091471</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)</GrantOrContributionPurposeTxt>
          <Amt>269368</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)</GrantOrContributionPurposeTxt>
          <Amt>269368</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SANTA BARBARA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UC SANTA BARBARA</AddressLine1Txt>
            <CityNm>SANTA BARBARA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>93106</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE SPECIFIC AID ALGORITHM FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1027327</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPITHELIAL MITOCHONDRIAL DYSFUNCTION AND EXTRACELLULAR VESICLES IN CROHNS DISEASE FIBROSTENOSIS.</GrantOrContributionPurposeTxt>
          <Amt>457178</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREPARE 4 AID PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY</GrantOrContributionPurposeTxt>
          <Amt>269500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE)</GrantOrContributionPurposeTxt>
          <Amt>315557</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING HUMAN ISLET MYELOID CELL POPULATIONS THROUGH PROGRESSION OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>291029</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEEDS PATHWAY SHARED EMPOWERMENT FOR EARLY DEVICE SUCCESS OF DIABETES TECHNOLOGY</GrantOrContributionPurposeTxt>
          <Amt>686820</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEEDS PATHWAY SHARED EMPOWERMENT FOR EARLY DEVICE SUCCESS OF DIABETES TECHNOLOGY</GrantOrContributionPurposeTxt>
          <Amt>598309</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPIGENOMIC BIOMARKERS OF THE INCOMPLETE MATERNAL PROTECTION IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>150914</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MAPPING THE B CELL HETEROGENEITY IN TYPE 1 DIABETES AT THE SINGLE-CELL LEVEL</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPLEMENT SYSTEM IN THE INITIATION AND PROGRESSION OF ISLET AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>124200</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T AND B CELL RECEPTOR ATLAS ACROSS TISSUES AND STAGES OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>501000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D</GrantOrContributionPurposeTxt>
          <Amt>200584</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM IN PRIMARY CARE - REFER OR LEARN IMPLEMENTATION AND EVALUATION</GrantOrContributionPurposeTxt>
          <Amt>332512</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)</GrantOrContributionPurposeTxt>
          <Amt>935698</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>513331</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ASK THE EXPERTS 2024</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNINGMCGILL UNIV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>845 SHERBROOKE STREET WEST</AddressLine1Txt>
            <CityNm>MONTREAL</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA GOVERNANCE RESOURCE</GrantOrContributionPurposeTxt>
          <Amt>190336</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2 KATZIR</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM CAPSULE &amp; OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)</GrantOrContributionPurposeTxt>
          <Amt>756699</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2 KATZIR</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE UTILITY OF HAND-HELD ULTRASOUND DEVICES TO DETECT BOWEL WALL INFLAMMATORY ACTIVITY IN CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>118210</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SONIA NABETA FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4705 5TH STREET UNIT 405</AddressLine1Txt>
            <CityNm>LONG ISLAND CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WORLD OF WARRIORS</GrantOrContributionPurposeTxt>
          <Amt>482110</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE STATE UNIVERSITY COLLEGE AT ONEONTA FOUNDATION CORPORATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>108 RAVINE PARKWAY</AddressLine1Txt>
            <CityNm>ONEONTA</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>13820</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TEL AVIV JAFFA ACADEMIC COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RABENU YERUHAM ST 2 POB 8401</AddressLine1Txt>
            <CityNm>TEL AVIV YAFFO</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEED-BASED SCHOLARSHIPS FOR NURSING STUDENTS</GrantOrContributionPurposeTxt>
          <Amt>266667</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TREVOR PROJECT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 69232</AddressLine1Txt>
            <CityNm>WEST HOLLYWOOD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90069</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LGBTQ YOUTH SUICIDE PREVENTION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>2081072</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADDING HEALTH QUESTIONS TO THE POVERTY TRACKER TO SURVEY THE HEALTHCARE NEEDS AND UTILIZATION PREFERENCES OF LOW-INCOME NEW YORKERS</GrantOrContributionPurposeTxt>
          <Amt>146689</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>413263</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>429646</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT FOR T1D TRANSITION PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF ADELAIDE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTH TERRACE</AddressLine1Txt>
            <CityNm>ADELAIDE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PANCREATIC EXOCRINE FUNCTION AND THE PROGRESSION TO TYPE 1 DIABETES IN YOUNG CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>55260</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5801 SOUTH ELLIS AVENUE</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60637</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT AND DISSEMINATION OF AN IBD MONITORING AND PREVENTION PROGRAM WITH A FOCUS ON INTESTINAL ULTRASOUND</GrantOrContributionPurposeTxt>
          <Amt>333042</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>SOUTH BRIDGE</AddressLine1Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING A CROSS-DISCIPLINE SCIENTIFIC APPROACH TOWARDS UNDERSTANDING CROHNS DISEASE - LEVERAGING UK HELMSLEY STUDIES</GrantOrContributionPurposeTxt>
          <Amt>47977</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>SOUTH BRIDGE</AddressLine1Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION IN CROHNS DISEASE (MUSIC)</GrantOrContributionPurposeTxt>
          <Amt>682311</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>SOUTH BRIDGE</AddressLine1Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>209222</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF QUEENSLAND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CUMBRAE STEWART BUILDING 72</AddressLine1Txt>
            <CityNm>BRISBANE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GUT MICROBIAL METABOLITES DURING EARLY-LIFE DEVELOPMENT AS PREDICTORS OF ISLET AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>69271</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF WESTERN AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>35 STIRLING HIGHWAY</AddressLine1Txt>
            <CityNm>CRAWLEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM ASSESSMENTS OF ENDIA CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>35866</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY CHILDHOOD DEVELOPMENT AND COMMUNITY CENTER AT THE WEIZMANN INSTITUTE OF SCIENCE</GrantOrContributionPurposeTxt>
          <Amt>3000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TIOGA MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 159</AddressLine1Txt>
            <CityNm>TIOGA</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58852</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TIOGA MEDICAL CENTER ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>326201</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TOWNER COUNTY MEDICAL CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7448 US 281</AddressLine1Txt>
            <CityNm>CANDO</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58324</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TOWNER COUNTY MEDICAL CENTER ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>241563</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRICKLE UP PROGRAM INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>31 WEST 34TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRINITY HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>407 3RD STREET</AddressLine1Txt>
            <CityNm>MINOT</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRINITY HEALTH ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>3020087</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES AND FRIENDS OF AGRICULTURAL RESEARCH AT THE VOLCANI CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HA MACABIM 68 PO BOX 15159</AddressLine1Txt>
            <CityNm>RISHON LEZION</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROTECTING FARMERS AND AGRICULTURAL WORKERS ACROSS NORTHERN ISRAEL</GrantOrContributionPurposeTxt>
          <Amt>962990</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF INDIANA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>509 EAST 3RD STREET</AddressLine1Txt>
            <CityNm>BLOOMINGTON</CityNm>
            <StateAbbreviationCd>ID</StateAbbreviationCd>
            <ZIPCd>474013654</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING METABOLIC DRIVERS OF B CELL DIFFERENTIATION IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>58372</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF INDIANA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>509 EAST 3RD STREET</AddressLine1Txt>
            <CityNm>BLOOMINGTON</CityNm>
            <StateAbbreviationCd>ID</StateAbbreviationCd>
            <ZIPCd>474013654</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE FINDING IMMUNE NASCENT DIABETES (FIND-T1D)</GrantOrContributionPurposeTxt>
          <Amt>160875</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3451 WALNUT STREET</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191046205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERING CAR REGULATORY T CELLS TO PROVIDE DURABLE TOLERANCE TO ALLOGENIC ISLET TRANSPLANTS</GrantOrContributionPurposeTxt>
          <Amt>407000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TZAFON MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DOV HOZ 0</AddressLine1Txt>
            <CityNm>TIBERIAS</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SECURING TZAFON MEDICAL CENTER'S ELECTRICAL CONNECTION TO ISRAEL'S POWER GRID</GrantOrContributionPurposeTxt>
          <Amt>895000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TZAFON MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DOV HOZ 0</AddressLine1Txt>
            <CityNm>TIBERIAS</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SHELTERED HOSPITALIZATION AREA</GrantOrContributionPurposeTxt>
          <Amt>340000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED JEWISH APPEAL FEDERATION OF JEWISH PHILANTHROPIES OF NY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>130 EAST 59TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10022</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT.</GrantOrContributionPurposeTxt>
          <Amt>18000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED JEWISH APPEAL FEDERATION OF JEWISH PHILANTHROPIES OF NY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>130 EAST 59TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10022</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED STATES FUND FOR UNICEF</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 MAIDEN LANE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>869232</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE CATHOLIQUE DE LOUVAIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLACE DE L UNIVERSITE 1</AddressLine1Txt>
            <CityNm>LOUVAINLANEUVE</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LONGITUDINAL STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN AND ADOLESCENTS WITH NEW-ONSET TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>62567</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE DE GENEVE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RUE MICHEL SERVET 1</AddressLine1Txt>
            <CityNm>GENEVE</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL TESTING OF S100A9 TO IMPROVE GLYCEMIC CONTROL IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1112238</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE LIBRE DE BRUXELLES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE FRANKLIN ROOSEVELT 50</AddressLine1Txt>
            <CityNm>BRUSSELS</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDYING THE SELECTIVE B CELL SENSITIVITY TO A HOMOZYGOUS PD-L1 MUTATION IN NEONATAL DIABETES</GrantOrContributionPurposeTxt>
          <Amt>213278</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE LIBRE DE BRUXELLES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE FRANKLIN ROOSEVELT 50</AddressLine1Txt>
            <CityNm>BRUSSELS</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERATION OF NEW ANTI- FXYD2A PROBES AND PRECLINICAL VALIDATION FOR HUMAN BETA CELL IMAGING</GrantOrContributionPurposeTxt>
          <Amt>213602</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P C</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1001 MAIN STREET</AddressLine1Txt>
            <CityNm>BUFFALO</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>14203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FINANCIAL VIABILITY OF TELEHEALTH SERVICES FOR UNDERSERVED T1D PEDIATRIC POPULATIONS</GrantOrContributionPurposeTxt>
          <Amt>419662</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P C</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1001 MAIN STREET</AddressLine1Txt>
            <CityNm>BUFFALO</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>14203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FINANCIAL VIABILITY OF TELEHEALTH SERVICES FOR UNDERSERVED T1D PEDIATRIC POPULATIONS</GrantOrContributionPurposeTxt>
          <Amt>118038</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY HOSPITALS HEALTH SYSTEM INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>11100 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44106</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS</GrantOrContributionPurposeTxt>
          <Amt>866199</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1800 W CHARLESTON BLVD</AddressLine1Txt>
            <CityNm>LAS VEGAS</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF AN EXTRACORPOREAL LIFE SUPPORT (ECLS) PROGRAM AT UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA</GrantOrContributionPurposeTxt>
          <Amt>387094</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF BIRMINGHAM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CHANCELLORS COURT</AddressLine1Txt>
            <CityNm>BIRMINGHAM</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR TYPE 1 DIABETES AN EXPERIMENTAL MEDICINE STUDY</GrantOrContributionPurposeTxt>
          <Amt>152801</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF BRISTOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TYNDALL AVENUE</AddressLine1Txt>
            <CityNm>BRISTOL</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RISK IN ADULTS (T1DRA) A GENERAL POPULATION STUDY</GrantOrContributionPurposeTxt>
          <Amt>431779</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CINCINNATI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>51 GOODMAN DRIVE SUITE 500</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45221</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDIES ON THE ROLE OF C-PEPTIDE TO REGULATE BLOOD GLUCOSE DURING SLEEP AND EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>416500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF DUNDEE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NETHERGATE</AddressLine1Txt>
            <CityNm>DUNDEE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HYPO-RESOLVE - UNDERSTANDING ORGAN SPECIFIC CONSEQUENCES OF HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>133804</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADVANCING B-CELL SPECIFIC THERAPY BY IDENTIFYING B-CELL REACTIVE HIGH AFFINITY T CELL RECEPTORS</GrantOrContributionPurposeTxt>
          <Amt>55571</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXTREMELY EARLY ONSET TYPE 1 DIABETES (EXE T1D) PHASE 2 FROM OBSERVATION TO MECHANISM</GrantOrContributionPurposeTxt>
          <Amt>206160</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STIMULATED GLUCAGON LEVELS AS A BIOMARKER OF HYPOGLYCEMIA RISK IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>95777</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>B CELL SIGNATURES IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>247813</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING T1D AND INSULIN-REQUIRING DIABETES IN FEDERALLY QUALIFIED HEALTH CENTERS (FQHC) A NATIONAL NEEDS ASSESSMENT</GrantOrContributionPurposeTxt>
          <Amt>548565</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERATING AUTOANTIGEN-SPECIFIC ANTIBODY-PRODUCING HYBRIDOMAS AS A RENEWABLE SOURCE OF ISLET AUTOANTIBODIES</GrantOrContributionPurposeTxt>
          <Amt>36272</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERATING AUTOANTIGEN-SPECIFIC ANTIBODY-PRODUCING HYBRIDOMAS AS A RENEWABLE SOURCE OF ISLET AUTOANTIBODIES</GrantOrContributionPurposeTxt>
          <Amt>27771</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>213106</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF GLASGOW COURT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY AVENUE</AddressLine1Txt>
            <CityNm>GLASGOW</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNRAVELING THE ROLE OF THE GUT MICROBIOME IN POSTOPERATIVE OUTCOMES AND DISEASE RECURRENCE IN ADULTS WITH CD TREATED WITH EXCLUSIVE ENTERAL NUTRITION.</GrantOrContributionPurposeTxt>
          <Amt>367104</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF GLASGOW COURT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY AVENUE</AddressLine1Txt>
            <CityNm>GLASGOW</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATION THERAPY WITH BIOLOGICS AND PARTIAL ENTERAL NUTRITION IN ADULTS WITH ACTIVE ILEOCOLONIC CROHNS DISEASE THE BIOPIC STUDY</GrantOrContributionPurposeTxt>
          <Amt>176239</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF IOWA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>112 NORTH CAPITOL STREET</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52442</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORTING THE RUPRI HEALTH PANEL TO BRING RESEARCH AND EXPERTISE TO INFORM POLICY DEVELOPMENT AND IMPLEMENTATION</GrantOrContributionPurposeTxt>
          <Amt>199968</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF IOWA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>112 NORTH CAPITOL STREET</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52442</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION IOWA (SIM-IA)</GrantOrContributionPurposeTxt>
          <Amt>714411</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 LAKE AVENUE NORTH</AddressLine1Txt>
            <CityNm>WORCESTER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01655</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIETA ANTI-INFLAMATORIA A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS</GrantOrContributionPurposeTxt>
          <Amt>473409</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MELBOURNE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>161 BARRY STREET</AddressLine1Txt>
            <CityNm>CARLTON</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USE OF WHEY PROTEIN TO REDUCE RISK OF HYPOGLYCEMIA DURING EXERCISE FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>371201</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MIAMI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1320 SOUTH DIXIE HIGHWAY SUITE 650</AddressLine1Txt>
            <CityNm>CORAL GABLES</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33146</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICES</GrantOrContributionPurposeTxt>
          <Amt>247023</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENOMIC AND MICROBIAL SIGNATURES PREDICT POST-OPERATIVE CROHNS DISEASE OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>149796</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING INTEGRATION OF PORTABLE ULTRASOUNDS</GrantOrContributionPurposeTxt>
          <Amt>1038654</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A CONTINUOUS INSULIN SENSOR</GrantOrContributionPurposeTxt>
          <Amt>837846</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH DAKOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1301 N COLUMBIA RD SUITE E105</AddressLine1Txt>
            <CityNm>GRAND FORKS</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION (SIM) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>46976</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NOTRE DAME DU LAC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>940 GRACE HALL</AddressLine1Txt>
            <CityNm>NOTRE DAME</CityNm>
            <StateAbbreviationCd>ID</StateAbbreviationCd>
            <ZIPCd>465565708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>705510</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NOTRE DAME DU LAC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>940 GRACE HALL</AddressLine1Txt>
            <CityNm>NOTRE DAME</CityNm>
            <StateAbbreviationCd>ID</StateAbbreviationCd>
            <ZIPCd>465565708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES</GrantOrContributionPurposeTxt>
          <Amt>483726</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NOTRE DAME DU LAC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>940 GRACE HALL</AddressLine1Txt>
            <CityNm>NOTRE DAME</CityNm>
            <StateAbbreviationCd>ID</StateAbbreviationCd>
            <ZIPCd>465565708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES</GrantOrContributionPurposeTxt>
          <Amt>188155</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF OULU</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PO BOX 8000</AddressLine1Txt>
            <CityNm>OULU</CityNm>
            <CountryCd>FI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING</GrantOrContributionPurposeTxt>
          <Amt>274391</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF PITTSBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3420 FORBES AVENUE</AddressLine1Txt>
            <CityNm>PITTSBURGH</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>152603203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>237102</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2304 WHITIS AVE</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>787121111</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN</GrantOrContributionPurposeTxt>
          <Amt>200927</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2304 WHITIS AVE</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>787121111</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN</GrantOrContributionPurposeTxt>
          <Amt>198646</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF UTAH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>201 S PRESIDENTS CIRCLE</AddressLine1Txt>
            <CityNm>SALT LAKE CITY</CityNm>
            <StateAbbreviationCd>UT</StateAbbreviationCd>
            <ZIPCd>84112</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INDUCTION OF PERIPHERAL TOLERANCE TO BETA CELL ANTIGENS BY SPECIFIC TARGETING OF LANGERIN DENDRITIC CELLS</GrantOrContributionPurposeTxt>
          <Amt>290806</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF VIRGINIA LAW SCHOOL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>580 MASSIE ROAD</AddressLine1Txt>
            <CityNm>CHARLOTTESVILLE</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22903</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR THE CATHERINE MURPHY KEATING '87 RESTRICTED FUND</GrantOrContributionPurposeTxt>
          <Amt>75000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WASHINGTON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4333 BROOKLYN AVENUE NE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981959472</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PATHOGENIC ACTION OF AUTOANTIBODIES ON ISLET FUNCTION AND VIABILITY IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>385000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WASHINGTON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4333 BROOKLYN AVENUE NE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981959472</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DESIGN OF ISLET TARGETED AGONISTS OF PD1 AND CTLA4</GrantOrContributionPurposeTxt>
          <Amt>387576</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UPPSALA UNIVERSITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AKADEMISKA SJUKHUSET</AddressLine1Txt>
            <CityNm>UPPSALA</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNE-EVASIVE ISLETS FOR TRANSPLANTATION</GrantOrContributionPurposeTxt>
          <Amt>1139284</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>URBAN PATHWAYS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>575 EIGHTH AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3319 WEST END AVENUE SUITE 970</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF PANCREATLAS CONNECTIVITY PLATFORM AND PHENOTYPING OF HANDEL SAMPLES BY CUTTING-EDGE SINGLE CELL MULTIOME TECHNOLOGY</GrantOrContributionPurposeTxt>
          <Amt>364886</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3319 WEST END AVENUE SUITE 970</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEW APPROACHES TO PREVENT HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3319 WEST END AVENUE SUITE 970</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCREENING HUMAN ISLETS TO IDENTIFY SMALL MOLECULES ENHANCING GLUCAGON SECRETION UNDER HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>330000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3319 WEST END AVENUE SUITE 970</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>121999</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3319 WEST END AVENUE SUITE 970</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>163405</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>110 21ST AVENUE SOUTH</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>372032417</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORMALIZING HYPOGLYCEMIA-INDUCED GLUCAGON SECRETION IN T1D THROUGH PHARMACOLOGICAL RESTORATION OF ALPHA-CELL CALCIUM HANDLING</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1913552</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1260384</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1865381</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VILLAGES OF HOPE AFRICA SOCIETY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2450 MILLTOWER COURT</AddressLine1Txt>
            <CityNm>MISSISSAUGA</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INFRASTRUCTURE IMPROVEMENTS AND EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>151152</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VIVLI INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 MIDDLESEX TURNPIKE SUITE 6</AddressLine1Txt>
            <CityNm>BURLINGTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>018034914</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA SHARING PLATFORM FOR T1-DEXI DATASETS</GrantOrContributionPurposeTxt>
          <Amt>74348</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WARREN MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>905 2ND ST</AddressLine1Txt>
            <CityNm>FRIEND</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68359</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT FRIEND COMMUNITY HEALTHCARE SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>11027</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 BROOKINGS DRIVE</AddressLine1Txt>
            <CityNm>SAINT LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>63130</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RESTORATION OF NORMAL GLUCAGON SECRETORY DYNAMICS BY DIRECT MANIPULATION OF ALPHA CELL SIGNALING</GrantOrContributionPurposeTxt>
          <Amt>330000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 BROOKINGS DRIVE</AddressLine1Txt>
            <CityNm>SAINT LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>63130</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL DEVELOPMENT TO ADVANCE A T1D ANTIGEN-SPECIFIC IMMUNOTHERAPY CALLED SAGA-T1D</GrantOrContributionPurposeTxt>
          <Amt>1271885</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 BROOKINGS DRIVE</AddressLine1Txt>
            <CityNm>SAINT LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>63130</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CELLULAR BIOMARKERS FOR PEDIATRIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>488300</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WATER4 INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2405 NW 10TH STREET</AddressLine1Txt>
            <CityNm>OKLAHOMA CITY</CityNm>
            <StateAbbreviationCd>OK</StateAbbreviationCd>
            <ZIPCd>73107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING NUMA IN NORTHERN GHANA</GrantOrContributionPurposeTxt>
          <Amt>1478953</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WEST RIVER HEALTH SERVICES FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1000 HIGHWAY 12</AddressLine1Txt>
            <CityNm>HETTINGER</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58639</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORTH DAKOTA US REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>68591</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WILCOX HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3-3420 KUHIO HIGHWAY</AddressLine1Txt>
            <CityNm>LIHUE</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96766</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WILCOX MEDICAL CENTER EQUIPMENT REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>3944163</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WILDLIFE CONSERVATION SOCIETY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2300 SOUTHERN BOULEVARD</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10460</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR ELEPHANTS</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WISHEK HOSPITAL CLINIC ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1007 4TH AVE SOUTH</AddressLine1Txt>
            <CityNm>WISHEK</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58495</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SOUTH CENTRAL HEALTH ULTRASOUND INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>83657</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WNET FOR THE WLIW-21 PUBLIC BROADCASTING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>825 EIGHTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100197435</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WORLD HEALTH ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE APPIA 20</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING INTEGRATED PREVENTION AND CONTROL OF CHRONIC AND SEVERE NCDS IN THE WHO AFRICAN REGION, USING T1D, SCD, ARF, AND RHD AS ENTRY POINTS</GrantOrContributionPurposeTxt>
          <Amt>3126083</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WORLD HEALTH ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE APPIA 20</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING THE CAPACITY OF THE GLOBAL DIABETES COMPACT</GrantOrContributionPurposeTxt>
          <Amt>3129504</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WYOMING ASSOCIATION OF SHERIFFS AND CHIEFS OF POLICE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 481</AddressLine1Txt>
            <CityNm>DOUGLAS</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82633</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING VIRTUAL CRISIS CARE PILOT PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>798469</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 208327</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING NEWLY DISCOVERED HOST-MICROBIOTA INTERACTION NODES TO TREAT OR PREVENT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>599035</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 208327</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>413016</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YITZHAK SHAMIR MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEER YAAKOV</AddressLine1Txt>
            <CityNm>TZRIFIN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION AND RENOVATION OF THE CANCER INSTITUTE AT SHAMIR MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>1978286</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YOUNG MEN'S CHRISTIAN ASSOCIATION OF RYE NY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>21 LOCUST AVE</AddressLine1Txt>
            <CityNm>RYE</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10580</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YOUNG MEN'S CHRISTIAN ASSOCIATION RETIREMENT FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>120 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10271</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YOUTH DEVELOPMENT ORGANIZATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15 UNION STREET 563</AddressLine1Txt>
            <CityNm>LAWRENCE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01840</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING PROJECT SUPPORT 2024-2026</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ZAKA - SEARCH AND RESCUE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 JAFFA STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY AND DISASTER PREPAREDNESS IN ISRAEL</GrantOrContributionPurposeTxt>
          <Amt>350000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ZIV MEDICAL CENTER ZEFAT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DERECH HARAMBAM 1</AddressLine1Txt>
            <CityNm>ZEFAT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW NEUROSURGERY DEPARTMENT</GrantOrContributionPurposeTxt>
          <Amt>2100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ZIV MEDICAL CENTER ZEFAT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DERECH HARAMBAM 1</AddressLine1Txt>
            <CityNm>ZEFAT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW THORACIC SURGERY UNIT</GrantOrContributionPurposeTxt>
          <Amt>1325000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <TotalGrantOrContriPdDurYrAmt>440927206</TotalGrantOrContriPdDurYrAmt>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ACADEMISCH ZIEKENHUIS LEIDEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2 ALBINUSDREEF</AddressLine1Txt>
            <CityNm>LEIDEN</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SAFETY AND EFFICACY OF IMMUNE INTERVENTION WITH TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH EARLY T1D (D-SENSE II)</GrantOrContributionPurposeTxt>
          <Amt>238910</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ACADEMISCH ZIEKENHUIS LEIDEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2 ALBINUSDREEF</AddressLine1Txt>
            <CityNm>LEIDEN</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SAFETY AND EFFICACY OF IMMUNE INTERVENTION WITH TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH EARLY T1D (D-SENSE II)</GrantOrContributionPurposeTxt>
          <Amt>93238</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ACTION4DIABETES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>9 PARKFIELD ROAD</AddressLine1Txt>
            <CityNm>TAUNTON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PHILIPPINES T1D TASK FORCE</GrantOrContributionPurposeTxt>
          <Amt>284390</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALBERT EINSTEIN COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 MORRIS PARK AVENUE</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>104611975</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENHANCING THE COMMUNITY HEALTH WORKER (CHW) MODEL TO PROMOTE DIABETES TECHNOLOGY USE IN YOUNG ADULTS FROM UNDERREPRESENTED MINORITY GROUPS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>171150</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALIMENTIV INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALIDATION OF THE PRO SYMPTOMS AND IMPACTS QUESTIONNAIRE FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>749412</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALIMENTIV INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALIDATION OF THE PRO SYMPTOMS AND IMPACTS QUESTIONNAIRE FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>55930</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN CAMPING ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5000 STATE ROAD 67 NORTH</AddressLine1Txt>
            <CityNm>MARTINSVILLE</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>46151</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACA PROFESSIONAL DEVELOPMENT 2024-2027</GrantOrContributionPurposeTxt>
          <Amt>60221</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN CAMPING ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5000 STATE ROAD 67 NORTH</AddressLine1Txt>
            <CityNm>MARTINSVILLE</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>46151</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACA PROFESSIONAL DEVELOPMENT 2024-2027</GrantOrContributionPurposeTxt>
          <Amt>65258</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2025-2027 TYPE 1 DIABETES CAMP INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>480260</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2025-2027 TYPE 1 DIABETES CAMP INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>480260</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING AND MENTORSHIP PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>805382</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEARTCORPS AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>850098</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING THE SYSTEM OF STROKE CARE IN MINNESOTA</GrantOrContributionPurposeTxt>
          <Amt>1563575</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AMERICAN HEART ASSOCIATION CENTER FOR TELEHEALTH</GrantOrContributionPurposeTxt>
          <Amt>4816553</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING THE SYSTEM OF STROKE CARE IN MINNESOTA</GrantOrContributionPurposeTxt>
          <Amt>1546123</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION LIFELINE STROKE SOUTH DAKOTA</GrantOrContributionPurposeTxt>
          <Amt>1592190</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION LIFELINE STROKE SOUTH DAKOTA</GrantOrContributionPurposeTxt>
          <Amt>1836354</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION LIFELINE STROKE HAWAII</GrantOrContributionPurposeTxt>
          <Amt>2220899</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION LIFELINE STROKE HAWAII</GrantOrContributionPurposeTxt>
          <Amt>1988020</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMSTERDAM UMC RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A PROSPECTIVE RANDOMIZED STUDY OF TREATMENT SELECTION BASED ON EPIGENETIC MARKERS IN CROHNS DISEASE OMICROHN</GrantOrContributionPurposeTxt>
          <Amt>1476985</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ANN &amp; ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 EAST CHICAGO AVENUE BOX 205</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60611</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D</GrantOrContributionPurposeTxt>
          <Amt>1542882</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ANN &amp; ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 EAST CHICAGO AVENUE BOX 205</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60611</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D</GrantOrContributionPurposeTxt>
          <Amt>1245216</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ANTHOS HOME INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>238 SEELEY ST</AddressLine1Txt>
            <CityNm>BROOKLYN</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11218</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>2750000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ANTHOS HOME INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>238 SEELEY ST</AddressLine1Txt>
            <CityNm>BROOKLYN</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11218</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>750000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>APHP ST ANTOINE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>184 RUE DU FAUBOURG SAINT-ANTOINE</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE)</GrantOrContributionPurposeTxt>
          <Amt>421681</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 SOUTH WACKER DRIVE SUITE 600</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60606</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DANATECH DIABETES TECHNOLOGY PLATFORM EXPANSION &amp; MAINTENANCE</GrantOrContributionPurposeTxt>
          <Amt>928645</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 SOUTH WACKER DRIVE SUITE 600</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60606</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DANATECH DIABETES TECHNOLOGY PLATFORM EXPANSION &amp; MAINTENANCE</GrantOrContributionPurposeTxt>
          <Amt>640509</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION SANTE DIABETE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>5 RUE FEDERICO GARCIA LORCA</AddressLine1Txt>
            <CityNm>GRENOBLE</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS</GrantOrContributionPurposeTxt>
          <Amt>587221</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION SANTE DIABETE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>5 RUE FEDERICO GARCIA LORCA</AddressLine1Txt>
            <CityNm>GRENOBLE</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS</GrantOrContributionPurposeTxt>
          <Amt>325558</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>55 VICTORIA PARADE</AddressLine1Txt>
            <CityNm>FITZROY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE THE MIRO (MICROBIOTA RESTORATION) STUDY.</GrantOrContributionPurposeTxt>
          <Amt>315421</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BALLAD RESEARCH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3525 JOHN HOPKINS COURT</AddressLine1Txt>
            <CityNm>SAN DIEGO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CD127-HIGH T-CELL POPULATIONS IN AUTOANTIBODY POSITIVE CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>243390</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAYLOR COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE BAYLOR PLAZA</AddressLine1Txt>
            <CityNm>HOUSTON</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREDICTIVE ANALYTICS AND TARGETED INTERVENTIONS SHIFTING THE PARADIGM FROM REACTIVE TO PROACTIVE DIABETES CARE</GrantOrContributionPurposeTxt>
          <Amt>282140</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 NINTH AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981012795</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN VIA RAPIDLY CONDUCTED IMMUNOTHERAPY TRIALS IN T1D</GrantOrContributionPurposeTxt>
          <Amt>288200</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 NINTH AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981012795</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MECHANISMS OF AUTOANTIBODY REVERSION IN AT-RISK SUBJECTS</GrantOrContributionPurposeTxt>
          <Amt>350194</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 NINTH AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981012795</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MECHANISMS OF AUTOANTIBODY REVERSION IN AT-RISK SUBJECTS</GrantOrContributionPurposeTxt>
          <Amt>348874</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEN-GURION UNIVERSITY OF THE NEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEN-GURION BLVD 1</AddressLine1Txt>
            <CityNm>BEER SHEVA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONSTRUCTION OF THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST COMPUTER SCIENCE BUILDING</GrantOrContributionPurposeTxt>
          <Amt>10542857</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BETH ISRAEL DEACONESS MEDICAL CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>330 BROOKLINE AVENUE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022155491</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD VERSUS STANDARD OF CARE IN PATIENTS WITH CROHNS DISEASE THE OPTIMIZE TRIAL</GrantOrContributionPurposeTxt>
          <Amt>797851</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEYOND TYPE 1</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 CONCAR DRIVE OFFICE 03-155</AddressLine1Txt>
            <CityNm>SAN MATEO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94402</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>645000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ECMO SERVICES AT BILLINGS CLINIC</GrantOrContributionPurposeTxt>
          <Amt>485826</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BILLINGS CLINIC TRANSFER CENTER</GrantOrContributionPurposeTxt>
          <Amt>880233</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BILLINGS CLINIC TRANSFER CENTER</GrantOrContributionPurposeTxt>
          <Amt>348798</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BIPARTISAN POLICY CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1225 I ST NW 1000</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING RURAL HEALTH CARE DELIVERY AND SERVICES</GrantOrContributionPurposeTxt>
          <Amt>584923</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF PERSONALIZED DECISION SUPPORT TOOL USING NETIOB TO HELP MANAGE EXERCISE FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1069498</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DETERMINING THE THERAPEUTIC POTENTIAL OF STATINS ON STRICTURING CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>775549</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DETERMINING THE THERAPEUTIC POTENTIAL OF STATINS ON STRICTURING CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>591775</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A MOLECULAR SWITCH BASED CONTINUOUS INSULIN SENSOR</GrantOrContributionPurposeTxt>
          <Amt>1333066</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A MOLECULAR SWITCH BASED CONTINUOUS INSULIN SENSOR</GrantOrContributionPurposeTxt>
          <Amt>1360687</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1006687</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABDOCS NATIONAL K12 SUPPLEMENT</GrantOrContributionPurposeTxt>
          <Amt>395280</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON MEDICAL CENTER CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE BOSTON MEDICAL PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02118</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPLEMENTAL FUNDING FOR AN EFFECTIVENESS TRIAL TO SUPPORT ADOPTION OF AID IN UNDERSERVED ADULTS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>257191</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON MEDICAL CENTER CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE BOSTON MEDICAL PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02118</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPLEMENTAL FUNDING FOR AN EFFECTIVENESS TRIAL TO SUPPORT ADOPTION OF AID IN UNDERSERVED ADULTS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>257191</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON MEDICAL CENTER CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE BOSTON MEDICAL PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02118</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPLEMENTAL FUNDING FOR AN EFFECTIVENESS TRIAL TO SUPPORT ADOPTION OF AID IN UNDERSERVED ADULTS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>257191</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BREAKING GROUND HOUSING DEVELOPMENT FUND CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 EIGHTH AVENUE 5TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING AND EVALUATING THE HEALTH EFFECTS OF ACCELERATED PLACEMENTS INTO PERMANENT SUPPORTIVE HOUSING</GrantOrContributionPurposeTxt>
          <Amt>585924</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BREAKTHROUGH T1D</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CO-FUNDED DEVELOPMENT OF A MICRONEEDLE SENSOR FOR SIMULTANEOUS CONTINUOUS MONITORING OF KETONES AND GLUCOSE</GrantOrContributionPurposeTxt>
          <Amt>133334</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BREAKTHROUGH T1D</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JOINING FORCES BUILDING A SHARED 'GRAND ACCESS STRATEGY' FOR SAVING T1D LIVES</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BREAKTHROUGH T1D</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY AND JDRF CO-FUNDED WORKSHOPS</GrantOrContributionPurposeTxt>
          <Amt>157366</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIDGES TO PROSPERITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1031 33RD STREET</AddressLine1Txt>
            <CityNm>DENVER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMATIVE CONNECTIVITY IN RURAL ZAMBIA</GrantOrContributionPurposeTxt>
          <Amt>2359636</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HILLS ROAD</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE UK IBD BIORESOURCE TRANSLATING TODAYS SCIENCE INTO TOMORROWS TREATMENTS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>657605</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARDIFF UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>30-36 NEWPORT RD</AddressLine1Txt>
            <CityNm>WALES</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T1D-PLUS AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D</GrantOrContributionPurposeTxt>
          <Amt>525638</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARDIFF UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>30-36 NEWPORT RD</AddressLine1Txt>
            <CityNm>WALES</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T1D-PLUS AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D</GrantOrContributionPurposeTxt>
          <Amt>525638</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARDIFF UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>30-36 NEWPORT RD</AddressLine1Txt>
            <CityNm>WALES</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T1D-PLUS AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D</GrantOrContributionPurposeTxt>
          <Amt>262543</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELPING MOTHERS AND NEWBORNS SURVIVE AND THRIVE</GrantOrContributionPurposeTxt>
          <Amt>1273764</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING COMMUNITY RECOVERY AND RESILIENCE</GrantOrContributionPurposeTxt>
          <Amt>1073759</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTER FOR HEALTH CARE STRATEGIES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 AMERICAN METRO BOULEVARD SUITE</AddressLine1Txt>
            <AddressLine2Txt>125</AddressLine2Txt>
            <CityNm>HAMILTON</CityNm>
            <StateAbbreviationCd>NJ</StateAbbreviationCd>
            <ZIPCd>08619</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM MEDICAID ACCESS ACCELERATOR - TARGETED RESOURCES AND TECHNICAL ASSISTANCE TO IMPROVE CARE FOR PEOPLE LIVING WITH DIABETES WHO USE INSULIN</GrantOrContributionPurposeTxt>
          <Amt>626707</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTER FOR URBAN COMMUNITY SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>198 EAST 121ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10035</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTER FOR URBAN COMMUNITY SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>198 EAST 121ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10035</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHANCELLOR MASTERS &amp; SCHOLARS OF THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLINGTON SQUARE</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERROGATING THE MECHANISM OF HYPERSENSITIVITY TO ANTIBODY-BASED DRUGS FOR DEVELOPMENT OF A NOVEL ANTI-TNF BIOLOGIC FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>93443</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHANCELLOR MASTERS &amp; SCHOLARS OF THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLINGTON SQUARE</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALPHA CELL FUNCTION IN PEOPLE WITH TYPE 1 DIABETES WITH AND WITHOUT SEVERE HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>515981</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHANCELLOR MASTERS &amp; SCHOLARS OF THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLINGTON SQUARE</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALPHA CELL FUNCTION IN PEOPLE WITH TYPE 1 DIABETES WITH AND WITHOUT SEVERE HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>202677</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHANCELLOR MASTERS &amp; SCHOLARS OF THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLINGTON SQUARE</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING THE SIGNALING CIRCUITS AND REGULONS MEDIATING CROHNS FIBROSIS.</GrantOrContributionPurposeTxt>
          <Amt>607072</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHANCELLOR MASTERS &amp; SCHOLARS OF THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLINGTON SQUARE</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING THE SIGNALING CIRCUITS AND REGULONS MEDIATING CROHNS FIBROSIS.</GrantOrContributionPurposeTxt>
          <Amt>625660</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHI HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>12809 WEST DODGE ROAD</AddressLine1Txt>
            <CityNm>OMAHA</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68154</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY</GrantOrContributionPurposeTxt>
          <Amt>229460</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 414413</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADVANCING THE DEVELOPMENT OF A NOVEL IMPLANTABLE GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>1332312</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 414413</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADVANCING THE DEVELOPMENT OF A NOVEL IMPLANTABLE GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>1378160</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4650 SUNSET BOULEVARD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90027</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BEYOND COYOT1 EXPANSION OF PATIENT-CENTERED VIRTUAL CARE</GrantOrContributionPurposeTxt>
          <Amt>531630</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALIDATION OF A PERIPHERAL BLOOD BIOMARKER SIGNATURE FOR ANTI-TNF RESPONSE IN PATIENTS WITH CROHNS DISEASE (ATPBIOS)</GrantOrContributionPurposeTxt>
          <Amt>560242</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALIDATION OF A PERIPHERAL BLOOD BIOMARKER SIGNATURE FOR ANTI-TNF RESPONSE IN PATIENTS WITH CROHNS DISEASE (ATPBIOS)</GrantOrContributionPurposeTxt>
          <Amt>733121</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL</GrantOrContributionPurposeTxt>
          <Amt>1016595</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL</GrantOrContributionPurposeTxt>
          <Amt>407932</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL OF PHILADELPHIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2716 SOUTH STREET</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191462305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LEVERAGING HLA PROTECTION AND HUMORAL IMMUNITY TO DEVELOP MICROBIAL THERAPEUTICS THAT PREVENT T1D</GrantOrContributionPurposeTxt>
          <Amt>121207</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY FUTURES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>80 8TH AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10011</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC GREENSPACE POLICY REPORTS FOCUSED ON PROMOTING RECREATION, AND IMPROVING ACCESS TO GREENSPACE</GrantOrContributionPurposeTxt>
          <Amt>75000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY FUTURES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>80 8TH AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10011</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC GREENSPACE POLICY REPORTS FOCUSED ON PROMOTING RECREATION, AND IMPROVING ACCESS TO GREENSPACE</GrantOrContributionPurposeTxt>
          <Amt>75000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY PARKS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>830 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CATALYST SUSTAINABILITY THE IMPORTANCE OF COMMUNITY ENGAGEMENT IN PARKS</GrantOrContributionPurposeTxt>
          <Amt>139790</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY PARKS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>830 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING NYCS URBAN FOREST PLAN PUBLIC PARK LANDS</GrantOrContributionPurposeTxt>
          <Amt>188595</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY PARKS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>830 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC GREEN FUND</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLINTON HEALTH ACCESS INITIATIVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>383 DORCHESTER AVENUE SUITE 400</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02127</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REACH EXPANDING ACCESS TO PRIMARY CARE FOR DIABETES AND HYPERTENSION (2024-2027)</GrantOrContributionPurposeTxt>
          <Amt>2901095</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLINTON HEALTH ACCESS INITIATIVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>383 DORCHESTER AVENUE SUITE 400</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02127</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REACH EXPANDING ACCESS TO PRIMARY CARE FOR DIABETES AND HYPERTENSION (2024-2027)</GrantOrContributionPurposeTxt>
          <Amt>3215685</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLINTON HEALTH ACCESS INITIATIVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>383 DORCHESTER AVENUE SUITE 400</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02127</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING MEDICAL OXYGEN PRODUCTION AND UTILIZATION</GrantOrContributionPurposeTxt>
          <Amt>1166919</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CONVERGENT IMPACT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3223 ARAPAHOE AVE</AddressLine1Txt>
            <CityNm>BOULDER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80303</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH</GrantOrContributionPurposeTxt>
          <Amt>492300</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CONVERGENT IMPACT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3223 ARAPAHOE AVE</AddressLine1Txt>
            <CityNm>BOULDER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80303</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH</GrantOrContributionPurposeTxt>
          <Amt>1212300</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COREWELL HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>100 MICHIGAN ST NE</AddressLine1Txt>
            <CityNm>GRAND RAPIDS</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>49503</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ACCESS TO ROBOTIC PCI AND ESTABLISHING A MULTI-STATE NETWORK TO STUDY THE FEASIBILITY OF TELEROBOTIC HEART ATTACK AND STROKE INTERVENTIONS</GrantOrContributionPurposeTxt>
          <Amt>5885473</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORK UNIVERSITY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WESTERN ROAD</AddressLine1Txt>
            <CityNm>CORK</CityNm>
            <CountryCd>EI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDOSCOPIC MULTIMODAL ASSESSMENT USING ADVANCED IMAGING INTEGRATED AI TO PREDICT RECURRENCE IN POST-OPERATIVE CROHNS DISEASE - PROSPERS</GrantOrContributionPurposeTxt>
          <Amt>663503</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORK UNIVERSITY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WESTERN ROAD</AddressLine1Txt>
            <CityNm>CORK</CityNm>
            <CountryCd>EI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDOSCOPIC MULTIMODAL ASSESSMENT USING ADVANCED IMAGING INTEGRATED AI TO PREDICT RECURRENCE IN POST-OPERATIVE CROHNS DISEASE - PROSPERS</GrantOrContributionPurposeTxt>
          <Amt>941943</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORNELL UNIVERSITY FOR THE JOAN &amp; SANFORD I WEILL MEDICAL COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 YORK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100654805</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING THE MYCOBIOME IN PATIENTS WITH CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>202620</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORPORATION FOR SUPPORTIVE HOUSING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING</GrantOrContributionPurposeTxt>
          <Amt>800000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORPORATION FOR SUPPORTIVE HOUSING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COUNCIL ON FOUNDATIONS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1255 23RD ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>34000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COZAD HOSPITAL DISTRICT NO 2</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 EAST 12TH STREET</AddressLine1Txt>
            <CityNm>COZAD</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69130</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY AT COZAD COMMUNITY HEALTH SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>17570</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACHIEVING REMISSION IN IBD OPTIMIZING TREAT-TO-TARGET IN CLINICAL PRACTICE</GrantOrContributionPurposeTxt>
          <Amt>1622595</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACHIEVING REMISSION IN IBD OPTIMIZING TREAT-TO-TARGET IN CLINICAL PRACTICE</GrantOrContributionPurposeTxt>
          <Amt>739745</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>APPLICATION OF MACHINE LEARNING TO PRECISION NUTRITION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>626728</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING ENROLLMENT IN IBD CLINICAL TRIALS</GrantOrContributionPurposeTxt>
          <Amt>375484</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS UK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 BISHOPS SQUARE</AddressLine1Txt>
            <CityNm>HATFIELD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF A LOWER GI DIAGNOSTIC PATHWAY IN PRIMARY HEALTHCARE AND DEVELOPMENT AND DISSEMINATION OF A LOWER GI PATIENT TOOLKIT</GrantOrContributionPurposeTxt>
          <Amt>170782</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S COLITIS CURE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>100 HARRIS STREET</AddressLine1Txt>
            <CityNm>PYRMONT NSW</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENHANCING INFLAMMATORY BOWEL DISEASE CARE CONSUMER-CENTRIC PORTAL FOR BETTER COMMUNICATION &amp; REDUCED NAVIGATION STRESS</GrantOrContributionPurposeTxt>
          <Amt>991768</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DARTMOUTH- HITCHCOCK CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE MEDICAL CENTER DRIVE</AddressLine1Txt>
            <CityNm>LEBANON</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03756</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING FOR DARTMOUTH-HITCHCOCK'S VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>268958</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DEUTSCHE WELTHUNGERHILFE EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>FRIEDRICH-EBERT-STRABE 1</AddressLine1Txt>
            <CityNm>BONN BAD GODESBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOLISTICALLY ADDRESSING AGROBUSINESS</GrantOrContributionPurposeTxt>
          <Amt>892391</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DEUTSCHE WELTHUNGERHILFE EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>FRIEDRICH-EBERT-STRAE 1</AddressLine1Txt>
            <CityNm>BONN BAD GODESBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOLISTICALLY ADDRESSING AGROBUSINESS</GrantOrContributionPurposeTxt>
          <Amt>1079659</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DIABETES AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>19-23 MOORE STREET GROUND FLOOR</AddressLine1Txt>
            <CityNm>TURNER</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVEMENTS IN OUTCOMES FOR YOUNG PEOPLE WITH DIABETES IN LESS-RESOURCED COUNTRIES, THROUGH GEOGRAPHIC EXPANSION AND COUNTRY DATA-DRIVEN INITIATIVES.</GrantOrContributionPurposeTxt>
          <Amt>2443661</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DUKE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2200 WEST MAIN STREET SUITE 1000</AddressLine1Txt>
            <CityNm>DURHAM</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>27705</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL ASSAYS FOR PROGLUCAGON PEPTIDES TO UNDERSTAND ALPHA CELL FUNCTION IN HEALTH AND DIABETES</GrantOrContributionPurposeTxt>
          <Amt>275096</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>EMORY UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1599 CLIFTON ROAD NE</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303224250</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>283099</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ENGINEERING MINISTRIES INTERNATIONAL USA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7025 CAMPUS DRIVE</AddressLine1Txt>
            <CityNm>COLORADO SPRINGS</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80920</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MINGA MISSION HOSPITAL DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>2112745</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ENGINEERING MINISTRIES INTERNATIONAL USA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7025 CAMPUS DRIVE</AddressLine1Txt>
            <CityNm>COLORADO SPRINGS</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80920</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MINGA MISSION HOSPITAL DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>1089542</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FJC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 WEST 39TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE WELLNESS CLASSROOM, A PROJECT OF FJC - A FOUNDATION OF PHILANTHROPIC FUNDS</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FJC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 WEST 39TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC FUND TO END YOUTH &amp; FAMILY HOMELESSNESS, A PROJECT OF FJC.</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FOR INSPIRATION AND RECOGNITION OF SCIENCE AND TECHNOLOGY (FIRST)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 BEDFORD STREET</AddressLine1Txt>
            <CityNm>MANCHESTER</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FIRST SENIOR MENTOR PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GALILEE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEN ZVI BLVD POB 21</AddressLine1Txt>
            <CityNm>NAHARIYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RENOVATION OF ONE FLOOR OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>750000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GATES PHILANTHROPY PARTNERS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 60555</AddressLine1Txt>
            <CityNm>CITY OF INDUSTRY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91716</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POLIO ERADICATION FUND SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GENETIC ALLIANCE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>25904 WOODFIELD ROAD</AddressLine1Txt>
            <CityNm>DAMASCUS</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>20872</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IHOPE GENETIC HEALTH</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLCOME GENOME CAMPUS</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCIBD-RESPONSE MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>143892</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEOSCIENCE AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 JERRABOMBERRA AVE</AddressLine1Txt>
            <CityNm>SYMONSTON</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGITAL EARTH AFRICA - SUSTAINABLE UPTAKE AND IMPACT</GrantOrContributionPurposeTxt>
          <Amt>2737545</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GRANTMAKERS FOR EFFECTIVE ORGANIZATIONS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1310 L STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>18920</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HAWAI'I HEALTH SYSTEMS CORP KAUA'I REGION FOR VETERANS MEMORIAL HOSP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4643 WAIMEA CANYON DRIVE</AddressLine1Txt>
            <CityNm>WAIMEA</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96796</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MEDICAL SIMULATION AT KAUA'I VETERANS MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEALING HANDS OF JOY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4747 HEDGEMORE DR</AddressLine1Txt>
            <CityNm>CHARLOTTE</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>28209</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ELIMINATION OF OBSTETRIC FISTULA</GrantOrContributionPurposeTxt>
          <Amt>335000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEALING HANDS OF JOY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4747 HEDGEMORE DR</AddressLine1Txt>
            <CityNm>CHARLOTTE</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>28209</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ELIMINATION OF OBSTETRIC FISTULA</GrantOrContributionPurposeTxt>
          <Amt>165000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>2482836</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>3716830</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>3716830</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>5172033</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>5172032</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1550379</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1550379</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1353865</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1353865</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1821858</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1821858</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>526471</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>4829040</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>4829040</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>5755302</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>5755301</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>5917762</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>5917761</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>4393010</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>4393009</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>3565907</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>3465906</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>1665293</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>1665293</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>4328576</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION 2025-2029</GrantOrContributionPurposeTxt>
          <Amt>1299716</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION 2025-2029</GrantOrContributionPurposeTxt>
          <Amt>1382183</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION 2025-2029</GrantOrContributionPurposeTxt>
          <Amt>912527</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION 2025-2029</GrantOrContributionPurposeTxt>
          <Amt>1272469</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>1176451</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EUROPEAN PRE-T1D REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>37585</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INGOLSTDTER LANDSTRAE 1</AddressLine1Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOSAMPLE RFP</GrantOrContributionPurposeTxt>
          <Amt>912618</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HENRY J KAISER FAMILY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>185 BERRY STREET NO 2000</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>KFF HEALTH NEWS RURAL HEALTH DESK</GrantOrContributionPurposeTxt>
          <Amt>1566728</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HENRY J KAISER FAMILY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>185 BERRY STREET NO 2000</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>KFF HEALTH NEWS RURAL HEALTH DESK</GrantOrContributionPurposeTxt>
          <Amt>1612177</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HERLEV OG GENTOFTE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERLEV RINGVEJ 75 OPG115</AddressLine1Txt>
            <CityNm>HERLEV</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D</GrantOrContributionPurposeTxt>
          <Amt>140000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HIGH QUALITY MEDICAL EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4117 PENFIELD CT S</AddressLine1Txt>
            <CityNm>AFTON</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR NORTH DAKOTA RURAL PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>1183489</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HIGH QUALITY MEDICAL EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4117 PENFIELD CT S</AddressLine1Txt>
            <CityNm>AFTON</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR NORTH DAKOTA RURAL PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>1213318</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HIGH QUALITY MEDICAL EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4117 PENFIELD CT S</AddressLine1Txt>
            <CityNm>AFTON</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>1705225</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HILLEL THE FOUNDATION FOR JEWISH CAMPUS LIFE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>180 S GARNER STREET</AddressLine1Txt>
            <CityNm>STATE COLLEGE</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>16804</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HOLON INSTITUTE OF TECHNOLOGY - HIT (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>52 GOLOMB ST</AddressLine1Txt>
            <CityNm>HOLON</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MEDICAL TECHNOLOGIES BUILDING AT THE HOLON INSTITUTE OF TECHNOLOGY (HIT)</GrantOrContributionPurposeTxt>
          <Amt>2725000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HOLON INSTITUTE OF TECHNOLOGY - HIT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>52 GOLOMB ST</AddressLine1Txt>
            <CityNm>HOLON</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MEDICAL TECHNOLOGIES BUILDING AT THE HOLON INSTITUTE OF TECHNOLOGY (HIT)</GrantOrContributionPurposeTxt>
          <Amt>2043650</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HUMBOLDT COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1000 N 15TH ST</AddressLine1Txt>
            <CityNm>HUMBOLDT</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50548</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT HUMBOLDT COUNTY MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>15775</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE WOMEN WITH INFLAMMATORY BOWEL DISEASE AND MOTHERHOOD (WISDOM) REGISTRY A PROSPECTIVE STUDY OF FEMALE FERTILITY IN IBD</GrantOrContributionPurposeTxt>
          <Amt>580306</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE WOMEN WITH INFLAMMATORY BOWEL DISEASE AND MOTHERHOOD (WISDOM) REGISTRY A PROSPECTIVE STUDY OF FEMALE FERTILITY IN IBD</GrantOrContributionPurposeTxt>
          <Amt>597244</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATION THERAPY OF RESILIENCE INTERVENTION WITH BIOLOGICS IN CROHNS DISEASE [CATHARSIS TRIAL]</GrantOrContributionPurposeTxt>
          <Amt>531966</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATION THERAPY OF RESILIENCE INTERVENTION WITH BIOLOGICS IN CROHNS DISEASE [CATHARSIS TRIAL]</GrantOrContributionPurposeTxt>
          <Amt>520141</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE REFLECTION STUDY PREDICTING OUTCOMES FOLLOWING ILEOCECAL RESECTION IN CROHNS DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>535412</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE REFLECTION STUDY PREDICTING OUTCOMES FOLLOWING ILEOCECAL RESECTION IN CROHNS DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>1367190</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY LIFE EXPOSOME BIOMARKERS AND CROHN'S DISEASE RISK THE EARLY-CD PROJECT</GrantOrContributionPurposeTxt>
          <Amt>663610</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE USE OF GLP-1R AGONISTS TO PROMOTE EPITHELIAL HEALING IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1232170</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE USE OF GLP-1R AGONISTS TO PROMOTE EPITHELIAL HEALING IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>809899</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING THE PRE-DISEASE PHASE OF CROHNS DISEASE PREDICT AND PREVENT</GrantOrContributionPurposeTxt>
          <Amt>587152</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF NOVEL LRRK2 INHIBITORS TO TREAT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>583880</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IDA COUNTY IOWA COMMUNITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>701 EAST SECOND STREET</AddressLine1Txt>
            <CityNm>IDA GROVE</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51445</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT HORN MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>17875</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IMPROVECARENOW INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4 CARMICHAEL ST UNIT 111</AddressLine1Txt>
            <CityNm>ESSEX JUNCTION</CityNm>
            <StateAbbreviationCd>VT</StateAbbreviationCd>
            <ZIPCd>05452</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTING THE COMBINE TRIAL RESULTS IN THE IMPROVECARENOW (ICN) LEARNING HEALTH NETWORK</GrantOrContributionPurposeTxt>
          <Amt>872406</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IMPROVECARENOW INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4 CARMICHAEL ST UNIT 111</AddressLine1Txt>
            <CityNm>ESSEX JUNCTION</CityNm>
            <StateAbbreviationCd>VT</StateAbbreviationCd>
            <ZIPCd>05452</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTING THE COMBINE TRIAL RESULTS IN THE IMPROVECARENOW (ICN) LEARNING HEALTH NETWORK</GrantOrContributionPurposeTxt>
          <Amt>771948</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INNODIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERESTRAAT 49</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INNODIA NONPROFIT LAUNCH</GrantOrContributionPurposeTxt>
          <Amt>426278</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>85150</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>108058</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>77919</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>116852</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>160613</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>86 RUE REGNAULT</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FROM BENIGN ISLET AUTOIMMUNITY TO TYPE 1 DIABETES HLA-A- VS. HLA-B-RESTRICTED CD8 T-CELL BIOMARKERS OF PROGRESSION</GrantOrContributionPurposeTxt>
          <Amt>278787</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>86 RUE REGNAULT</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FROM BENIGN ISLET AUTOIMMUNITY TO TYPE 1 DIABETES HLA-A- VS. HLA-B-RESTRICTED CD8 T-CELL BIOMARKERS OF PROGRESSION</GrantOrContributionPurposeTxt>
          <Amt>186090</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUTE FOR COMMUNITY LIVING INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 BROAD STREET</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUTE FOR COMMUNITY LIVING INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 BROAD STREET</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUTE FOR COMMUNITY LIVING INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 BROAD STREET</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING A THREE-YEAR IMT/ACT STEP-DOWN PROJECT</GrantOrContributionPurposeTxt>
          <Amt>749790</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSULIN FOR LIFE USA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2555 SW 76TH STREET 130</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>32608</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING ORGANIZATIONAL CAPACITY II</GrantOrContributionPurposeTxt>
          <Amt>215700</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSULIN FOR LIFE USA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2555 SW 76TH STREET 130</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>32608</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING ORGANIZATIONAL CAPACITY II</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSULIN FOR LIFE USA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2555 SW 76TH STREET 130</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>32608</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING ORGANIZATIONAL CAPACITY II</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSULIN FOR LIFE USA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2555 SW 76TH STREET 130</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>32608</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING ORGANIZATIONAL CAPACITY II</GrantOrContributionPurposeTxt>
          <Amt>165700</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSULIN FOR LIFE USA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2555 SW 76TH STREET 130</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>32608</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING ORGANIZATIONAL CAPACITY II</GrantOrContributionPurposeTxt>
          <Amt>265700</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL ALLIANCE FOR DIABETES ACTION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 STATE STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEED FUNDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>971684</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION GLOBALLY (IBUS EIUS ED)</GrantOrContributionPurposeTxt>
          <Amt>296500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE EXTENT STUDY (CALCULATING THE LEMANN INDEX USING INTESTINAL ULTRASOUND)</GrantOrContributionPurposeTxt>
          <Amt>688466</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL WATER MANAGEMENT INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>127 SUNIL MAWATHA</AddressLine1Txt>
            <CityNm>BATTARAMULLA</CityNm>
            <CountryCd>CE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGITAL INNOVATIONS FOR A WATER SECURE AFRICA</GrantOrContributionPurposeTxt>
          <Amt>1550680</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INT'L BANK FOR RECONSTRUCTION &amp; DEV AND INT'L DEVELOPMENT ASSOC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1818 H STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20433</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH SYSTEM TRANSFORMATION AND RESILIENCE MULTI-DONOR TRUST FUND - NONCOMMUNICABLE DISEASE PARTNERSHIP GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>2500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRIAL EVALUATING THE EFFECT OF INHALED TECHNOSPHERE INSULIN VERSUS RAPID ACTING ANALOGUE INSULIN ON EXERCISE-INDUCED HYPOGLYCEMIA IN ADULTS WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>191816</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VIRTUAL DIABETES SPECIALTY CLINIC (VDISC) - A STUDY EVALUATING REMOTE INITIATION OF CONTINUOUS GLUCOSE MONITORING</GrantOrContributionPurposeTxt>
          <Amt>273882</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>309895</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>299921</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>531921</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREGNANCY DATA REPOSITORY TO ASSESS MANAGEMENT OF TYPE 1 DIABETES WITH DIABETES TECHNOLOGY (PRAM-T1D)</GrantOrContributionPurposeTxt>
          <Amt>1256044</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREGNANCY DATA REPOSITORY TO ASSESS MANAGEMENT OF TYPE 1 DIABETES WITH DIABETES TECHNOLOGY (PRAM-T1D)</GrantOrContributionPurposeTxt>
          <Amt>1223066</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM FOR THE EARLY DETECTION AND MANAGEMENT OF DYSGLYCEMIA IN PREGNANCY (IMAGINE)</GrantOrContributionPurposeTxt>
          <Amt>1108482</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM FOR THE EARLY DETECTION AND MANAGEMENT OF DYSGLYCEMIA IN PREGNANCY (IMAGINE)</GrantOrContributionPurposeTxt>
          <Amt>1131140</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDUCATIONAL INTERVENTION TO SUPPORT DIABETES GUIDANCE FOR EXERCISE (EDGE)</GrantOrContributionPurposeTxt>
          <Amt>805385</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE IN DIABETES INITIATIVE LARGE ADULT STUDY</GrantOrContributionPurposeTxt>
          <Amt>159838</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>80-84 CHANDOS STREET</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDIA FOLLOW UP 2023-2025 SAMPLES ANALYSIS RFA</GrantOrContributionPurposeTxt>
          <Amt>448818</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JERUSALEM FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>420 LEXINGTON AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10170</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING A NEW HOME FOR TSAD KADIMA</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JEWISH BOARD OF FAMILY &amp; CHILDREN'S SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>463 7TH AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JEWISH BOARD OF FAMILY &amp; CHILDREN'S SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>463 7TH AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 NORTH BROADWAY MRB 117</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETED, SUSTAINED RELEASE ANTIFIBROTIC THERAPIES FOR CROHNS DISEASE PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>571287</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOSLIN DIABETES CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE JOSLIN PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02215</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES</GrantOrContributionPurposeTxt>
          <Amt>287280</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KAISER FOUNDATION HEALTH PLAN OF GEORGIA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1375 PEACHTREE STREET NE</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>30309</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF THE T1DES PILOT TO A PUBLIC HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>213776</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING CHRONIC INFLAMMATION AND TISSUE REMODELLING IN CROHN'S DISEASE WITH ENGINEERED T CELLS</GrantOrContributionPurposeTxt>
          <Amt>389044</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CROHNS DISEASE THE OATS STUDY</GrantOrContributionPurposeTxt>
          <Amt>490041</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMBODY EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY</GrantOrContributionPurposeTxt>
          <Amt>199460</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMBODY EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY</GrantOrContributionPurposeTxt>
          <Amt>205983</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FAT AS A VILLAIN IN CROHN'S DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>1344948</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDENT1FI</GrantOrContributionPurposeTxt>
          <Amt>1555353</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDENT1FI</GrantOrContributionPurposeTxt>
          <Amt>944656</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T CELL RECEPTOR SEQUENCING IN TYPE 1 DIABETES - BIOMARKER DISCOVERY AND TECHNOLOGY DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>115097</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HYPO - RESOLVE - EVALUATION OF BIOLOGICAL, SOCIAL AND ECONOMIC IMPACT OF HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>307779</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RESOLVING HARMFUL ACCUMULATION OF INNATE LYMPHOID CELLS DURING CROHNS DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>325389</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6) SUBJECTS</GrantOrContributionPurposeTxt>
          <Amt>260566</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6) SUBJECTS</GrantOrContributionPurposeTxt>
          <Amt>218298</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY)</GrantOrContributionPurposeTxt>
          <Amt>805337</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY)</GrantOrContributionPurposeTxt>
          <Amt>579408</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1069889</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1079926</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1147254</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1296483</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1325562</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III</GrantOrContributionPurposeTxt>
          <Amt>369984</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY STAGE III</GrantOrContributionPurposeTxt>
          <Amt>778535</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>FEODOR-LYNEN-STRAE 17</AddressLine1Txt>
            <CityNm>MUNCHEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>949869</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITT MNCHEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>FEODOR-LYNEN-STRABE 17</AddressLine1Txt>
            <CityNm>MUNCHEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>907027</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KYLER CARES FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8070 CROWDER BOULEVARD SUITE B</AddressLine1Txt>
            <CityNm>NEW ORLEANS</CityNm>
            <StateAbbreviationCd>LA</StateAbbreviationCd>
            <ZIPCd>70126</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>495000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KYLER CARES FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8070 CROWDER BOULEVARD SUITE B</AddressLine1Txt>
            <CityNm>NEW ORLEANS</CityNm>
            <StateAbbreviationCd>LA</StateAbbreviationCd>
            <ZIPCd>70126</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>251700</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LIVING WATER INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4001 GREENBRIAR DRIVE</AddressLine1Txt>
            <CityNm>STAFFORD</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77477</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING INTEGRATED WASH SERVICES</GrantOrContributionPurposeTxt>
          <Amt>2432337</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING PROGRESS AND PROMOTING QUALITY T1D CARE FOR THE POOREST BILLION THROUGH THE GLOBAL PEN-PLUS PARTNERSHIP</GrantOrContributionPurposeTxt>
          <Amt>8560477</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING PROGRESS AND PROMOTING QUALITY T1D CARE FOR THE POOREST BILLION THROUGH THE GLOBAL PEN-PLUS PARTNERSHIP</GrantOrContributionPurposeTxt>
          <Amt>9684661</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REAL-TIME POST-OP TOUCHLESS, REMOTE MONITORING IN CROHNS DISEASE THE SAPPHIRE TRIAL</GrantOrContributionPurposeTxt>
          <Amt>1445272</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REAL-TIME POST-OP TOUCHLESS, REMOTE MONITORING IN CROHNS DISEASE THE SAPPHIRE TRIAL</GrantOrContributionPurposeTxt>
          <Amt>767141</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>U.S. PREVENTIVE TYPE 1 DIABETES COALITION</GrantOrContributionPurposeTxt>
          <Amt>469406</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>U.S. PREVENTIVE TYPE 1 DIABETES COALITION</GrantOrContributionPurposeTxt>
          <Amt>429475</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>U.S. PREVENTIVE TYPE 1 DIABETES COALITION</GrantOrContributionPurposeTxt>
          <Amt>320341</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALIDATION OF WIRELESS THERMAL AND MICROSCOPIC IMAGING TECHNOLOGY FOR QUANTIFYING INFLAMMATION AND FIBROSIS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>123922</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALIDATION OF WIRELESS THERMAL AND MICROSCOPIC IMAGING TECHNOLOGY FOR QUANTIFYING INFLAMMATION AND FIBROSIS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>65218</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALIDATION OF WIRELESS THERMAL AND MICROSCOPIC IMAGING TECHNOLOGY FOR QUANTIFYING INFLAMMATION AND FIBROSIS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>781613</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALIDATION OF WIRELESS THERMAL AND MICROSCOPIC IMAGING TECHNOLOGY FOR QUANTIFYING INFLAMMATION AND FIBROSIS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>734202</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MILITARY SCIENCES MEDICAL TRAINING 2024-2026</GrantOrContributionPurposeTxt>
          <Amt>249920</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEDICAL UNIVERSITY OF SOUTH CAROLINA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>179 ASHLEY AVENUE</AddressLine1Txt>
            <CityNm>CHARLESTON</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>29425</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>384392</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MICHIGAN STATE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>426 AUDITORIUM ROAD ROOM 2</AddressLine1Txt>
            <CityNm>EAST LANSING</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>488242601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A C-PEPTIDE COMPLEX FOR IMPROVED GLUCOSE METABOLISM IN PEOPLE WITH TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>896270</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MILLE LACS HEALTH SYSTEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 ELM STREET NORTH</AddressLine1Txt>
            <CityNm>ONAMIA</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56359</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-PHARMACY AT MILLE LACS HEALTH SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>6809</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MINNESOTA RURAL HEALTH ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>27011 460TH AVE</AddressLine1Txt>
            <CityNm>HENNING</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56551</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL MINNESOTA</GrantOrContributionPurposeTxt>
          <Amt>378700</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MINNESOTA STATE COLLEGES AND UNIVERSITIES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>30 E 7TH STREET</AddressLine1Txt>
            <CityNm>ST PAUL</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING RURAL SONOGRAPHY EXPERTISE IN MINNESOTA</GrantOrContributionPurposeTxt>
          <Amt>205285</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONTANA PEDIATRICS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>259 W FRONT STREET</AddressLine1Txt>
            <CityNm>MISSOULA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59802</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATING A STATEWIDE MODEL OF CARE FOR CHILDREN WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>536186</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL ACADEMY OF SCIENCES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>500 5TH STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING MINORITY SERVING INSTITUTIONS</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL ASSOCIATION OF SCHOOL NURSES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 WAYNE AVE</AddressLine1Txt>
            <CityNm>SILVER SPRING</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>20910</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROVIDING COORDINATED CARE AND CAPTURING OUTCOMES FOR STUDENTS WITH T1D SCHOOL NURSE-LED PILOT PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1110787</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATURAL AREAS CONSERVANCY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1234 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING NYC'S URBAN FOREST PLAN NATURAL AREAS</GrantOrContributionPurposeTxt>
          <Amt>206868</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NCD ALLIANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>31-33 AVENUE GIUSEPPE MOTTA</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2023-2025 PARTNERSHIP</GrantOrContributionPurposeTxt>
          <Amt>1759350</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4126 TECHNOLOGY WAY</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89706</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEVADA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>60670</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW VENTURE FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1828 L STREET NW SUITE 300-A</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES CAMPS PROJECT (2025-2028)</GrantOrContributionPurposeTxt>
          <Amt>1894037</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW VENTURE FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1828 L STREET NW SUITE 300-A</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES CAMPS PROJECT (2025-2028)</GrantOrContributionPurposeTxt>
          <Amt>1842898</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK CITY HEALTH AND HOSPITALS CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>50 WATER STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROJECT ASAP BUILDING CAPACITY FOR SUPPORTIVE HOUSING FACILITATION AND BRIDGE CARE IN NYC'S PUBLIC HOSPITALS</GrantOrContributionPurposeTxt>
          <Amt>800000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK CITY HEALTH AND HOSPITALS CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>50 WATER STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROJECT ASAP BUILDING CAPACITY FOR SUPPORTIVE HOUSING FACILITATION AND BRIDGE CARE IN NYC'S PUBLIC HOSPITALS</GrantOrContributionPurposeTxt>
          <Amt>800000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK RESTORATION PROJECT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>254 WEST 31ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC URBAN REFORESTATION &amp; EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>306464</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK RESTORATION PROJECT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>254 WEST 31ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC URBAN REFORESTATION &amp; EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>665 BROADWAY SUITE 801</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANALYSIS OF MEDICAID AND RELATED DATA ON CARE TO HOMELESS SHELTER PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>100307</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>665 BROADWAY SUITE 801</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANALYSIS OF MEDICAID AND RELATED DATA ON CARE TO HOMELESS SHELTER PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>40419</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>665 BROADWAY SUITE 801</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANALYSIS OF MEDICAID AND RELATED DATA ON CARE TO HOMELESS SHELTER PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>55372</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>665 BROADWAY SUITE 801</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH</GrantOrContributionPurposeTxt>
          <Amt>1360453</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NORTH DAKOTA STATE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1301 12TH AVENUE N</AddressLine1Txt>
            <CityNm>FARGO</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING RURAL SONOGRAPHY EXPERTISE IN NORTH DAKOTA</GrantOrContributionPurposeTxt>
          <Amt>1295711</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NORTH DAKOTA STATE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1301 12TH AVENUE N</AddressLine1Txt>
            <CityNm>FARGO</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING RURAL SONOGRAPHY EXPERTISE IN NORTH DAKOTA</GrantOrContributionPurposeTxt>
          <Amt>494155</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OAKLAND UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2200 NORTH SQUIRREL ROAD</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48309</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2)</GrantOrContributionPurposeTxt>
          <Amt>1139629</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OAKLAND UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2200 NORTH SQUIRREL ROAD</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48309</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2)</GrantOrContributionPurposeTxt>
          <Amt>1019181</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OREGON HEALTH &amp; SCIENCE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3181 SW SAM JACKSON PARK ROAD</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>972393098</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN MDI DECISION SUPPORT SYSTEM WITH CDCES AND BEHAVIORAL HEALTH SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1783316</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PANORAMA GLOBAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2101 FOURTH AVENUE SUITE 2100</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T1D COMMUNITY FUND STAGE II</GrantOrContributionPurposeTxt>
          <Amt>1535971</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PANORAMA GLOBAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2101 FOURTH AVENUE SUITE 2100</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T1D COMMUNITY FUND STAGE II</GrantOrContributionPurposeTxt>
          <Amt>1444887</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PAPAHANAUMOKUAKEA MARINE DEBRIS PROJECT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>905 KALANIANAOLE HWY</AddressLine1Txt>
            <CityNm>KAILUA</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96734</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PAPAHANAUMOKUAKEA MARINE DEBRIS PROJECT CAPACITY-BUILDING</GrantOrContributionPurposeTxt>
          <Amt>268067</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PAPAHANAUMOKUAKEA MARINE DEBRIS PROJECT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>905 KALANIANAOLE HWY</AddressLine1Txt>
            <CityNm>KAILUA</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96734</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PAPAHANAUMOKUAKEA MARINE DEBRIS PROJECT CAPACITY-BUILDING</GrantOrContributionPurposeTxt>
          <Amt>225393</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 LETTERMAN DRIVE</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94129</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING AUTOIMMUNE DIABETES FOLLOWING CERTAIN CANCER IMMUNOTHERAPIES.</GrantOrContributionPurposeTxt>
          <Amt>358140</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PERKINS COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>900 LINCOLN AVE</AddressLine1Txt>
            <CityNm>GRANT</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69140</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES FOR PERKINS COUNTY HEALTH SERVICES</GrantOrContributionPurposeTxt>
          <Amt>14706</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PROJECT CONCERN ZAMBIA LIMITED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLOT 37/1P</AddressLine1Txt>
            <CityNm>LUSAKA</CityNm>
            <CountryCd>ZA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMPOWERED CHILDREN AND ADOLESCENTS PROGRAM PLUS</GrantOrContributionPurposeTxt>
          <Amt>1590680</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PULITZER CENTER ON CRISIS REPORTING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1779 MASSACHUSETTS AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INSIGHT AND CONNECTION THROUGH JOURNALISM AND EDUCATION</GrantOrContributionPurposeTxt>
          <Amt>400371</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PULITZER CENTER ON CRISIS REPORTING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1779 MASSACHUSETTS AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INSIGHT AND CONNECTION THROUGH JOURNALISM AND EDUCATION</GrantOrContributionPurposeTxt>
          <Amt>34097</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RAMBAM HEALTH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HAALIA HASNIA 8</AddressLine1Txt>
            <CityNm>HAIFA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM MICROBIAL AND DIETARY EFFECTS ON IMMUNE COMPOSITION AND FUNCTION IN PATIENTS WITH CD.</GrantOrContributionPurposeTxt>
          <Amt>746990</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REACHANOTHER FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1900 NE 3RD ST STE 106-307</AddressLine1Txt>
            <CityNm>BEND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>97701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>190186</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REACHANOTHER FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1900 NE 3RD ST STE 106-307</AddressLine1Txt>
            <CityNm>BEND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>97701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMING PEDIATRIC NEUROSURGERY SERVICES</GrantOrContributionPurposeTxt>
          <Amt>1119929</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REACHANOTHER FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1900 NE 3RD ST STE 106-307</AddressLine1Txt>
            <CityNm>BEND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>97701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMING PEDIATRIC NEUROSURGERY SERVICES</GrantOrContributionPurposeTxt>
          <Amt>122978</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MICHIGAN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS</GrantOrContributionPurposeTxt>
          <Amt>232662</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 OAK STREET SE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUING DEVELOPMENT OF OXYGEN SUPER-SATURATED SALINE FOR DEPLOYMENT IN MEDICAL EMERGENCIES</GrantOrContributionPurposeTxt>
          <Amt>269189</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 OAK STREET SE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES (PHASE 3)</GrantOrContributionPurposeTxt>
          <Amt>502750</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 OAK STREET SE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STANDARDIZED MICROBIOTA TRANSPLANT THERAPY IN CROHNS DISEASE. PILOT TRIAL.</GrantOrContributionPurposeTxt>
          <Amt>1454586</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 OAK STREET SE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STANDARDIZED MICROBIOTA TRANSPLANT THERAPY IN CROHNS DISEASE. PILOT TRIAL.</GrantOrContributionPurposeTxt>
          <Amt>585172</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 OAK STREET SE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THERAPEUTIC USE OF PEPTIDEMHC MABS FOR T1D</GrantOrContributionPurposeTxt>
          <Amt>220565</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 OAK STREET SE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THERAPEUTIC USE OF PEPTIDEMHC MABS FOR T1D</GrantOrContributionPurposeTxt>
          <Amt>166880</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGION HOVEDSTADEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>KONGENS VAENGE 2</AddressLine1Txt>
            <CityNm>HILLEROD</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAN MICROCHIMERISM EXPLAIN DIFFERENCES IN PARENTAL TYPE 1 DIABETES CONFERRED RISK OF OFFSPRING TYPE 1 DIABETES?</GrantOrContributionPurposeTxt>
          <Amt>113358</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RENOWN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1155 MILL ST</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89502</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RENOWN HEALTH TO BRING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) TO NORTHERN NEVADA</GrantOrContributionPurposeTxt>
          <Amt>243019</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RESEARCH TRIANGLE INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3040 EAST CORNWALLIS ROAD</AddressLine1Txt>
            <CityNm>DURHAM</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>277092194</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USING GENOME SEQUENCING AND GENETIC RISK SCORES TO IDENTIFY NEWBORNS WITH SERIOUS HEALTH CONDITIONS A STATEWIDE IMPLEMENTATION STUDY</GrantOrContributionPurposeTxt>
          <Amt>826376</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAFE WATER NETWORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>122 EAST 42ND STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10168</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING SUSTAINABLE SAFE WATER ACCESS</GrantOrContributionPurposeTxt>
          <Amt>1932000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAFE WATER NETWORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>122 EAST 42ND STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10168</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING SUSTAINABLE SAFE WATER ACCESS</GrantOrContributionPurposeTxt>
          <Amt>998000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SANFORD RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1305 W 18TH ST</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>571040569</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PLEDGE PHASE 3</GrantOrContributionPurposeTxt>
          <Amt>583363</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SANFORD RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1305 W 18TH ST</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>571040569</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PLEDGE PHASE 3</GrantOrContributionPurposeTxt>
          <Amt>1093143</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SANFORD WORLD CLINICS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1305 W 18TH ST</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROGRAM DETEKTA DETECTING TYPE 1 DIABETES AND PREVENTING DIABETIC KETOACIDOSIS (DKA)</GrantOrContributionPurposeTxt>
          <Amt>112523</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SANFORD WORLD CLINICS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1305 W 18TH ST</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROGRAM DETEKTA DETECTING TYPE 1 DIABETES AND PREVENTING DIABETIC KETOACIDOSIS (DKA)</GrantOrContributionPurposeTxt>
          <Amt>145752</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SEATTLE CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 5731 M/S S-200</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981455005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING USE OF ENGINEERED TREGS IN T1D THERAPY (PHASE 4)</GrantOrContributionPurposeTxt>
          <Amt>616923</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF THE HELMSLEY COMPREHENSIVE CARDIAC CARE CENTER</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF THE HELMSLEY COMPREHENSIVE CARDIAC CARE CENTER</GrantOrContributionPurposeTxt>
          <Amt>2000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF THE HELMSLEY SURGICAL WING</GrantOrContributionPurposeTxt>
          <Amt>2500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF THE HELMSLEY SURGICAL WING</GrantOrContributionPurposeTxt>
          <Amt>3500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHARE TRUST INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>310 DEDHAM ST</AddressLine1Txt>
            <CityNm>DOVER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING COMMUNITY DRIVEN COLLECTIVE ACTION</GrantOrContributionPurposeTxt>
          <Amt>1540658</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHATTERPROOF A NONPROFIT CORP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 MERRITT 7 CORPORATE PARK 1ST</AddressLine1Txt>
            <AddressLine2Txt>FLOOR</AddressLine2Txt>
            <CityNm>NORWALK</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06851</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>170000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIMULATION IN MOTION MONTANA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2021 11TH AVE SUITE 1</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SNV NETHERLANDS DEVELOPMENT ORGANISATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PARKSTRAAT 83</AddressLine1Txt>
            <CityNm>DEN HAAG</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING THE HEALTHY FUTURE FOR ALL MODEL</GrantOrContributionPurposeTxt>
          <Amt>1144205</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SNV NETHERLANDS DEVELOPMENT ORGANISATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PARKSTRAAT 83</AddressLine1Txt>
            <CityNm>DEN HAAG</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING THE HEALTHY FUTURE FOR ALL MODEL</GrantOrContributionPurposeTxt>
          <Amt>626684</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOLIDARIDAD NETWORK FOUNDATION LIMITED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>163 KUDU ROAD</AddressLine1Txt>
            <CityNm>LUSAKA</CityNm>
            <CountryCd>ZA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOOVES FOR SUSTAINABILITY (H4S)</GrantOrContributionPurposeTxt>
          <Amt>273384</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST LUKE HEALTH CARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>28W609 HICKORY LN</AddressLine1Txt>
            <CityNm>WEST CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60185</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOPE CENTER FOR WOMEN AND CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>4790316</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST LUKE HEALTH CARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>28W609 HICKORY LN</AddressLine1Txt>
            <CityNm>WEST CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60185</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOPE CENTER FOR WOMEN AND CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>1908524</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST MARK'S HOSPITAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>ACTON LANE</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PERIANAL CROHNS DISEASE (PCD) EDUCATIONAL MEETING AND TOPCLASS CONSORTIUM MEMBER CONFERENCE</GrantOrContributionPurposeTxt>
          <Amt>164712</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ROSE DOMINICAN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>102 E LAKE MEAD PARKWAY</AddressLine1Txt>
            <CityNm>HENDERSON</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89015</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGNITY HEALTH-ST. ROSE DOMINICAN - SIENA CAMPUS CATH LAB REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>172840</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ROSE DOMINICAN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>102 E LAKE MEAD PARKWAY</AddressLine1Txt>
            <CityNm>HENDERSON</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89015</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGNITY HEALTH-ST. ROSE DOMINICAN - SIENA CAMPUS CATH LAB REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>87671</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ROSE DOMINICAN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>102 E LAKE MEAD PARKWAY</AddressLine1Txt>
            <CityNm>HENDERSON</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89015</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGNITY HEALTH - ST. ROSE DOMINICAN - SIENA CAMPUS ECMO PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>101195</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>9 PRINCES ST</AddressLine1Txt>
            <CityNm>MELBOURNE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WHICH CHECKPOINTS MAINTAIN IMMUNE TOLERANCE TO BETA-CELLS IN GENETICALLY AT-RISK PEOPLE WHO DONT HAVE T1D?</GrantOrContributionPurposeTxt>
          <Amt>255857</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STATE UNIVERSITY OF IOWA FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE WEST PARK ROAD</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52242</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION-IOWA ENDOWMENT</GrantOrContributionPurposeTxt>
          <Amt>135000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STATE UNIVERSITY OF IOWA FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE WEST PARK ROAD</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52242</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION-IOWA ENDOWMENT</GrantOrContributionPurposeTxt>
          <Amt>135000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STATE UNIVERSITY OF IOWA FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE WEST PARK ROAD</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52242</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION-IOWA ENDOWMENT</GrantOrContributionPurposeTxt>
          <Amt>130000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING ACCESS TO MEDICINE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NARITAWEG 227 SUITE A</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ACCESS TO DIABETES CARE</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING ACCESS TO MEDICINE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NARITAWEG 227 SUITE A</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ACCESS TO DIABETES CARE</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING HEALTH ACTION INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OVERTOOM 60/II</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV</GrantOrContributionPurposeTxt>
          <Amt>1300026</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING HEALTH ACTION INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OVERTOOM 60/II</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV</GrantOrContributionPurposeTxt>
          <Amt>998988</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING PHARMACCESS INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AHTC TOWER C4 PAASHEUVELWEG 25</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SAFECARE A BUSINESS MODEL FOR HEALTHCARE QUALITY</GrantOrContributionPurposeTxt>
          <Amt>538692</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING THE OCEAN CLEANUP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BATAVIERENSTRAAT 15</AddressLine1Txt>
            <CityNm>ROTTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AND SCALE TECHNOLOGIES TO RID THE OCEANS OF PLASTICS</GrantOrContributionPurposeTxt>
          <Amt>5000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STIFTELSEN FOR UTBILDNING (IOIBD)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LINKPING UNIVERSITY HOSPITAL FLOOR</AddressLine1Txt>
            <AddressLine2Txt>14</AddressLine2Txt>
            <CityNm>OREBRO</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INVESTIGATIVE CAREERS IN IBD</GrantOrContributionPurposeTxt>
          <Amt>132000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SUPPORTIVE HOUSING NETWORK OF NEW YORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>247 W 37TH ST</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING ACADEMY AND COMMUNITY OF PRACTICE FOR SUPPORTIVE HOUSING PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>251200</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SUSTAINABLE COASTLINES HAWAII</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3160 WAIALAE AVE</AddressLine1Txt>
            <CityNm>HONOLULU</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96816</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING SUSTAINABLE COASTLINES HAWAII BUILDING LEADERSHIP FOR LONG-TERM GROWTH AND IMPACT</GrantOrContributionPurposeTxt>
          <Amt>274787</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SUSTAINABLE COASTLINES HAWAII</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3160 WAIALAE AVE</AddressLine1Txt>
            <CityNm>HONOLULU</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96816</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING SUSTAINABLE COASTLINES HAWAII BUILDING LEADERSHIP FOR LONG-TERM GROWTH AND IMPACT</GrantOrContributionPurposeTxt>
          <Amt>176000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TAMPERE UNIVERSITY FOUNDATION SR</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>KALEVANTIE 4 33100</AddressLine1Txt>
            <CityNm>TAMPERE</CityNm>
            <CountryCd>FI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENTEROVIRUS-INDUCED TYPE 1 DIABETES MECHANISMS AND BIOMARKERS FOR RISK</GrantOrContributionPurposeTxt>
          <Amt>419684</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TAMPERE UNIVERSITY FOUNDATION SR</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>KALEVANTIE 4 33100</AddressLine1Txt>
            <CityNm>TAMPERE</CityNm>
            <CountryCd>FI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENTEROVIRUS-INDUCED TYPE 1 DIABETES MECHANISMS AND BIOMARKERS FOR RISK</GrantOrContributionPurposeTxt>
          <Amt>283718</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WEIZMANN ST 6</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONSTRUCTION OF THE SHELTERED -5 FLOOR OF THE NORTH TOWER</GrantOrContributionPurposeTxt>
          <Amt>5120490</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WEIZMANN ST 6</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENETICS INSTITUTE AND GENOMICS CENTER</GrantOrContributionPurposeTxt>
          <Amt>2538786</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL-AVIV UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PO 39040</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY MEDICAL SIMULATION CENTER</GrantOrContributionPurposeTxt>
          <Amt>6828500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL-AVIV UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PO 39040</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY MEDICAL SIMULATION CENTER</GrantOrContributionPurposeTxt>
          <Amt>1524350</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL-AVIV UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PO 39040</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY MEDICAL SIMULATION CENTER</GrantOrContributionPurposeTxt>
          <Amt>1324350</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ACADEMIC COLLEGE AT TEL-HAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MOBILE POST 12210</AddressLine1Txt>
            <CityNm>UPPER GALILEE</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY FELLOWSHIPS FOR SUSTAINABILITY AND HEALTH</GrantOrContributionPurposeTxt>
          <Amt>3225321</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2012100 HALUTZ</AddressLine1Txt>
            <CityNm>RAMAT HANEGEV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RAMAT HANEGEV SENIOR CITIZEN CENTER</GrantOrContributionPurposeTxt>
          <Amt>699190</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2012100 HALUTZ</AddressLine1Txt>
            <CityNm>RAMAT HANEGEV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RAMAT HANEGEV CENTRAL AUDITORIUM</GrantOrContributionPurposeTxt>
          <Amt>1109829</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BIONICS INSTITUTE OF AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>384-388 ALBERT STREET</AddressLine1Txt>
            <CityNm>EAST MELBOURNE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PATIENT-SPECIFIC ADAPTIVE, ELECTRIC THERAPY FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>932181</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BIONICS INSTITUTE OF AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>384-388 ALBERT STREET</AddressLine1Txt>
            <CityNm>EAST MELBOURNE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PATIENT-SPECIFIC ADAPTIVE, ELECTRIC THERAPY FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>477568</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNCOVERING CROHN'S GENETIC RISK IN AFRICAN-AMERICAN AND HISPANIC/LATINO POPULATIONS</GrantOrContributionPurposeTxt>
          <Amt>1129976</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>3499051</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>3477159</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TRINITY LANE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPIGENETIC REGULATION OF INTESTINAL EPITHELIAL MHC CLASS 1 SIGNALLING - A NOVEL MECHANISM IN THE PATHOGENESIS OF CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>718215</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TRINITY LANE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH TYPE 1 DIABETES AGES 10 TO 18 YEARS (PART 2)</GrantOrContributionPurposeTxt>
          <Amt>353223</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TRINITY LANE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DOES THE WESTERN DIET TRIGGER CROHN'S DISEASE VIA OSMOTIC STRESS?</GrantOrContributionPurposeTxt>
          <Amt>726752</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TRINITY LANE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW INSIGHTS INTO CROHN'S DISEASE FROM STUDYING NAKED MOLE RATS</GrantOrContributionPurposeTxt>
          <Amt>347219</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TRINITY LANE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DOES BIOCHEMISTRY AT THE CENTRE OF LIFE DRIVE CROHN'S DISEASE?</GrantOrContributionPurposeTxt>
          <Amt>851645</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TRINITY LANE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DOES BIOCHEMISTRY AT THE CENTRE OF LIFE DRIVE CROHN'S DISEASE?</GrantOrContributionPurposeTxt>
          <Amt>820911</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CD318 MEDIATED REGULATION OF ISLET AUTOANTIGEN SPECIFIC T CELL IMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>371800</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MECHANOBIOLOGY OF THE INTESTINAL EPITHELIAL BARRIER DISRUPTION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>342955</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>719051</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE END FUND INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10016</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TACKLING TRACHOMA SURGERY DISPARITIES</GrantOrContributionPurposeTxt>
          <Amt>2124880</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE END FUND INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10016</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TACKLING TRACHOMA SURGERY DISPARITIES</GrantOrContributionPurposeTxt>
          <Amt>2132360</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A DRUG-WIDE SCAN TO IDENTIFY REPURPOSED MEDICATIONS FOR CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>430190</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A DRUG-WIDE SCAN TO IDENTIFY REPURPOSED MEDICATIONS FOR CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>424253</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HOSPITAL FOR SICK CHILDREN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>555 UNIVERSITY AVE</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNE RESPONSES TO GUT MICROBES ASSOCIATED WITH T1D RISK AND PROGRESSION</GrantOrContributionPurposeTxt>
          <Amt>250415</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>EXHIBITION RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION</GrantOrContributionPurposeTxt>
          <Amt>340788</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>EXHIBITION RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION</GrantOrContributionPurposeTxt>
          <Amt>234854</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>EXHIBITION RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNRAVELING THE IMMUNOPATHOLOGY OF PERIANAL FISTULIZING CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1081289</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE LANIADO KIRIAT SANZ HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DIVREI KHAYIM ST 16</AddressLine1Txt>
            <CityNm>NATANIYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW MATERNITY FLOOR C</GrantOrContributionPurposeTxt>
          <Amt>1350000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL LTD (CC)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>YEZREEL VALLEY</AddressLine1Txt>
            <CityNm>YEZREEL VALLEY</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>OPPORTUNITY FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS PURSUING NURSING DEGREES</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL LTD (CC)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>YEZREEL VALLEY</AddressLine1Txt>
            <CityNm>YEZREEL VALLEY</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>OPPORTUNITY FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS PURSUING NURSING DEGREES</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>120 THEORY SUITE 200</AddressLine1Txt>
            <CityNm>IRVINE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>926971050</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A MULTI-ANALYTE SENSOR - GLUCOSE, LACTATE, OXYGEN, KETONES, INSULIN FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>620649</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 GILMAN DRIVE</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92093</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MECHANISM OF ACTION AND SAFETY STUDY OF LIVER TARGETED INSULIN</GrantOrContributionPurposeTxt>
          <Amt>471131</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 GILMAN DRIVE</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92093</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DRUGGABLE GPCROME IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1092733</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF A DATA COMMONS</GrantOrContributionPurposeTxt>
          <Amt>458242</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF A DATA COMMONS</GrantOrContributionPurposeTxt>
          <Amt>217916</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SANTA BARBARA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>552 UNIVERSITY ROAD</AddressLine1Txt>
            <CityNm>SANTA BARBARA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>93106</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE SPECIFIC AID ALGORITHM FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1116996</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPITHELIAL MITOCHONDRIAL DYSFUNCTION AND EXTRACELLULAR VESICLES IN CROHNS DISEASE FIBROSTENOSIS.</GrantOrContributionPurposeTxt>
          <Amt>431482</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREPARE 4 AID PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY</GrantOrContributionPurposeTxt>
          <Amt>1840786</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREPARE 4 AID PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY</GrantOrContributionPurposeTxt>
          <Amt>996486</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE)</GrantOrContributionPurposeTxt>
          <Amt>807989</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE)</GrantOrContributionPurposeTxt>
          <Amt>706939</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING HUMAN ISLET MYELOID CELL POPULATIONS THROUGH PROGRESSION OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>226229</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING HUMAN ISLET MYELOID CELL POPULATIONS THROUGH PROGRESSION OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>239819</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPIGENOMIC BIOMARKERS OF THE INCOMPLETE MATERNAL PROTECTION IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>459401</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPIGENOMIC BIOMARKERS OF THE INCOMPLETE MATERNAL PROTECTION IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>329695</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T AND B CELL RECEPTOR ATLAS ACROSS TISSUES AND STAGES OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>501000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)</GrantOrContributionPurposeTxt>
          <Amt>1036513</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)</GrantOrContributionPurposeTxt>
          <Amt>552433</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>1215803</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>319937</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ASK THE EXPERTS 2024</GrantOrContributionPurposeTxt>
          <Amt>499998</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>13001 E 17TH PLACE</AddressLine1Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ASK THE EXPERTS 2024</GrantOrContributionPurposeTxt>
          <Amt>499995</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNINGMCGILL UNIV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>845 SHERBROOKE STREET WEST</AddressLine1Txt>
            <CityNm>MONTREAL</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA GOVERNANCE RESOURCE</GrantOrContributionPurposeTxt>
          <Amt>185694</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNINGMCGILL UNIV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>845 SHERBROOKE STREET WEST</AddressLine1Txt>
            <CityNm>MONTREAL</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA GOVERNANCE RESOURCE</GrantOrContributionPurposeTxt>
          <Amt>182394</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SCRIPPS RESEARCH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10550 NORTH TORREY PINES ROAD</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GUT-RETAINED NRF2/ARE ACTIVATORS FOR IBD</GrantOrContributionPurposeTxt>
          <Amt>1836022</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SDEROT DEVELOPMENT FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>6 BAR LEV STREET</AddressLine1Txt>
            <CityNm>SDEROT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SDEROT MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>993626</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2 KATZIR</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM CAPSULE &amp; OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)</GrantOrContributionPurposeTxt>
          <Amt>188118</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2 KATZIR</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE UTILITY OF HAND-HELD ULTRASOUND DEVICES TO DETECT BOWEL WALL INFLAMMATORY ACTIVITY IN CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>84659</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SONIA NABETA FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4705 5TH STREET UNIT 405</AddressLine1Txt>
            <CityNm>LONG ISLAND CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WORLD OF WARRIORS</GrantOrContributionPurposeTxt>
          <Amt>514210</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SONIA NABETA FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4705 5TH STREET UNIT 405</AddressLine1Txt>
            <CityNm>LONG ISLAND CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WORLD OF WARRIORS</GrantOrContributionPurposeTxt>
          <Amt>578470</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TEL AVIV JAFFA ACADEMIC COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RABENU YERUHAM ST 2 POB 8401</AddressLine1Txt>
            <CityNm>TEL AVIV YAFFO</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEED-BASED SCHOLARSHIPS FOR NURSING STUDENTS</GrantOrContributionPurposeTxt>
          <Amt>266666</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TREVOR PROJECT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 69232</AddressLine1Txt>
            <CityNm>WEST HOLLYWOOD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90069</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LGBTQ YOUTH SUICIDE PREVENTION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1536740</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TREVOR PROJECT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 69232</AddressLine1Txt>
            <CityNm>WEST HOLLYWOOD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90069</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LGBTQ YOUTH SUICIDE PREVENTION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1282735</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT FOR T1D TRANSITION PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF ADELAIDE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTH TERRACE</AddressLine1Txt>
            <CityNm>ADELAIDE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PANCREATIC EXOCRINE FUNCTION AND THE PROGRESSION TO TYPE 1 DIABETES IN YOUNG CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>43631</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>SOUTH BRIDGE</AddressLine1Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REPURPOSING POSITIVE ALLOSTERIC MODULATORS OF GLUTAMATE RECEPTORS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES A PILOT CLINICAL STUDY</GrantOrContributionPurposeTxt>
          <Amt>646292</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>SOUTH BRIDGE</AddressLine1Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REPURPOSING POSITIVE ALLOSTERIC MODULATORS OF GLUTAMATE RECEPTORS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES A PILOT CLINICAL STUDY</GrantOrContributionPurposeTxt>
          <Amt>426524</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF MANCHESTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OXFORD RD</AddressLine1Txt>
            <CityNm>MANCHESTER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A MAP OF THE INTESTINE FOLLOWING REGULATORY T CELL INFUSION INTO PATIENTS WITH ACTIVE CROHNS DISEASE AT SINGLE-CELL AND SPATIAL RESOLUTION</GrantOrContributionPurposeTxt>
          <Amt>692839</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY CHILDHOOD DEVELOPMENT AND COMMUNITY CENTER AT THE WEIZMANN INSTITUTE OF SCIENCE</GrantOrContributionPurposeTxt>
          <Amt>3000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS</GrantOrContributionPurposeTxt>
          <Amt>1302462</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF INDIANA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>509 EAST 3RD STREET</AddressLine1Txt>
            <CityNm>BLOOMINGTON</CityNm>
            <StateAbbreviationCd>ID</StateAbbreviationCd>
            <ZIPCd>474013654</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE FINDING IMMUNE NASCENT DIABETES (FIND-T1D)</GrantOrContributionPurposeTxt>
          <Amt>452575</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF INDIANA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>509 EAST 3RD STREET</AddressLine1Txt>
            <CityNm>BLOOMINGTON</CityNm>
            <StateAbbreviationCd>ID</StateAbbreviationCd>
            <ZIPCd>474013654</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE FINDING IMMUNE NASCENT DIABETES (FIND-T1D)</GrantOrContributionPurposeTxt>
          <Amt>475212</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSIT DEGLI STUDI DI MILANO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>VIA FESTA DEL PERDONO 7</AddressLine1Txt>
            <CityNm>MILAN</CityNm>
            <CountryCd>IT</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNRAVELING THE ROLE OF CD45RACCR7 CD4 T CELLS IN THE PATHOGENESIS OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>321749</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITA DEGLI STUDI DI MILANO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>VIA FESTA DEL PERDONO 7</AddressLine1Txt>
            <CityNm>MILAN</CityNm>
            <CountryCd>IT</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNRAVELING THE ROLE OF CD45RACCR7 CD4 T CELLS IN THE PATHOGENESIS OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>213050</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE CATHOLIQUE DE LOUVAIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLACE DE LUNIVERSITE 1</AddressLine1Txt>
            <CityNm>LOUVAINLANEUVE</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEARCH FOR MECHANISMS RESPONSIBLE FOR THE IMPAIRED GLUCAGON SECRETION IN T1D AND FOR STRATEGIES TO CORRECT THEM</GrantOrContributionPurposeTxt>
          <Amt>304033</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE CATHOLIQUE DE LOUVAIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLACE DE LUNIVERSITE 1</AddressLine1Txt>
            <CityNm>LOUVAINLANEUVE</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEARCH FOR MECHANISMS RESPONSIBLE FOR THE IMPAIRED GLUCAGON SECRETION IN T1D AND FOR STRATEGIES TO CORRECT THEM</GrantOrContributionPurposeTxt>
          <Amt>152546</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE LIBRE DE BRUXELLES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE FRANKLIN ROOSEVELT 50</AddressLine1Txt>
            <CityNm>BRUSSELS</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDYING THE SELECTIVEB CELL SENSITIVITY TO A HOMOZYGOUS PD-L1 MUTATION IN NEONATAL DIABETES</GrantOrContributionPurposeTxt>
          <Amt>217239</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY HOSPITALS HEALTH SYSTEM INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>11100 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44106</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS</GrantOrContributionPurposeTxt>
          <Amt>677700</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1800 W CHARLESTON BLVD</AddressLine1Txt>
            <CityNm>LAS VEGAS</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF AN EXTRACORPOREAL LIFE SUPPORT (ECLS) PROGRAM AT UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA</GrantOrContributionPurposeTxt>
          <Amt>84783</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF BIRMINGHAM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CHANCELLORS COURT</AddressLine1Txt>
            <CityNm>BIRMINGHAM</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATING AN OPTIMISED ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>479888</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF BRISTOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TYNDALL AVENUE</AddressLine1Txt>
            <CityNm>BRISTOL</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RISK IN ADULTS (T1DRA) A GENERAL POPULATION STUDY</GrantOrContributionPurposeTxt>
          <Amt>358900</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CINCINNATI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>51 GOODMAN DRIVE SUITE 500</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45221</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDIES ON THE ROLE OF C-PEPTIDE TO REGULATE BLOOD GLUCOSE DURING SLEEP AND EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>429700</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADVANCINGB-CELL SPECIFIC THERAPY BY IDENTIFYINGB-CELL REACTIVE HIGH AFFINITY T CELL RECEPTORS</GrantOrContributionPurposeTxt>
          <Amt>70533</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXTREMELY EARLY ONSET TYPE 1 DIABETES (EXE T1D) PHASE 2 FROM OBSERVATION TO MECHANISM</GrantOrContributionPurposeTxt>
          <Amt>465868</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNCOVERING NEW GENETIC MECHANISMS UNDERLYING EXTREME EARLY-ONSET TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>692073</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNCOVERING NEW GENETIC MECHANISMS UNDERLYING EXTREME EARLY-ONSET TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>189671</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>B CELL SIGNATURES IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>260351</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>B CELL SIGNATURES IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>40825</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING T1D AND INSULIN-REQUIRING DIABETES IN FEDERALLY QUALIFIED HEALTH CENTERS (FQHC) A NATIONAL NEEDS ASSESSMENT</GrantOrContributionPurposeTxt>
          <Amt>208595</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>586219</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>435671</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF GLASGOW COURT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY AVENUE</AddressLine1Txt>
            <CityNm>GLASGOW</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ROLE OF THE GUT MICROBIOME IN POSTOPERATIVE OUTCOMES AND DISEASE RECURRENCE IN SURGICAL ADULTS WITH CD TREATED WITH EXCLUSIVE ENTERAL NUTRITION.</GrantOrContributionPurposeTxt>
          <Amt>425075</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF GLASGOW COURT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY AVENUE</AddressLine1Txt>
            <CityNm>GLASGOW</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ROLE OF THE GUT MICROBIOME IN POSTOPERATIVE OUTCOMES AND DISEASE RECURRENCE IN SURGICAL ADULTS WITH CD TREATED WITH EXCLUSIVE ENTERAL NUTRITION.</GrantOrContributionPurposeTxt>
          <Amt>1968566</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF GLASGOW COURT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY AVENUE</AddressLine1Txt>
            <CityNm>GLASGOW</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ROLE OF THE GUT MICROBIOME IN POSTOPERATIVE OUTCOMES AND DISEASE RECURRENCE IN SURGICAL ADULTS WITH CD TREATED WITH EXCLUSIVE ENTERAL NUTRITION.</GrantOrContributionPurposeTxt>
          <Amt>426282</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF HAWAII</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2444 DOLE STREET</AddressLine1Txt>
            <CityNm>HONOLULU</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96822</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING HEALTH ACROSS RURAL HAWAII THROUGH RESEARCH AND POLICY</GrantOrContributionPurposeTxt>
          <Amt>193410</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF HAWAII</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2444 DOLE STREET</AddressLine1Txt>
            <CityNm>HONOLULU</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96822</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING HEALTH ACROSS RURAL HAWAII THROUGH RESEARCH AND POLICY</GrantOrContributionPurposeTxt>
          <Amt>190434</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF IOWA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>112 NORTH CAPITOL STREET</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52442</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORTING THE RUPRI HEALTH PANEL TO BRING RESEARCH AND EXPERTISE TO INFORM POLICY DEVELOPMENT AND IMPLEMENTATION</GrantOrContributionPurposeTxt>
          <Amt>204566</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MELBOURNE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>161 BARRY STREET</AddressLine1Txt>
            <CityNm>VICTORIA</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USE OF WHEY PROTEIN TO REDUCE RISK OF HYPOGLYCEMIA DURING EXERCISE FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>524787</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MIAMI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1320 SOUTH DIXIE HIGHWAY SUITE 650</AddressLine1Txt>
            <CityNm>CORAL GABLES</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33146</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICES</GrantOrContributionPurposeTxt>
          <Amt>282000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FREQUENCY AND TITER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AUTO-ANTIBODIES IN PATIENTS WITH CD-LIKE DISEASE OF THE POUCH</GrantOrContributionPurposeTxt>
          <Amt>336550</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FREQUENCY AND TITER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AUTO-ANTIBODIES IN PATIENTS WITH CD-LIKE DISEASE OF THE POUCH</GrantOrContributionPurposeTxt>
          <Amt>71233</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING INTEGRATION OF PORTABLE ULTRASOUNDS</GrantOrContributionPurposeTxt>
          <Amt>1058738</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A CONTINUOUS INSULIN SENSOR</GrantOrContributionPurposeTxt>
          <Amt>1306168</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH DAKOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1301 N COLUMBIA RD SUITE E105</AddressLine1Txt>
            <CityNm>GRAND FORKS</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION (SIM) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>54673</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF OULU</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PO BOX 8000</AddressLine1Txt>
            <CityNm>OULU</CityNm>
            <CountryCd>FI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING</GrantOrContributionPurposeTxt>
          <Amt>135549</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF PITTSBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3420 FORBES AVENUE</AddressLine1Txt>
            <CityNm>PITTSBURGH</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>152603203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANALOGUE VS HUMAN INSULIN FOR YOUTH WITH TYPE 1 DIABETES IN LOW-RESOURCE SETTINGS A RANDOMIZED CONTROLLED TRIAL (ANHUT1D TRIAL)</GrantOrContributionPurposeTxt>
          <Amt>307891</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2304 WHITIS AVE</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>787121111</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN</GrantOrContributionPurposeTxt>
          <Amt>200927</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WASHINGTON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4333 BROOKLYN AVENUE NE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981959472</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PATHOGENIC ACTION OF AUTOANTIBODIES ON ISLET FUNCTION AND VIABILITY IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>385000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WESTERN ONTARIO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>339 WINDERMERE RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>756873</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WESTERN ONTARIO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>339 WINDERMERE RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>606448</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WYOMING FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>222 S 22ND ST</AddressLine1Txt>
            <CityNm>LARAMIE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRASOUND TRAINING INITIATIVE IN WYOMING</GrantOrContributionPurposeTxt>
          <Amt>458857</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WYOMING FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>222 S 22ND ST</AddressLine1Txt>
            <CityNm>LARAMIE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRASOUND TRAINING INITIATIVE IN WYOMING</GrantOrContributionPurposeTxt>
          <Amt>458857</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UPPSALA UNIVERSITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AKADEMISKA SJUKHUSET</AddressLine1Txt>
            <CityNm>UPPSALA</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNE-EVASIVE ISLETS FOR TRANSPLANTATION</GrantOrContributionPurposeTxt>
          <Amt>360374</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>URBAN PATHWAYS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>575 EIGHTH AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>URBAN PATHWAYS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>575 EIGHTH AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH (CH4H) STEERING COMMITTEE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3319 WEST END AVENUE SUITE 970</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF PANCREATLAS CONNECTIVITY PLATFORM AND PHENOTYPING OF HANDEL SAMPLES BY CUTTING-EDGE SINGLE CELL MULTIOME TECHNOLOGY</GrantOrContributionPurposeTxt>
          <Amt>149050</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3319 WEST END AVENUE SUITE 970</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEW APPROACHES TO PREVENT HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>104599</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3319 WEST END AVENUE SUITE 970</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>232525</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3319 WEST END AVENUE SUITE 970</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>182168</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOT TO DESIGN A VALUE BASED PAYMENT ECOSYSTEM TO IMPROVE HEALTH AND EQUITY FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>318000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1242777</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>2000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>4275632</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 BROOKINGS DRIVE</AddressLine1Txt>
            <CityNm>SAINT LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>63130</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL DEVELOPMENT TO ADVANCE A T1D ANTIGEN-SPECIFIC IMMUNOTHERAPY CALLED SAGA-T1D</GrantOrContributionPurposeTxt>
          <Amt>1319373</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WATER4 INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2405 NW 10TH STREET</AddressLine1Txt>
            <CityNm>OKLAHOMA CITY</CityNm>
            <StateAbbreviationCd>OK</StateAbbreviationCd>
            <ZIPCd>73107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING NUMA IN NORTHERN GHANA</GrantOrContributionPurposeTxt>
          <Amt>2294479</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WATER4 INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2405 NW 10TH STREET</AddressLine1Txt>
            <CityNm>OKLAHOMA CITY</CityNm>
            <StateAbbreviationCd>OK</StateAbbreviationCd>
            <ZIPCd>73107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING NUMA IN NORTHERN GHANA</GrantOrContributionPurposeTxt>
          <Amt>2647448</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>POB 26</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS</GrantOrContributionPurposeTxt>
          <Amt>1397538</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WESTCHESTER JEWISH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>175 ROCKLAND AVE</AddressLine1Txt>
            <CityNm>MAMARONECK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10543</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>7500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WILCOX HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3-3420 KUHIO HIGHWAY</AddressLine1Txt>
            <CityNm>LIHUE</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96766</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WILCOX MEDICAL CENTER EQUIPMENT REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>6273000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WILCOX HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3-3420 KUHIO HIGHWAY</AddressLine1Txt>
            <CityNm>LIHUE</CityNm>
            <StateAbbreviationCd>HI</StateAbbreviationCd>
            <ZIPCd>96766</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WILCOX MEDICAL CENTER EQUIPMENT REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>409000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WORLD HEALTH ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE APPIA 20</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING INTEGRATED PREVENTION AND CONTROL OF CHRONIC AND SEVERE NCDS IN THE WHO AFRICAN REGION, USING T1D, SCD, ARF, AND RHD AS ENTRY POINTS</GrantOrContributionPurposeTxt>
          <Amt>3010445</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WORLD HEALTH ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE APPIA 20</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING THE CAPACITY OF THE GLOBAL DIABETES COMPACT</GrantOrContributionPurposeTxt>
          <Amt>3130872</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WYOMING ASSOCIATION OF SHERIFFS AND CHIEFS OF POLICE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 481</AddressLine1Txt>
            <CityNm>DOUGLAS</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82633</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING VIRTUAL CRISIS CARE PILOT PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>851113</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WYOMING ASSOCIATION OF SHERIFFS AND CHIEFS OF POLICE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 481</AddressLine1Txt>
            <CityNm>DOUGLAS</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82633</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING VIRTUAL CRISIS CARE PILOT PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>746408</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 208327</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING NEWLY DISCOVERED HOST-MICROBIOTA INTERACTION NODES TO TREAT OR PREVENT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>605522</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YEHUDA ABARBANEL GOVERNMENT HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>15 KEREN KAYEMET ST</AddressLine1Txt>
            <CityNm>BAT YAM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MODERNIZATION OF ABARBANELS INFORMATION TECHNOLOGY AND SECURITY SYSTEMS</GrantOrContributionPurposeTxt>
          <Amt>454960</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YOUTH DEVELOPMENT ORGANIZATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15 UNION STREET 563</AddressLine1Txt>
            <CityNm>LAWRENCE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01840</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING PROJECT SUPPORT 2024-2026</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <TotalGrantOrContriApprvFutAmt>482120897</TotalGrantOrContriApprvFutAmt>
      </SupplementaryInformationGrp>
      <AnalysisIncomeProducingActyGrp>
        <IntOnSavAndTempCashInvstGrp>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>3123289</ExclusionAmt>
        </IntOnSavAndTempCashInvstGrp>
        <DividendsAndInterestFromSecDtl>
          <BusinessCd>901101</BusinessCd>
          <UnrelatedBusinessTaxblIncmAmt>3051525</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>66448142</ExclusionAmt>
        </DividendsAndInterestFromSecDtl>
        <OtherInvestmentIncomeGrp>
          <BusinessCd>901101</BusinessCd>
          <UnrelatedBusinessTaxblIncmAmt>14231233</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>11117546</ExclusionAmt>
        </OtherInvestmentIncomeGrp>
        <GainSalesAstOthThanInvntryGrp>
          <BusinessCd>901101</BusinessCd>
          <UnrelatedBusinessTaxblIncmAmt>3193622</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionCd>18</ExclusionCd>
          <ExclusionAmt>385444220</ExclusionAmt>
        </GainSalesAstOthThanInvntryGrp>
        <OtherRevenueDescribedGrp>
          <Desc>GRANT RECOVERIES</Desc>
          <ExclusionCd>01</ExclusionCd>
          <ExclusionAmt>7276276</ExclusionAmt>
        </OtherRevenueDescribedGrp>
        <OtherRevenueDescribedGrp>
          <Desc>OTHER NON-TAXABLE INCOME</Desc>
          <ExclusionCd>01</ExclusionCd>
          <ExclusionAmt>27454</ExclusionAmt>
        </OtherRevenueDescribedGrp>
        <OtherRevenueDescribedGrp>
          <Desc>FEDERAL EXCISE TAX BENEFIT</Desc>
          <ExclusionCd>01</ExclusionCd>
          <ExclusionAmt>3842567</ExclusionAmt>
        </OtherRevenueDescribedGrp>
        <OtherRevenueDescribedGrp>
          <Desc>FX TRANSACTION NET LOSS - BOOK</Desc>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>-496216</ExclusionAmt>
        </OtherRevenueDescribedGrp>
        <SubtotalsIncmProducingActyGrp>
          <UnrelatedBusinessTaxblIncmAmt>20476380</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionAmt>476783278</ExclusionAmt>
          <RelatedOrExemptFunctionIncmAmt>0</RelatedOrExemptFunctionIncmAmt>
        </SubtotalsIncmProducingActyGrp>
        <TotalIncomeProducingActyAmt>497259658</TotalIncomeProducingActyAmt>
      </AnalysisIncomeProducingActyGrp>
      <TrnsfrTransRlnNonchrtblEOGrp>
        <TrnsfrOfCashToNonchrtblEOInd>1</TrnsfrOfCashToNonchrtblEOInd>
        <TrnsfrOtherAssetNonchrtblEOInd>0</TrnsfrOtherAssetNonchrtblEOInd>
        <SalesOrExchangesOfAssetsInd>0</SalesOrExchangesOfAssetsInd>
        <PurchaseOfAssetsNonchrtblEOInd>0</PurchaseOfAssetsNonchrtblEOInd>
        <RentalOfFacilitiesOthAssetsInd>0</RentalOfFacilitiesOthAssetsInd>
        <ReimbursementArrangementsInd>0</ReimbursementArrangementsInd>
        <LoansOrLoanGuaranteesInd>0</LoansOrLoanGuaranteesInd>
        <PerformanceOfServicesEtcInd>0</PerformanceOfServicesEtcInd>
        <SharingOfFacilitiesEtcInd>0</SharingOfFacilitiesEtcInd>
        <TransferScheduleDetail>
          <LineNumberTxt>1a(1)</LineNumberTxt>
          <InvolvedAmt>1885608</InvolvedAmt>
          <NoncharitableExemptOrgName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </NoncharitableExemptOrgName>
          <TransfersTransAndShrArrngmDesc>GRANT IN SUPPORT OF EXPANSION OF THE DANATECH PLATFORM TO IMPROVE T1D CARE</TransfersTransAndShrArrngmDesc>
        </TransferScheduleDetail>
        <RelationshipsNonchrtblEOInd>0</RelationshipsNonchrtblEOInd>
      </TrnsfrTransRlnNonchrtblEOGrp>
    </IRS990PF>
    <AccountingFeesSchedule documentId="RetDoc2002200001">
      <AccountingFeesDetail>
        <CategoryTxt>AUDIT AND TAX PREPARATION</CategoryTxt>
        <Amt>224069</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>151031</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
      <AccountingFeesDetail>
        <CategoryTxt>BOOKKEEPING</CategoryTxt>
        <Amt>33406</Amt>
        <NetInvestmentIncomeAmt>6023</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>31269</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
      <AccountingFeesDetail>
        <CategoryTxt>OTHER ACCOUNTING SERVICES</CategoryTxt>
        <Amt>46450</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>46450</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
    </AccountingFeesSchedule>
    <AllOthProgRltdInvestmentsSch documentId="RetDoc2063500001">
      <AllOtherProgramRelatedInvstGrp>
        <Desc>ABVANCE THERAPEUTICS, INC. - DEVELOPMENT OF ABV100, A FIXED-RATIO COFORMULATION OF INSULIN AND GLUCAGON</Desc>
        <Amt>1170000</Amt>
      </AllOtherProgramRelatedInvstGrp>
      <AllOtherProgramRelatedInvstGrp>
        <Desc>IMMUNOMOLECULAR THERAPEUTICS, INC. - TARGETED IMMUNOTHERAPY TO TREAT TYPE 1 DIABETES</Desc>
        <Amt>350000</Amt>
      </AllOtherProgramRelatedInvstGrp>
    </AllOthProgRltdInvestmentsSch>
    <ExpenditureResponsibilityStmt documentId="RetDoc2118100001">
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>A GLIMMER OF HOPE FOUNDATION</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 579</AddressLine1Txt>
          <CityNm>CEDAR PARK</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>78630</ZIPCd>
        </USAddress>
        <GrantDt>2018-02-20</GrantDt>
        <GrantAmt>5000000</GrantAmt>
        <PurposeOfGrantTxt>INTEGRATED COMMUNITY DEVELOPMENT IN AMHARA, ETHIOPIA</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>5000000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 1/2020, 2/2021, 1/2022, 1/2023, 1/2024, 2/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>A GLIMMER OF HOPE FOUNDATION</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 579</AddressLine1Txt>
          <CityNm>CEDAR PARK</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>78630</ZIPCd>
        </USAddress>
        <GrantDt>2022-12-20</GrantDt>
        <GrantAmt>4800000</GrantAmt>
        <PurposeOfGrantTxt>EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2799822</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>1/2024, 1/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ABVANCE THERAPEUTICS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>38 BENNINGTON COURT</AddressLine1Txt>
          <CityNm>RENO</CityNm>
          <StateAbbreviationCd>NV</StateAbbreviationCd>
          <ZIPCd>89511</ZIPCd>
        </USAddress>
        <GrantDt>2024-06-18</GrantDt>
        <GrantAmt>3920820</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF ABV100, A FIXED-RATIO COFORMULATION OF INSULIN AND GLUCAGON</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1203212</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>10/2024, 3/2025, 4/2025, 7/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>AKSTON BIOSCIENCES CORPORATION</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>100 CUMMINGS CENTER SUITE 454C</AddressLine1Txt>
          <CityNm>BEVERLY</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>01915</ZIPCd>
        </USAddress>
        <GrantDt>2017-03-01</GrantDt>
        <GrantAmt>6194000</GrantAmt>
        <PurposeOfGrantTxt>PRECLINICAL TRIAL OF INSULIN-FUSION TO END AUTOIMMUNITY &amp; IMPROVE QUALITY OF LIFE FOR PEOPLE LIVING WITH T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>6194000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 3/2024, 6/2024, 9/2024, 10/2024, 3/2025, 5/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ALIMENTIV INC (FKA ROBARTS)</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
          <CityNm>LONDON</CityNm>
          <ProvinceOrStateNm>ON</ProvinceOrStateNm>
          <CountryCd>CA</CountryCd>
        </ForeignAddress>
        <GrantDt>2024-11-05</GrantDt>
        <GrantAmt>1275257</GrantAmt>
        <PurposeOfGrantTxt>VALIDATION OF THE PRO SYMPTOMS AND IMPACTS QUESTIONNAIRE FOR CROHNS DISEASE</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>24517</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>1/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ALIMENTIV INC (FKA ROBARTS)</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
          <CityNm>LONDON</CityNm>
          <ProvinceOrStateNm>ONTARIO</ProvinceOrStateNm>
          <CountryCd>CA</CountryCd>
        </ForeignAddress>
        <GrantDt>2018-11-20</GrantDt>
        <GrantAmt>3390428</GrantAmt>
        <PurposeOfGrantTxt>STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM TO IMPROVE CARE OF CD PATIENTS</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2751742</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 6/2022, 2/2023, 7/2023, 11/2023, 3/2024, 3/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ALIMENTIV INC (FKA ROBARTS)</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
          <CityNm>LONDON</CityNm>
          <ProvinceOrStateNm>ONTARIO</ProvinceOrStateNm>
          <CountryCd>CA</CountryCd>
        </ForeignAddress>
        <GrantDt>2022-02-10</GrantDt>
        <GrantAmt>894043</GrantAmt>
        <PurposeOfGrantTxt>DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD AND IMPROVE HEALTH OUTCOMES FOR PATIENTS</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>411228</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>2/2023, 6/2023, 3/2024, 1/2025, 4/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>125 S WACKER DRIVE SUITE 600</AddressLine1Txt>
          <CityNm>CHICAGO</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>60606</ZIPCd>
        </USAddress>
        <GrantDt>2025-01-22</GrantDt>
        <GrantAmt>2599216</GrantAmt>
        <PurposeOfGrantTxt>DANATECH DIABETES TECHNOLOGY PLATFORM EXPANSION &amp; MAINTENANCE</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>0</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PENDING</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>125 S WACKER DRIVE SUITE 600</AddressLine1Txt>
          <CityNm>CHICAGO</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>60606</ZIPCd>
        </USAddress>
        <GrantDt>2021-11-20</GrantDt>
        <GrantAmt>2500000</GrantAmt>
        <PurposeOfGrantTxt>EXPANSION OF THE DANATECH PLATFORM TO IMPROVE T1D CARE</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2500000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 1/2023, 12/2023, 1/2024, 12/2024, 1/2025, 4/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>55 VICTORIA PARADE LEVEL 2</AddressLine1Txt>
          <CityNm>FITZROY</CityNm>
          <CountryCd>AS</CountryCd>
        </ForeignAddress>
        <GrantDt>2020-07-23</GrantDt>
        <GrantAmt>3560371</GrantAmt>
        <PurposeOfGrantTxt>FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE: THE MIRO STUDY TO IMPROVE HEALTH OUTCOMES</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>3560371</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 2/2023, 8/2023, 3/2024, 8/2024, 2/2025, 8/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>BIORASIS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1392 STORRS RD U4213 ATL ROOM 106</AddressLine1Txt>
          <CityNm>STORRS</CityNm>
          <StateAbbreviationCd>CT</StateAbbreviationCd>
          <ZIPCd>06269</ZIPCd>
        </USAddress>
        <GrantDt>2018-02-06</GrantDt>
        <GrantAmt>3016000</GrantAmt>
        <PurposeOfGrantTxt>EARLY FEASIBILITY STUDIES OF THE GLUCOWIZZARD IN CARE FOR T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2676000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 6/2024, 7/2024, 10/2024, 2/2025, 5/2025, 6/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>CAPILLARY BIOMEDICAL INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2 WRIGLEY</AddressLine1Txt>
          <CityNm>IRVINE</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92617</ZIPCd>
        </USAddress>
        <GrantDt>2020-09-02</GrantDt>
        <GrantAmt>1500000</GrantAmt>
        <PurposeOfGrantTxt>ADVANCED EXTENDED INFUSION SET TO IMPROVE CARE OF T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1428325</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 1/2022, 5/2022, 6/2022, 3/2023, 8/2023, 8/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>DIABETOMICS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2345 NE OVERLOOK DRIVE SUITE 140</AddressLine1Txt>
          <CityNm>HILLSBORO</CityNm>
          <StateAbbreviationCd>OR</StateAbbreviationCd>
          <ZIPCd>97006</ZIPCd>
        </USAddress>
        <GrantDt>2018-01-11</GrantDt>
        <GrantAmt>4031900</GrantAmt>
        <PurposeOfGrantTxt>POINT-OF-CARE RAPID TESTS FOR TID SCREENING AND INTERVENTION</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>4031900</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 10/2023, 7/2024, 10/2024, 1/2025, 4/2025, 8/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>DREAMED DIABETES LTD</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>14 KAPLAN ST</AddressLine1Txt>
          <CityNm>PETAH TIKVA</CityNm>
          <ProvinceOrStateNm>TEL AVIV</ProvinceOrStateNm>
          <CountryCd>IS</CountryCd>
        </ForeignAddress>
        <GrantDt>2023-02-23</GrantDt>
        <GrantAmt>2850000</GrantAmt>
        <PurposeOfGrantTxt>INCREASING ACCESS TO DECISION SUPPORT TOOLS FOR IMPROVED INSULIN DOSING FOR PEOPLE WITH DIABETES</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2683341</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>5/2023, 10/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>IMMUNOMOLECULAR THERAPEUTICS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>299 WASHINGTON STREET</AddressLine1Txt>
          <CityNm>WOBURN</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>01801</ZIPCd>
        </USAddress>
        <GrantDt>2024-09-24</GrantDt>
        <GrantAmt>5450000</GrantAmt>
        <PurposeOfGrantTxt>TARGETED IMMUNOTHERAPY TO TREAT TYPE 1 DIABETES</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>108524</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>12/2024, 1/2025, 2/2025, 6/2025, 8/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
          <CityNm>MUNSTER</CityNm>
          <CountryCd>GM</CountryCd>
        </ForeignAddress>
        <GrantDt>2023-11-08</GrantDt>
        <GrantAmt>1614000</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>464198</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>1/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
          <CityNm>MUNSTER</CityNm>
          <CountryCd>GM</CountryCd>
        </ForeignAddress>
        <GrantDt>2020-10-22</GrantDt>
        <GrantAmt>4752086</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF AN INTESTINAL ULTRASOUND SCORE TO EVALUATE INFLAMMATION AND TREATMENT RESPONSE IN CROHNS DISEASE.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2141708</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 11/2022, 12/2022, 8/2023, 2/2024, 1/2025, 5/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
          <CityNm>MUNSTER</CityNm>
          <CountryCd>GM</CountryCd>
        </ForeignAddress>
        <GrantDt>2022-03-23</GrantDt>
        <GrantAmt>342387</GrantAmt>
        <PurposeOfGrantTxt>POINT-OF-CARE INTESTINAL ULTRASOUND TRAINING IN THE UNITED STATES: INTRODUCTION TO INTESTINAL ULTRASONOGRAPHY FOR CD PATIENTS</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>342384</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>3/2023, 1/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
          <CityNm>MUNSTER</CityNm>
          <CountryCd>GM</CountryCd>
        </ForeignAddress>
        <GrantDt>2023-06-22</GrantDt>
        <GrantAmt>1556119</GrantAmt>
        <PurposeOfGrantTxt>THE EXTENT STUDY TO IMPROVE THE CARE OF CROHN'S DISEASE.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>637199</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>5/2024, 8/2024, 1/2025, 8/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NUDGE BG INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>725 OLD FARM ROAD</AddressLine1Txt>
          <CityNm>THOUSAND OAKS</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>91360</ZIPCd>
        </USAddress>
        <GrantDt>2025-04-08</GrantDt>
        <GrantAmt>1000000</GrantAmt>
        <PurposeOfGrantTxt>AUTOMATED INSULIN DELIVERY INTEROPERABILITY FRAMEWORK (AIDIF)</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>0</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PENDING</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>PERCUSENSE INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>25134 RYE CANYON LOOP</AddressLine1Txt>
          <CityNm>VALENCIA</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>91355</ZIPCd>
        </USAddress>
        <GrantDt>2020-09-02</GrantDt>
        <GrantAmt>2700000</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF CONTINUOUS GLUCOSE AND KETONE METER TO IMPROVE CARE OF T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1850000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 8/2023, 10/2023, 6/2024, 9/2024, 3/2025, 8/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>PHENOTAP INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>106 WEST 32ND STREET 2ND FLOOR</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10001</ZIPCd>
        </USAddress>
        <GrantDt>2025-03-05</GrantDt>
        <GrantAmt>3000000</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF A BHBOX ENZYME TO ENABLE CONTINUOUS KETONE SENSING</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>0</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>7/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>STARTUP HEALTH T1D PRI LP</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2000 BROADWAY 18TH FLOOR</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10023</ZIPCd>
        </USAddress>
        <GrantDt>2023-01-30</GrantDt>
        <GrantAmt>5000000</GrantAmt>
        <PurposeOfGrantTxt>CATALYZING SEED AND EARLY-STAGE COMPANIES DEVELOPING INNOVATIVE T1D CARE SOLUTIONS</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>3151963</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 11/2023, 6/2024, 9/2024, 12/2024, 2/2025, 5/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>THE UNIVERSITY OF QUEENSLAND</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>CUMBRAE STEWART BUILDING 72 THE</AddressLine1Txt>
          <AddressLine2Txt>UNIVERSITY OF QUEENSLAND</AddressLine2Txt>
          <CityNm>BRISBANE</CityNm>
          <ProvinceOrStateNm>QUEENSLAND</ProvinceOrStateNm>
          <CountryCd>AS</CountryCd>
        </ForeignAddress>
        <GrantDt>2021-09-08</GrantDt>
        <GrantAmt>2493864</GrantAmt>
        <PurposeOfGrantTxt>LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET TYPE 1 DIABETES</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2493864</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>1/2023, 3/2024, 2/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>THE UNIVERSITY OF QUEENSLAND</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>CUMBRAE STEWART BUILDING 72 THE</AddressLine1Txt>
          <AddressLine2Txt>UNIVERSITY OF QUEENSLAND</AddressLine2Txt>
          <CityNm>BRISBANE</CityNm>
          <ProvinceOrStateNm>QUEENSLAND</ProvinceOrStateNm>
          <CountryCd>AS</CountryCd>
        </ForeignAddress>
        <GrantDt>2023-05-22</GrantDt>
        <GrantAmt>226017</GrantAmt>
        <PurposeOfGrantTxt>GUT MICROBIAL METABOLITES DURING EARLY-LIFE DEVELOPMENT AS PREDICTORS OF ISLET AUTOIMMUNITY</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>189690</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>3/2024, 9/2024, 5/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>THETIS PHARMACEUTICALS LLC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>54 DANBURY ROAD SUITE 285</AddressLine1Txt>
          <CityNm>RIDGEFIELD</CityNm>
          <StateAbbreviationCd>NJ</StateAbbreviationCd>
          <ZIPCd>06877</ZIPCd>
        </USAddress>
        <GrantDt>2022-02-24</GrantDt>
        <GrantAmt>14044660</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF A NOVEL RESOLVIN E1 THERAPY FOR TREATMENT OF CROHNS DISEASE</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>5912106</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 4/2024, 6/2024, 7/2024, 12/2024, 4/2025, 6/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>TIXIMED INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1927 FIRST AVENUE NORTH</AddressLine1Txt>
          <CityNm>BIRMINGHAM</CityNm>
          <StateAbbreviationCd>AL</StateAbbreviationCd>
          <ZIPCd>35203</ZIPCd>
        </USAddress>
        <GrantDt>2024-12-03</GrantDt>
        <GrantAmt>2650000</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPING A DRUG TO PROTECT BETA CELLS DURING TYPE 1 DIABETES DEVELOPMENT</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1734080</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>5/2025, 7/2025</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
    </ExpenditureResponsibilityStmt>
    <GeneralExplanationAttachment documentId="RetDoc1175200001">
      <GeneralExplanationGrp>
        <IdentifierTxt>CONTROLLED ENTITIES</IdentifierTxt>
        <FormAndLineReferenceDesc>FORM 990-PF, PART VI-A, LINE 11:</FormAndLineReferenceDesc>
        <MediumExplanationTxt>THE FOLLOWING CONTROLLED ENTITIES ARE NOT EXCESS BUSINESS HOLDINGS:ESTATE OF LEONA M. HELMSLEY230 PARK AVENUE, SUITE 659NEW YORK, NY 10169EIN# 20-7535047HELMSLEY ENTERPRISES, INC.230 PARK AVENUE, SUITE 659NEW YORK, NY 10169EIN# 13-2665914LACM WORLD SMALL CAP EQUITY FUND, L.P.11150 SANTA MONICA BLVD., STE. 200LOS ANGELES, CA 90025EIN# 83-2888004MARATHON-LONDON GLOBAL SELECTORION HOUSE, 5 UPPER ST. MARTIN'S LANELONDON, UK WC2H 9EAEIN# 61-1915057MHR LONGEVITY PARTNERS40 WEST 57TH STREET, FLOOR 24NEW YORK, NY 10019EIN# 98-1471155NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER, L.P.1325 NORTH BEACH STREET, SUITE 201PHILADELPHIA, PA 19125EIN# 98-1142649PITANGO SPVBEIT ACKERSHTEIN - BLDG. B, 11 HAMENOFIM ST. 11TH FL.HERZLIYA, ISRAELEIN# 98-1492234STARTUP HEALTH T1D PRI LP2000 BROADWAY, 18TH FLOORNEW YORK, NY 10023EIN# 93-2618051</MediumExplanationTxt>
      </GeneralExplanationGrp>
      <GeneralExplanationGrp>
        <FormAndLineReferenceDesc>FORM 990-PF, PART VII, LINE 1 AND 2, COLUMN (C), COMPENSATION:</FormAndLineReferenceDesc>
        <MediumExplanationTxt>ALL REPORTED COMPENSATION AMOUNTS INCLUDE "SALARY, FEES, BONUSES AND SEVERANCE PAYMENTS RECEIVED BY EACH PERSON LISTED," AS WELL AS CURRENT YEAR PAYMENTS OF AMOUNTS REPORTED OR REPORTABLE AS DEFERRED COMPENSATION IN CURRENT OR PRIOR YEARS.</MediumExplanationTxt>
      </GeneralExplanationGrp>
    </GeneralExplanationAttachment>
    <InvestmentsCorpStockSchedule documentId="RetDoc2018900001">
      <InvestmentsCorporateStockGrp>
        <StockNm>WASTE CONNECTIONS INC, 31,189 SHRS</StockNm>
        <EOYBookValueAmt>6087781</EOYBookValueAmt>
        <EOYFMVAmt>6087781</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ASML HOLDING NV, 6,798 SHRS</StockNm>
        <EOYBookValueAmt>4504559</EOYBookValueAmt>
        <EOYFMVAmt>4504559</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALPHABET INC, 49,324 SHRS</StockNm>
        <EOYBookValueAmt>7705889</EOYBookValueAmt>
        <EOYFMVAmt>7705889</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AMAZON.COM INC, 56,745 SHRS</StockNm>
        <EOYBookValueAmt>10796304</EOYBookValueAmt>
        <EOYFMVAmt>10796304</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ANSYS INC, 17,725 SHRS</StockNm>
        <EOYBookValueAmt>5611026</EOYBookValueAmt>
        <EOYFMVAmt>5611026</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ATLASSIAN CORP, 10,030 SHRS</StockNm>
        <EOYBookValueAmt>2128466</EOYBookValueAmt>
        <EOYFMVAmt>2128466</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BIO-TECHNE CORP, 77,353 SHRS</StockNm>
        <EOYBookValueAmt>4535206</EOYBookValueAmt>
        <EOYFMVAmt>4535206</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BOOZ ALLEN HAMILTON HOLDING CO, 24,977 SHRS</StockNm>
        <EOYBookValueAmt>2612095</EOYBookValueAmt>
        <EOYFMVAmt>2612095</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CBRE GROUP INC, 41,905 SHRS</StockNm>
        <EOYBookValueAmt>5480336</EOYBookValueAmt>
        <EOYFMVAmt>5480336</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CADENCE DESIGN SYSTEMS INC, 19,189 SHRS</StockNm>
        <EOYBookValueAmt>4880338</EOYBookValueAmt>
        <EOYFMVAmt>4880338</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>COPART INC, 51,249 SHRS</StockNm>
        <EOYBookValueAmt>2900181</EOYBookValueAmt>
        <EOYFMVAmt>2900181</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>COSTAR GROUP INC, 56,648 SHRS</StockNm>
        <EOYBookValueAmt>4488221</EOYBookValueAmt>
        <EOYFMVAmt>4488221</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DANAHER CORP, 28,442 SHRS</StockNm>
        <EOYBookValueAmt>5830610</EOYBookValueAmt>
        <EOYFMVAmt>5830610</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ECOLAB INC, 15,801 SHRS</StockNm>
        <EOYBookValueAmt>4005870</EOYBookValueAmt>
        <EOYFMVAmt>4005870</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FASTENAL CO, 26,379 SHRS</StockNm>
        <EOYBookValueAmt>2045691</EOYBookValueAmt>
        <EOYFMVAmt>2045691</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>GUIDEWIRE SOFTWARE INC, 21,690 SHRS</StockNm>
        <EOYBookValueAmt>4063838</EOYBookValueAmt>
        <EOYFMVAmt>4063838</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>HEICO CORP, 39,020 SHRS</StockNm>
        <EOYBookValueAmt>8232049</EOYBookValueAmt>
        <EOYFMVAmt>8232049</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>INTUIT INC, 7,419 SHRS</StockNm>
        <EOYBookValueAmt>4555192</EOYBookValueAmt>
        <EOYFMVAmt>4555192</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>INTUITIVE SURGICAL INC, 8,518 SHRS</StockNm>
        <EOYBookValueAmt>4218710</EOYBookValueAmt>
        <EOYFMVAmt>4218710</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>KINSALE CAPITAL GROUP INC, 7,556 SHRS</StockNm>
        <EOYBookValueAmt>3677581</EOYBookValueAmt>
        <EOYFMVAmt>3677581</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MANHATTAN ASSOCIATES INC, 18,581 SHRS</StockNm>
        <EOYBookValueAmt>3215256</EOYBookValueAmt>
        <EOYFMVAmt>3215256</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MASTERCARD INC, 18,961 SHRS</StockNm>
        <EOYBookValueAmt>10392903</EOYBookValueAmt>
        <EOYFMVAmt>10392903</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MICROSOFT CORP, 20,472 SHRS</StockNm>
        <EOYBookValueAmt>7684984</EOYBookValueAmt>
        <EOYFMVAmt>7684984</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MONOLITHIC POWER SYSTEMS INC, 7,694 SHRS</StockNm>
        <EOYBookValueAmt>4462366</EOYBookValueAmt>
        <EOYFMVAmt>4462366</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MOODY'S CORP, 12,092 SHRS</StockNm>
        <EOYBookValueAmt>5631123</EOYBookValueAmt>
        <EOYFMVAmt>5631123</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MOTOROLA SOLUTIONS INC, 5,167 SHRS</StockNm>
        <EOYBookValueAmt>2262164</EOYBookValueAmt>
        <EOYFMVAmt>2262164</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>OLD DOMINION FREIGHT LINE INC, 34,487 SHRS</StockNm>
        <EOYBookValueAmt>5705874</EOYBookValueAmt>
        <EOYFMVAmt>5705874</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>S&amp;P GLOBAL INC, 12,553 SHRS</StockNm>
        <EOYBookValueAmt>6378179</EOYBookValueAmt>
        <EOYFMVAmt>6378179</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SERVICENOW INC, 4,067 SHRS</StockNm>
        <EOYBookValueAmt>3237901</EOYBookValueAmt>
        <EOYFMVAmt>3237901</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SHERWIN-WILLIAMS CO/THE, 15,113 SHRS</StockNm>
        <EOYBookValueAmt>5277308</EOYBookValueAmt>
        <EOYFMVAmt>5277308</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>THERMO FISHER SCIENTIFIC INC, 10,030 SHRS</StockNm>
        <EOYBookValueAmt>4990928</EOYBookValueAmt>
        <EOYFMVAmt>4990928</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TRANSDIGM GROUP INC, 5,495 SHRS</StockNm>
        <EOYBookValueAmt>7601179</EOYBookValueAmt>
        <EOYFMVAmt>7601179</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TYLER TECHNOLOGIES INC, 3,847 SHRS</StockNm>
        <EOYBookValueAmt>2236607</EOYBookValueAmt>
        <EOYFMVAmt>2236607</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UBER TECHNOLOGIES INC, 82,728 SHRS</StockNm>
        <EOYBookValueAmt>6027562</EOYBookValueAmt>
        <EOYFMVAmt>6027562</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VEEVA SYSTEMS INC, 26,243 SHRS</StockNm>
        <EOYBookValueAmt>6078666</EOYBookValueAmt>
        <EOYFMVAmt>6078666</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VERALTO CORP, 56,194 SHRS</StockNm>
        <EOYBookValueAmt>5476105</EOYBookValueAmt>
        <EOYFMVAmt>5476105</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VISA INC, 32,563 SHRS</StockNm>
        <EOYBookValueAmt>11412029</EOYBookValueAmt>
        <EOYFMVAmt>11412029</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VULCAN MATERIALS CO, 24,319 SHRS</StockNm>
        <EOYBookValueAmt>5673623</EOYBookValueAmt>
        <EOYFMVAmt>5673623</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WEST PHARMACEUTICAL SERVICES I, 18,135 SHRS</StockNm>
        <EOYBookValueAmt>4060064</EOYBookValueAmt>
        <EOYFMVAmt>4060064</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ZOETIS INC, 29,428 SHRS</StockNm>
        <EOYBookValueAmt>4845320</EOYBookValueAmt>
        <EOYFMVAmt>4845320</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SCHLUMBERGER LTD, 74,480 SHRS</StockNm>
        <EOYBookValueAmt>3113264</EOYBookValueAmt>
        <EOYFMVAmt>3113264</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FRESENIUS MEDICAL CARE AG, 141,319 SHRS</StockNm>
        <EOYBookValueAmt>3518843</EOYBookValueAmt>
        <EOYFMVAmt>3518843</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALLEGION PLC, 20,244 SHRS</StockNm>
        <EOYBookValueAmt>2641032</EOYBookValueAmt>
        <EOYFMVAmt>2641032</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SONY GROUP CORP, 230,530 SHRS</StockNm>
        <EOYBookValueAmt>5853157</EOYBookValueAmt>
        <EOYFMVAmt>5853157</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>KONINKLIJKE PHILIPS NV, 176,944 SHRS</StockNm>
        <EOYBookValueAmt>4494378</EOYBookValueAmt>
        <EOYFMVAmt>4494378</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SMITH &amp; NEPHEW PLC, 89,859 SHRS</StockNm>
        <EOYBookValueAmt>2549300</EOYBookValueAmt>
        <EOYFMVAmt>2549300</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNILEVER PLC, 81,279 SHRS</StockNm>
        <EOYBookValueAmt>4840164</EOYBookValueAmt>
        <EOYFMVAmt>4840164</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALPHABET INC, 31,362 SHRS</StockNm>
        <EOYBookValueAmt>4849820</EOYBookValueAmt>
        <EOYFMVAmt>4849820</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ARAMARK, 175,247 SHRS</StockNm>
        <EOYBookValueAmt>6049526</EOYBookValueAmt>
        <EOYFMVAmt>6049526</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AVERY DENNISON CORP, 29,869 SHRS</StockNm>
        <EOYBookValueAmt>5315786</EOYBookValueAmt>
        <EOYFMVAmt>5315786</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BERKSHIRE HATHAWAY INC, 15,142 SHRS</StockNm>
        <EOYBookValueAmt>8064326</EOYBookValueAmt>
        <EOYFMVAmt>8064326</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BLACKROCK INC, 2,036 SHRS</StockNm>
        <EOYBookValueAmt>1927033</EOYBookValueAmt>
        <EOYFMVAmt>1927033</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BOOKING HOLDINGS INC, 1,484 SHRS</StockNm>
        <EOYBookValueAmt>6836654</EOYBookValueAmt>
        <EOYFMVAmt>6836654</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CDW CORP/DE, 16,609 SHRS</StockNm>
        <EOYBookValueAmt>2661758</EOYBookValueAmt>
        <EOYFMVAmt>2661758</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CSX CORP, 147,478 SHRS</StockNm>
        <EOYBookValueAmt>4340278</EOYBookValueAmt>
        <EOYFMVAmt>4340278</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CARLISLE COS INC, 6,663 SHRS</StockNm>
        <EOYBookValueAmt>2268752</EOYBookValueAmt>
        <EOYFMVAmt>2268752</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CARMAX INC, 62,091 SHRS</StockNm>
        <EOYBookValueAmt>4838131</EOYBookValueAmt>
        <EOYFMVAmt>4838131</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CARRIER GLOBAL CORP, 86,144 SHRS</StockNm>
        <EOYBookValueAmt>5461530</EOYBookValueAmt>
        <EOYFMVAmt>5461530</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DOLLAR TREE INC, 31,754 SHRS</StockNm>
        <EOYBookValueAmt>2383773</EOYBookValueAmt>
        <EOYFMVAmt>2383773</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FERGUSON ENTERPRISES INC, 36,995 SHRS</StockNm>
        <EOYBookValueAmt>5927709</EOYBookValueAmt>
        <EOYFMVAmt>5927709</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MASCO CORP, 72,819 SHRS</StockNm>
        <EOYBookValueAmt>5063833</EOYBookValueAmt>
        <EOYFMVAmt>5063833</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MICROCHIP TECHNOLOGY INC, 61,499 SHRS</StockNm>
        <EOYBookValueAmt>2977167</EOYBookValueAmt>
        <EOYFMVAmt>2977167</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>O'REILLY AUTOMOTIVE INC, 2,722 SHRS</StockNm>
        <EOYBookValueAmt>3899483</EOYBookValueAmt>
        <EOYFMVAmt>3899483</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PROGRESSIVE CORP/THE, 19,411 SHRS</StockNm>
        <EOYBookValueAmt>5493507</EOYBookValueAmt>
        <EOYFMVAmt>5493507</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>QUEST DIAGNOSTICS INC, 29,141 SHRS</StockNm>
        <EOYBookValueAmt>4930657</EOYBookValueAmt>
        <EOYFMVAmt>4930657</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CHARLES SCHWAB CORP/THE, 106,941 SHRS</StockNm>
        <EOYBookValueAmt>8371341</EOYBookValueAmt>
        <EOYFMVAmt>8371341</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SYSCO CORP, 57,302 SHRS</StockNm>
        <EOYBookValueAmt>4299942</EOYBookValueAmt>
        <EOYFMVAmt>4299942</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNITEDHEALTH GROUP INC, 11,037 SHRS</StockNm>
        <EOYBookValueAmt>5780629</EOYBookValueAmt>
        <EOYFMVAmt>5780629</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>RB GLOBAL INC, 72,772 SHRS</StockNm>
        <EOYBookValueAmt>7299032</EOYBookValueAmt>
        <EOYFMVAmt>7299032</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VIVENDI SE, 890,005 SHRS</StockNm>
        <EOYBookValueAmt>2650534</EOYBookValueAmt>
        <EOYFMVAmt>2650534</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AON PLC, 18,887 SHRS</StockNm>
        <EOYBookValueAmt>7537613</EOYBookValueAmt>
        <EOYFMVAmt>7537613</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NINTENDO CO LTD, 168,200 SHRS</StockNm>
        <EOYBookValueAmt>11371553</EOYBookValueAmt>
        <EOYFMVAmt>11371553</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SHISEIDO CO LTD, 416,100 SHRS</StockNm>
        <EOYBookValueAmt>7846743</EOYBookValueAmt>
        <EOYFMVAmt>7846743</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NOVARTIS AG, 125,364 SHRS</StockNm>
        <EOYBookValueAmt>13863367</EOYBookValueAmt>
        <EOYFMVAmt>13863367</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NESTLE SA, 32,891 SHRS</StockNm>
        <EOYBookValueAmt>3321257</EOYBookValueAmt>
        <EOYFMVAmt>3321257</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CIE FINANCIERE RICHEMONT SA, 47,477 SHRS</StockNm>
        <EOYBookValueAmt>8207524</EOYBookValueAmt>
        <EOYFMVAmt>8207524</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNILEVER PLC, 214,237 SHRS</StockNm>
        <EOYBookValueAmt>12737291</EOYBookValueAmt>
        <EOYFMVAmt>12737291</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>RENTOKIL INITIAL PLC, 1865,670 SHRS</StockNm>
        <EOYBookValueAmt>8370603</EOYBookValueAmt>
        <EOYFMVAmt>8370603</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>RECKITT BENCKISER GROUP PLC, 177,062 SHRS</StockNm>
        <EOYBookValueAmt>11952787</EOYBookValueAmt>
        <EOYFMVAmt>11952787</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>INFORMA PLC, 1003,213 SHRS</StockNm>
        <EOYBookValueAmt>9962939</EOYBookValueAmt>
        <EOYFMVAmt>9962939</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>HALEON PLC, 2295,109 SHRS</StockNm>
        <EOYBookValueAmt>11591918</EOYBookValueAmt>
        <EOYFMVAmt>11591918</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>GSK PLC, 744,353 SHRS</StockNm>
        <EOYBookValueAmt>14046511</EOYBookValueAmt>
        <EOYFMVAmt>14046511</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>RENTOKIL INITIAL PLC, 7,123 SHRS</StockNm>
        <EOYBookValueAmt>163117</EOYBookValueAmt>
        <EOYFMVAmt>163117</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BRISTOL-MYERS SQUIBB CO, 233,005 SHRS</StockNm>
        <EOYBookValueAmt>14210975</EOYBookValueAmt>
        <EOYFMVAmt>14210975</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CORTEVA INC, 215,129 SHRS</StockNm>
        <EOYBookValueAmt>13538068</EOYBookValueAmt>
        <EOYFMVAmt>13538068</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>EBAY INC, 150,383 SHRS</StockNm>
        <EOYBookValueAmt>10185441</EOYBookValueAmt>
        <EOYFMVAmt>10185441</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ELECTRONIC ARTS INC, 56,582 SHRS</StockNm>
        <EOYBookValueAmt>8177231</EOYBookValueAmt>
        <EOYFMVAmt>8177231</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FOX CORP, 152,390 SHRS</StockNm>
        <EOYBookValueAmt>8625274</EOYBookValueAmt>
        <EOYFMVAmt>8625274</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FOX CORP, 68,592 SHRS</StockNm>
        <EOYBookValueAmt>3615484</EOYBookValueAmt>
        <EOYFMVAmt>3615484</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>INTERCONTINENTAL EXCHANGE INC, 81,240 SHRS</StockNm>
        <EOYBookValueAmt>14013900</EOYBookValueAmt>
        <EOYFMVAmt>14013900</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>JOHNSON &amp; JOHNSON, 73,505 SHRS</StockNm>
        <EOYBookValueAmt>12190069</EOYBookValueAmt>
        <EOYFMVAmt>12190069</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ESTEE LAUDER COS INC/THE, 102,083 SHRS</StockNm>
        <EOYBookValueAmt>6737478</EOYBookValueAmt>
        <EOYFMVAmt>6737478</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>LIVE NATION ENTERTAINMENT INC, 73,216 SHRS</StockNm>
        <EOYBookValueAmt>9560545</EOYBookValueAmt>
        <EOYFMVAmt>9560545</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NEWS CORP, 347,717 SHRS</StockNm>
        <EOYBookValueAmt>9464857</EOYBookValueAmt>
        <EOYFMVAmt>9464857</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NEWS CORP, 124,376 SHRS</StockNm>
        <EOYBookValueAmt>3777299</EOYBookValueAmt>
        <EOYFMVAmt>3777299</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ORACLE CORP, 55,200 SHRS</StockNm>
        <EOYBookValueAmt>7717512</EOYBookValueAmt>
        <EOYFMVAmt>7717512</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SOLVENTUM CORP, 61,649 SHRS</StockNm>
        <EOYBookValueAmt>4687790</EOYBookValueAmt>
        <EOYFMVAmt>4687790</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TKO GROUP HOLDINGS INC, 39,558 SHRS</StockNm>
        <EOYBookValueAmt>6044858</EOYBookValueAmt>
        <EOYFMVAmt>6044858</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TRANSUNION, 27,518 SHRS</StockNm>
        <EOYBookValueAmt>2283719</EOYBookValueAmt>
        <EOYFMVAmt>2283719</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WARNER MUSIC GROUP CORP, 110,454 SHRS</StockNm>
        <EOYBookValueAmt>3462733</EOYBookValueAmt>
        <EOYFMVAmt>3462733</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ZILLOW GROUP INC, 26,341 SHRS</StockNm>
        <EOYBookValueAmt>1761159</EOYBookValueAmt>
        <EOYFMVAmt>1761159</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ZILLOW GROUP INC, 135,353 SHRS</StockNm>
        <EOYBookValueAmt>9279802</EOYBookValueAmt>
        <EOYFMVAmt>9279802</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>QANTAS AIRWAYS LTD, 39,302 SHRS</StockNm>
        <EOYBookValueAmt>221644</EOYBookValueAmt>
        <EOYFMVAmt>221644</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NORTHERN STAR RESOURCES LTD, 58,974 SHRS</StockNm>
        <EOYBookValueAmt>673254</EOYBookValueAmt>
        <EOYFMVAmt>673254</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ERSTE GROUP BANK AG, 422 SHRS</StockNm>
        <EOYBookValueAmt>29046</EOYBookValueAmt>
        <EOYFMVAmt>29046</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AGNICO EAGLE MINES LIMITED, 7,865 SHRS</StockNm>
        <EOYBookValueAmt>851994</EOYBookValueAmt>
        <EOYFMVAmt>851994</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BARRICK GOLD CORP, 68,600 SHRS</StockNm>
        <EOYBookValueAmt>1331724</EOYBookValueAmt>
        <EOYFMVAmt>1331724</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ENBRIDGE INC, 500 SHRS</StockNm>
        <EOYBookValueAmt>22126</EOYBookValueAmt>
        <EOYFMVAmt>22126</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>LOBLAW COMPANIES LTD, 600 SHRS</StockNm>
        <EOYBookValueAmt>84069</EOYBookValueAmt>
        <EOYFMVAmt>84069</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PAN AMERICAN SILVER CORP, 18,700 SHRS</StockNm>
        <EOYBookValueAmt>482945</EOYBookValueAmt>
        <EOYFMVAmt>482945</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WESTON (GEORGE) LTD, 400 SHRS</StockNm>
        <EOYBookValueAmt>68183</EOYBookValueAmt>
        <EOYFMVAmt>68183</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>KINROSS GOLD CORP, 62,545 SHRS</StockNm>
        <EOYBookValueAmt>787869</EOYBookValueAmt>
        <EOYFMVAmt>787869</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TMX GROUP LTD, 800 SHRS</StockNm>
        <EOYBookValueAmt>29204</EOYBookValueAmt>
        <EOYFMVAmt>29204</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WHEATON PRECIOUS METALS CORP, 2,600 SHRS</StockNm>
        <EOYBookValueAmt>201731</EOYBookValueAmt>
        <EOYFMVAmt>201731</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WSP GLOBAL INC, 3,200 SHRS</StockNm>
        <EOYBookValueAmt>542972</EOYBookValueAmt>
        <EOYFMVAmt>542972</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>IA FINANCIAL CORP INC, 4,800 SHRS</StockNm>
        <EOYBookValueAmt>455771</EOYBookValueAmt>
        <EOYFMVAmt>455771</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SHOPIFY INC, 8,200 SHRS</StockNm>
        <EOYBookValueAmt>779976</EOYBookValueAmt>
        <EOYFMVAmt>779976</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SEA LTD, 8,755 SHRS</StockNm>
        <EOYBookValueAmt>1142440</EOYBookValueAmt>
        <EOYFMVAmt>1142440</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>GRAB HOLDINGS LTD, 6,774 SHRS</StockNm>
        <EOYBookValueAmt>30686</EOYBookValueAmt>
        <EOYFMVAmt>30686</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>YANGZIJIANG SHIPBUILDING HOLDI, 131,300 SHRS</StockNm>
        <EOYBookValueAmt>231516</EOYBookValueAmt>
        <EOYFMVAmt>231516</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NOVO NORDISK A/S, 22,888 SHRS</StockNm>
        <EOYBookValueAmt>1556863</EOYBookValueAmt>
        <EOYFMVAmt>1556863</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WARTSILA OYJ ABP, 25,517 SHRS</StockNm>
        <EOYBookValueAmt>451903</EOYBookValueAmt>
        <EOYFMVAmt>451903</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NOKIA OYJ, 141,686 SHRS</StockNm>
        <EOYBookValueAmt>740758</EOYBookValueAmt>
        <EOYFMVAmt>740758</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ORION OYJ, 5,521 SHRS</StockNm>
        <EOYBookValueAmt>327173</EOYBookValueAmt>
        <EOYFMVAmt>327173</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>THALES SA, 179 SHRS</StockNm>
        <EOYBookValueAmt>47488</EOYBookValueAmt>
        <EOYFMVAmt>47488</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>HANNOVER RUECK SE, 1,465 SHRS</StockNm>
        <EOYBookValueAmt>434711</EOYBookValueAmt>
        <EOYFMVAmt>434711</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>RHEINMETALL AG, 1,704 SHRS</StockNm>
        <EOYBookValueAmt>2427832</EOYBookValueAmt>
        <EOYFMVAmt>2427832</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DEUTSCHE TELEKOM AG, 77,111 SHRS</StockNm>
        <EOYBookValueAmt>2850365</EOYBookValueAmt>
        <EOYFMVAmt>2850365</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>RATIONAL AG, 259 SHRS</StockNm>
        <EOYBookValueAmt>214025</EOYBookValueAmt>
        <EOYFMVAmt>214025</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MTU AERO ENGINES AG, 744 SHRS</StockNm>
        <EOYBookValueAmt>257415</EOYBookValueAmt>
        <EOYFMVAmt>257415</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TALANX AG, 3,275 SHRS</StockNm>
        <EOYBookValueAmt>342091</EOYBookValueAmt>
        <EOYFMVAmt>342091</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>COMMERZBANK AG, 1,955 SHRS</StockNm>
        <EOYBookValueAmt>44284</EOYBookValueAmt>
        <EOYFMVAmt>44284</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>LEG IMMOBILIEN SE, 892 SHRS</StockNm>
        <EOYBookValueAmt>63073</EOYBookValueAmt>
        <EOYFMVAmt>63073</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VONOVIA SE, 1,865 SHRS</StockNm>
        <EOYBookValueAmt>50284</EOYBookValueAmt>
        <EOYFMVAmt>50284</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SIEMENS ENERGY AG, 849 SHRS</StockNm>
        <EOYBookValueAmt>49376</EOYBookValueAmt>
        <EOYFMVAmt>49376</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DAIMLER TRUCK HOLDING AG, 16,684 SHRS</StockNm>
        <EOYBookValueAmt>668979</EOYBookValueAmt>
        <EOYFMVAmt>668979</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BOC HONG KONG HOLDINGS LTD, 187,500 SHRS</StockNm>
        <EOYBookValueAmt>756719</EOYBookValueAmt>
        <EOYFMVAmt>756719</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AIA GROUP LTD, 137,200 SHRS</StockNm>
        <EOYBookValueAmt>1033369</EOYBookValueAmt>
        <EOYFMVAmt>1033369</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CRH PLC, 1,524 SHRS</StockNm>
        <EOYBookValueAmt>134066</EOYBookValueAmt>
        <EOYFMVAmt>134066</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>EATON CORP PLC, 4,142 SHRS</StockNm>
        <EOYBookValueAmt>1125920</EOYBookValueAmt>
        <EOYFMVAmt>1125920</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FLUTTER ENTERTAINMENT PLC, 741 SHRS</StockNm>
        <EOYBookValueAmt>164169</EOYBookValueAmt>
        <EOYFMVAmt>164169</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SEAGATE TECHNOLOGY HOLDINGS PL, 10,692 SHRS</StockNm>
        <EOYBookValueAmt>908285</EOYBookValueAmt>
        <EOYFMVAmt>908285</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TRANE TECHNOLOGIES PLC, 1,808 SHRS</StockNm>
        <EOYBookValueAmt>609151</EOYBookValueAmt>
        <EOYFMVAmt>609151</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BANK HAPOALIM BM, 40,669 SHRS</StockNm>
        <EOYBookValueAmt>546480</EOYBookValueAmt>
        <EOYFMVAmt>546480</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BANK LEUMI LE-ISRAEL BM, 39,827 SHRS</StockNm>
        <EOYBookValueAmt>532387</EOYBookValueAmt>
        <EOYFMVAmt>532387</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ISRAEL DISCOUNT BANK LTD, 24,965 SHRS</StockNm>
        <EOYBookValueAmt>172286</EOYBookValueAmt>
        <EOYFMVAmt>172286</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MIZRAHI TEFAHOT BANK LTD, 7,869 SHRS</StockNm>
        <EOYBookValueAmt>351544</EOYBookValueAmt>
        <EOYFMVAmt>351544</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WIX.COM LTD, 212 SHRS</StockNm>
        <EOYBookValueAmt>34637</EOYBookValueAmt>
        <EOYFMVAmt>34637</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FERRARI NV, 1,278 SHRS</StockNm>
        <EOYBookValueAmt>541430</EOYBookValueAmt>
        <EOYFMVAmt>541430</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FINECOBANK BANCA FINECO SPA, 27,842 SHRS</StockNm>
        <EOYBookValueAmt>547213</EOYBookValueAmt>
        <EOYFMVAmt>547213</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BANCO BPM SPA, 59,401 SHRS</StockNm>
        <EOYBookValueAmt>599686</EOYBookValueAmt>
        <EOYFMVAmt>599686</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNICREDIT SPA, 38,704 SHRS</StockNm>
        <EOYBookValueAmt>2154369</EOYBookValueAmt>
        <EOYFMVAmt>2154369</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ANA HOLDINGS INC, 8,100 SHRS</StockNm>
        <EOYBookValueAmt>149471</EOYBookValueAmt>
        <EOYFMVAmt>149471</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ASAHI KASEI CORP, 4,800 SHRS</StockNm>
        <EOYBookValueAmt>33607</EOYBookValueAmt>
        <EOYFMVAmt>33607</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ASICS CORP, 5,600 SHRS</StockNm>
        <EOYBookValueAmt>117775</EOYBookValueAmt>
        <EOYFMVAmt>117775</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TREND MICRO INC/JAPAN, 4,900 SHRS</StockNm>
        <EOYBookValueAmt>328163</EOYBookValueAmt>
        <EOYFMVAmt>328163</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DAIFUKU CO LTD, 16,500 SHRS</StockNm>
        <EOYBookValueAmt>401852</EOYBookValueAmt>
        <EOYFMVAmt>401852</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DAITO TRUST CONSTRUCTION CO LT, 2,900 SHRS</StockNm>
        <EOYBookValueAmt>297001</EOYBookValueAmt>
        <EOYFMVAmt>297001</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>OTSUKA CORP, 11,200 SHRS</StockNm>
        <EOYBookValueAmt>242365</EOYBookValueAmt>
        <EOYFMVAmt>242365</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>HITACHI LTD, 12,800 SHRS</StockNm>
        <EOYBookValueAmt>295990</EOYBookValueAmt>
        <EOYFMVAmt>295990</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SUMITOMO MITSUI TRUST GROUP IN, 19,800 SHRS</StockNm>
        <EOYBookValueAmt>492550</EOYBookValueAmt>
        <EOYFMVAmt>492550</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>KOMATSU LTD, 18,500 SHRS</StockNm>
        <EOYBookValueAmt>532707</EOYBookValueAmt>
        <EOYFMVAmt>532707</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>KONAMI GROUP CORP, 5,100 SHRS</StockNm>
        <EOYBookValueAmt>599559</EOYBookValueAmt>
        <EOYFMVAmt>599559</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>LASERTEC CORP, 200 SHRS</StockNm>
        <EOYBookValueAmt>16959</EOYBookValueAmt>
        <EOYFMVAmt>16959</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TOKIO MARINE HOLDINGS INC, 23,900 SHRS</StockNm>
        <EOYBookValueAmt>916747</EOYBookValueAmt>
        <EOYFMVAmt>916747</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SUMITOMO MITSUI FINANCIAL GROU, 12,100 SHRS</StockNm>
        <EOYBookValueAmt>307072</EOYBookValueAmt>
        <EOYFMVAmt>307072</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NOMURA HOLDINGS INC, 12,700 SHRS</StockNm>
        <EOYBookValueAmt>77131</EOYBookValueAmt>
        <EOYFMVAmt>77131</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NIPPON YUSEN KK, 22,400 SHRS</StockNm>
        <EOYBookValueAmt>737130</EOYBookValueAmt>
        <EOYFMVAmt>737130</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>OBAYASHI CORP, 15,300 SHRS</StockNm>
        <EOYBookValueAmt>202991</EOYBookValueAmt>
        <EOYFMVAmt>202991</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ONO PHARMACEUTICAL CO LTD, 1,700 SHRS</StockNm>
        <EOYBookValueAmt>18218</EOYBookValueAmt>
        <EOYFMVAmt>18218</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ORIX CORP, 50,100 SHRS</StockNm>
        <EOYBookValueAmt>1033225</EOYBookValueAmt>
        <EOYFMVAmt>1033225</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>T&amp;D HOLDINGS INC, 25,000 SHRS</StockNm>
        <EOYBookValueAmt>530627</EOYBookValueAmt>
        <EOYFMVAmt>530627</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SUZUKI MOTOR CORP, 2,500 SHRS</StockNm>
        <EOYBookValueAmt>30259</EOYBookValueAmt>
        <EOYFMVAmt>30259</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TOKYO ELECTRON LTD, 2,600 SHRS</StockNm>
        <EOYBookValueAmt>349646</EOYBookValueAmt>
        <EOYFMVAmt>349646</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ASTELLAS PHARMA INC, 40,900 SHRS</StockNm>
        <EOYBookValueAmt>395626</EOYBookValueAmt>
        <EOYFMVAmt>395626</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DAIICHI SANKYO CO LTD, 14,100 SHRS</StockNm>
        <EOYBookValueAmt>331049</EOYBookValueAmt>
        <EOYFMVAmt>331049</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BANDAI NAMCO HOLDINGS INC, 15,500 SHRS</StockNm>
        <EOYBookValueAmt>518671</EOYBookValueAmt>
        <EOYFMVAmt>518671</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MS&amp;AD INSURANCE GROUP HOLDINGS, 21,800 SHRS</StockNm>
        <EOYBookValueAmt>470142</EOYBookValueAmt>
        <EOYFMVAmt>470142</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ENEOS HOLDINGS INC, 139,600 SHRS</StockNm>
        <EOYBookValueAmt>730300</EOYBookValueAmt>
        <EOYFMVAmt>730300</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>JAPAN AIRLINES CO LTD, 7,300 SHRS</StockNm>
        <EOYBookValueAmt>124799</EOYBookValueAmt>
        <EOYFMVAmt>124799</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CONCORDIA FINANCIAL GROUP LTD, 3,800 SHRS</StockNm>
        <EOYBookValueAmt>24934</EOYBookValueAmt>
        <EOYFMVAmt>24934</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ASR NEDERLAND NV, 1,730 SHRS</StockNm>
        <EOYBookValueAmt>99006</EOYBookValueAmt>
        <EOYFMVAmt>99006</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NN GROUP NV, 1,956 SHRS</StockNm>
        <EOYBookValueAmt>108348</EOYBookValueAmt>
        <EOYFMVAmt>108348</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TELENOR ASA, 4,749 SHRS</StockNm>
        <EOYBookValueAmt>67845</EOYBookValueAmt>
        <EOYFMVAmt>67845</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>KONGSBERG GRUPPEN ASA, 994 SHRS</StockNm>
        <EOYBookValueAmt>144835</EOYBookValueAmt>
        <EOYFMVAmt>144835</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NORSK HYDRO ASA, 2,941 SHRS</StockNm>
        <EOYBookValueAmt>16840</EOYBookValueAmt>
        <EOYFMVAmt>16840</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DNB BANK ASA, 35,370 SHRS</StockNm>
        <EOYBookValueAmt>924989</EOYBookValueAmt>
        <EOYFMVAmt>924989</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CARNIVAL CORP, 25,323 SHRS</StockNm>
        <EOYBookValueAmt>494558</EOYBookValueAmt>
        <EOYFMVAmt>494558</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>INPOST SA, 9,235 SHRS</StockNm>
        <EOYBookValueAmt>134671</EOYBookValueAmt>
        <EOYFMVAmt>134671</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SINGAPORE TECHNOLOGIES ENGINEE, 37,800 SHRS</StockNm>
        <EOYBookValueAmt>190955</EOYBookValueAmt>
        <EOYFMVAmt>190955</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DBS GROUP HOLDINGS LTD, 900 SHRS</StockNm>
        <EOYBookValueAmt>31116</EOYBookValueAmt>
        <EOYFMVAmt>31116</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SINGAPORE EXCHANGE LTD, 22,100 SHRS</StockNm>
        <EOYBookValueAmt>219833</EOYBookValueAmt>
        <EOYFMVAmt>219833</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNITED OVERSEAS BANK LTD, 8,600 SHRS</StockNm>
        <EOYBookValueAmt>243713</EOYBookValueAmt>
        <EOYFMVAmt>243713</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>OVERSEA-CHINESE BANKING CORP L, 2,100 SHRS</StockNm>
        <EOYBookValueAmt>27029</EOYBookValueAmt>
        <EOYFMVAmt>27029</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SINGAPORE TECHNOLOGIES ENGINEE, 41,400 SHRS</StockNm>
        <EOYBookValueAmt>211140</EOYBookValueAmt>
        <EOYFMVAmt>211140</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BANCO BILBAO VIZCAYA ARGENTARI, 76,025 SHRS</StockNm>
        <EOYBookValueAmt>1030223</EOYBookValueAmt>
        <EOYFMVAmt>1030223</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BANCO SANTANDER SA, 17,990 SHRS</StockNm>
        <EOYBookValueAmt>120406</EOYBookValueAmt>
        <EOYFMVAmt>120406</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CAIXABANK SA, 142,302 SHRS</StockNm>
        <EOYBookValueAmt>1102749</EOYBookValueAmt>
        <EOYFMVAmt>1102749</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TELEFONAKTIEBOLAGET LM ERICSSO, 80,203 SHRS</StockNm>
        <EOYBookValueAmt>620220</EOYBookValueAmt>
        <EOYFMVAmt>620220</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TELIA CO AB, 12,362 SHRS</StockNm>
        <EOYBookValueAmt>44660</EOYBookValueAmt>
        <EOYFMVAmt>44660</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SKANSKA AB, 17,265 SHRS</StockNm>
        <EOYBookValueAmt>379672</EOYBookValueAmt>
        <EOYFMVAmt>379672</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALFA LAVAL AB, 1,801 SHRS</StockNm>
        <EOYBookValueAmt>76898</EOYBookValueAmt>
        <EOYFMVAmt>76898</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SWEDISH ORPHAN BIOVITRUM AB, 2,110 SHRS</StockNm>
        <EOYBookValueAmt>60369</EOYBookValueAmt>
        <EOYFMVAmt>60369</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VOLVO AB, 1,649 SHRS</StockNm>
        <EOYBookValueAmt>48132</EOYBookValueAmt>
        <EOYFMVAmt>48132</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ADDTECH AB, 1,192 SHRS</StockNm>
        <EOYBookValueAmt>34745</EOYBookValueAmt>
        <EOYFMVAmt>34745</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SVENSKA HANDELSBANKEN AB, 2,458 SHRS</StockNm>
        <EOYBookValueAmt>27687</EOYBookValueAmt>
        <EOYFMVAmt>27687</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ZURICH INSURANCE GROUP AG, 576 SHRS</StockNm>
        <EOYBookValueAmt>400384</EOYBookValueAmt>
        <EOYFMVAmt>400384</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NOVARTIS AG, 4,910 SHRS</StockNm>
        <EOYBookValueAmt>542972</EOYBookValueAmt>
        <EOYFMVAmt>542972</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ABB LTD, 2,738 SHRS</StockNm>
        <EOYBookValueAmt>139941</EOYBookValueAmt>
        <EOYFMVAmt>139941</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SWISS RE AG, 1,365 SHRS</StockNm>
        <EOYBookValueAmt>231421</EOYBookValueAmt>
        <EOYFMVAmt>231421</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UBS GROUP AG, 10,996 SHRS</StockNm>
        <EOYBookValueAmt>333950</EOYBookValueAmt>
        <EOYFMVAmt>333950</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>GARMIN LTD, 2,544 SHRS</StockNm>
        <EOYBookValueAmt>552379</EOYBookValueAmt>
        <EOYFMVAmt>552379</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BAE SYSTEMS PLC, 61,871 SHRS</StockNm>
        <EOYBookValueAmt>1245417</EOYBookValueAmt>
        <EOYFMVAmt>1245417</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>HSBC HOLDINGS PLC, 23,693 SHRS</StockNm>
        <EOYBookValueAmt>267254</EOYBookValueAmt>
        <EOYFMVAmt>267254</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MARKS &amp; SPENCER GROUP PLC, 6,830 SHRS</StockNm>
        <EOYBookValueAmt>31340</EOYBookValueAmt>
        <EOYFMVAmt>31340</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ROLLS-ROYCE HOLDINGS PLC, 17,822 SHRS</StockNm>
        <EOYBookValueAmt>172298</EOYBookValueAmt>
        <EOYFMVAmt>172298</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ROYALTY PHARMA PLC, 19,160 SHRS</StockNm>
        <EOYBookValueAmt>596451</EOYBookValueAmt>
        <EOYFMVAmt>596451</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AT&amp;T INC, 13,220 SHRS</StockNm>
        <EOYBookValueAmt>373862</EOYBookValueAmt>
        <EOYFMVAmt>373862</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ABBVIE INC, 13,736 SHRS</StockNm>
        <EOYBookValueAmt>2877967</EOYBookValueAmt>
        <EOYFMVAmt>2877967</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AECOM, 6,271 SHRS</StockNm>
        <EOYBookValueAmt>581510</EOYBookValueAmt>
        <EOYFMVAmt>581510</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALLSTATE CORP/THE, 5,185 SHRS</StockNm>
        <EOYBookValueAmt>1073658</EOYBookValueAmt>
        <EOYFMVAmt>1073658</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALNYLAM PHARMACEUTICALS INC, 966 SHRS</StockNm>
        <EOYBookValueAmt>260839</EOYBookValueAmt>
        <EOYFMVAmt>260839</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALPHABET INC, 2,536 SHRS</StockNm>
        <EOYBookValueAmt>396199</EOYBookValueAmt>
        <EOYFMVAmt>396199</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALPHABET INC, 2,865 SHRS</StockNm>
        <EOYBookValueAmt>443044</EOYBookValueAmt>
        <EOYFMVAmt>443044</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALTRIA GROUP INC, 24,639 SHRS</StockNm>
        <EOYBookValueAmt>1478833</EOYBookValueAmt>
        <EOYFMVAmt>1478833</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AMAZON.COM INC, 5,724 SHRS</StockNm>
        <EOYBookValueAmt>1089048</EOYBookValueAmt>
        <EOYFMVAmt>1089048</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AMERICAN EXPRESS CO, 4,573 SHRS</StockNm>
        <EOYBookValueAmt>1230366</EOYBookValueAmt>
        <EOYFMVAmt>1230366</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AMPHENOL CORP, 23,232 SHRS</StockNm>
        <EOYBookValueAmt>1523787</EOYBookValueAmt>
        <EOYFMVAmt>1523787</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ANALOG DEVICES INC, 499 SHRS</StockNm>
        <EOYBookValueAmt>100633</EOYBookValueAmt>
        <EOYFMVAmt>100633</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>APPLE INC, 10,715 SHRS</StockNm>
        <EOYBookValueAmt>2380123</EOYBookValueAmt>
        <EOYFMVAmt>2380123</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>APPLOVIN CORP, 499 SHRS</StockNm>
        <EOYBookValueAmt>132220</EOYBookValueAmt>
        <EOYFMVAmt>132220</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ARISTA NETWORKS INC, 4,852 SHRS</StockNm>
        <EOYBookValueAmt>375933</EOYBookValueAmt>
        <EOYFMVAmt>375933</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ATLASSIAN CORP, 4,639 SHRS</StockNm>
        <EOYBookValueAmt>984442</EOYBookValueAmt>
        <EOYFMVAmt>984442</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BLACKSTONE INC, 3,414 SHRS</StockNm>
        <EOYBookValueAmt>477209</EOYBookValueAmt>
        <EOYFMVAmt>477209</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BOOZ ALLEN HAMILTON HOLDING CO, 5,994 SHRS</StockNm>
        <EOYBookValueAmt>626853</EOYBookValueAmt>
        <EOYFMVAmt>626853</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BRISTOL-MYERS SQUIBB CO, 4,448 SHRS</StockNm>
        <EOYBookValueAmt>271284</EOYBookValueAmt>
        <EOYFMVAmt>271284</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BROADCOM INC, 12,323 SHRS</StockNm>
        <EOYBookValueAmt>2063240</EOYBookValueAmt>
        <EOYFMVAmt>2063240</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BROWN &amp; BROWN INC, 2,698 SHRS</StockNm>
        <EOYBookValueAmt>335631</EOYBookValueAmt>
        <EOYFMVAmt>335631</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CAPITAL ONE FINANCIAL CORP, 6,720 SHRS</StockNm>
        <EOYBookValueAmt>1204896</EOYBookValueAmt>
        <EOYFMVAmt>1204896</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CHARTER COMMUNICATIONS INC, 312 SHRS</StockNm>
        <EOYBookValueAmt>114981</EOYBookValueAmt>
        <EOYFMVAmt>114981</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CHENIERE ENERGY INC, 7,420 SHRS</StockNm>
        <EOYBookValueAmt>1716988</EOYBookValueAmt>
        <EOYFMVAmt>1716988</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CISCO SYSTEMS INC, 20,303 SHRS</StockNm>
        <EOYBookValueAmt>1252898</EOYBookValueAmt>
        <EOYFMVAmt>1252898</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CITIGROUP INC, 3,588 SHRS</StockNm>
        <EOYBookValueAmt>254712</EOYBookValueAmt>
        <EOYFMVAmt>254712</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>COMCAST CORP, 22,716 SHRS</StockNm>
        <EOYBookValueAmt>838220</EOYBookValueAmt>
        <EOYFMVAmt>838220</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CORNING INC, 19,794 SHRS</StockNm>
        <EOYBookValueAmt>906169</EOYBookValueAmt>
        <EOYFMVAmt>906169</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DELTA AIR LINES INC, 8,235 SHRS</StockNm>
        <EOYBookValueAmt>359046</EOYBookValueAmt>
        <EOYFMVAmt>359046</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DOCUSIGN INC, 991 SHRS</StockNm>
        <EOYBookValueAmt>80667</EOYBookValueAmt>
        <EOYFMVAmt>80667</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DOORDASH INC, 2,967 SHRS</StockNm>
        <EOYBookValueAmt>542279</EOYBookValueAmt>
        <EOYFMVAmt>542279</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>EDISON INTERNATIONAL, 11,710 SHRS</StockNm>
        <EOYBookValueAmt>689953</EOYBookValueAmt>
        <EOYFMVAmt>689953</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>EMCOR GROUP INC, 1,356 SHRS</StockNm>
        <EOYBookValueAmt>501218</EOYBookValueAmt>
        <EOYFMVAmt>501218</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>EQUITABLE HOLDINGS INC, 13,677 SHRS</StockNm>
        <EOYBookValueAmt>712435</EOYBookValueAmt>
        <EOYFMVAmt>712435</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>EXPEDIA GROUP INC, 5,973 SHRS</StockNm>
        <EOYBookValueAmt>1004061</EOYBookValueAmt>
        <EOYFMVAmt>1004061</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>META PLATFORMS INC, 942 SHRS</StockNm>
        <EOYBookValueAmt>542931</EOYBookValueAmt>
        <EOYFMVAmt>542931</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>F5 INC, 2,709 SHRS</StockNm>
        <EOYBookValueAmt>721325</EOYBookValueAmt>
        <EOYFMVAmt>721325</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FORTINET INC, 14,669 SHRS</StockNm>
        <EOYBookValueAmt>1412038</EOYBookValueAmt>
        <EOYFMVAmt>1412038</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FREEPORT-MCMORAN INC, 40,617 SHRS</StockNm>
        <EOYBookValueAmt>1537760</EOYBookValueAmt>
        <EOYFMVAmt>1537760</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>GE AEROSPACE, 1,294 SHRS</StockNm>
        <EOYBookValueAmt>258994</EOYBookValueAmt>
        <EOYFMVAmt>258994</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>GILEAD SCIENCES INC, 22,495 SHRS</StockNm>
        <EOYBookValueAmt>2520565</EOYBookValueAmt>
        <EOYFMVAmt>2520565</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>HCA HEALTHCARE INC, 200 SHRS</StockNm>
        <EOYBookValueAmt>69110</EOYBookValueAmt>
        <EOYFMVAmt>69110</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>HOWMET AEROSPACE INC, 16,398 SHRS</StockNm>
        <EOYBookValueAmt>2127313</EOYBookValueAmt>
        <EOYFMVAmt>2127313</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>INCYTE CORP, 4,902 SHRS</StockNm>
        <EOYBookValueAmt>296816</EOYBookValueAmt>
        <EOYFMVAmt>296816</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>JOHNSON &amp; JOHNSON, 16,144 SHRS</StockNm>
        <EOYBookValueAmt>2677321</EOYBookValueAmt>
        <EOYFMVAmt>2677321</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>KLA CORP, 738 SHRS</StockNm>
        <EOYBookValueAmt>501692</EOYBookValueAmt>
        <EOYFMVAmt>501692</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>LAM RESEARCH CORP, 6,198 SHRS</StockNm>
        <EOYBookValueAmt>450595</EOYBookValueAmt>
        <EOYFMVAmt>450595</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ELI LILLY &amp; CO, 103 SHRS</StockNm>
        <EOYBookValueAmt>85069</EOYBookValueAmt>
        <EOYFMVAmt>85069</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>LOCKHEED MARTIN CORP, 239 SHRS</StockNm>
        <EOYBookValueAmt>106764</EOYBookValueAmt>
        <EOYFMVAmt>106764</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>LULULEMON ATHLETICA INC, 2,632 SHRS</StockNm>
        <EOYBookValueAmt>745014</EOYBookValueAmt>
        <EOYFMVAmt>745014</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MERCADOLIBRE INC, 11 SHRS</StockNm>
        <EOYBookValueAmt>21460</EOYBookValueAmt>
        <EOYFMVAmt>21460</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MERCK &amp; CO INC, 2,899 SHRS</StockNm>
        <EOYBookValueAmt>260214</EOYBookValueAmt>
        <EOYFMVAmt>260214</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MICROSOFT CORP, 1,966 SHRS</StockNm>
        <EOYBookValueAmt>738017</EOYBookValueAmt>
        <EOYFMVAmt>738017</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MOLINA HEALTHCARE INC, 1,621 SHRS</StockNm>
        <EOYBookValueAmt>533941</EOYBookValueAmt>
        <EOYFMVAmt>533941</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MOODY'S CORP, 417 SHRS</StockNm>
        <EOYBookValueAmt>194193</EOYBookValueAmt>
        <EOYFMVAmt>194193</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MOTOROLA SOLUTIONS INC, 1,206 SHRS</StockNm>
        <EOYBookValueAmt>527999</EOYBookValueAmt>
        <EOYFMVAmt>527999</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NRG ENERGY INC, 9,467 SHRS</StockNm>
        <EOYBookValueAmt>903720</EOYBookValueAmt>
        <EOYFMVAmt>903720</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NETFLIX INC, 1,827 SHRS</StockNm>
        <EOYBookValueAmt>1703732</EOYBookValueAmt>
        <EOYFMVAmt>1703732</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NORTHROP GRUMMAN CORP, 55 SHRS</StockNm>
        <EOYBookValueAmt>28161</EOYBookValueAmt>
        <EOYFMVAmt>28161</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NVIDIA CORP, 42,681 SHRS</StockNm>
        <EOYBookValueAmt>4625767</EOYBookValueAmt>
        <EOYFMVAmt>4625767</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PALANTIR TECHNOLOGIES INC, 3,345 SHRS</StockNm>
        <EOYBookValueAmt>282318</EOYBookValueAmt>
        <EOYFMVAmt>282318</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PARKER-HANNIFIN CORP, 479 SHRS</StockNm>
        <EOYBookValueAmt>291160</EOYBookValueAmt>
        <EOYFMVAmt>291160</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PFIZER INC, 38,902 SHRS</StockNm>
        <EOYBookValueAmt>985777</EOYBookValueAmt>
        <EOYFMVAmt>985777</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PHILIP MORRIS INTERNATIONAL IN, 12,570 SHRS</StockNm>
        <EOYBookValueAmt>1995236</EOYBookValueAmt>
        <EOYFMVAmt>1995236</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PROGRESSIVE CORP/THE, 1,302 SHRS</StockNm>
        <EOYBookValueAmt>368479</EOYBookValueAmt>
        <EOYFMVAmt>368479</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>RAYMOND JAMES FINANCIAL INC, 3,722 SHRS</StockNm>
        <EOYBookValueAmt>517023</EOYBookValueAmt>
        <EOYFMVAmt>517023</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>RTX CORP, 2,778 SHRS</StockNm>
        <EOYBookValueAmt>367974</EOYBookValueAmt>
        <EOYFMVAmt>367974</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>RESMED INC, 259 SHRS</StockNm>
        <EOYBookValueAmt>57977</EOYBookValueAmt>
        <EOYFMVAmt>57977</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CHARLES SCHWAB CORP/THE, 26,230 SHRS</StockNm>
        <EOYBookValueAmt>2053284</EOYBookValueAmt>
        <EOYFMVAmt>2053284</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SIMON PROPERTY GROUP INC, 12,119 SHRS</StockNm>
        <EOYBookValueAmt>2012724</EOYBookValueAmt>
        <EOYFMVAmt>2012724</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SNAP INC, 6,292 SHRS</StockNm>
        <EOYBookValueAmt>54803</EOYBookValueAmt>
        <EOYFMVAmt>54803</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SNOWFLAKE INC, 351 SHRS</StockNm>
        <EOYBookValueAmt>51302</EOYBookValueAmt>
        <EOYFMVAmt>51302</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SYNCHRONY FINANCIAL, 13,535 SHRS</StockNm>
        <EOYBookValueAmt>716543</EOYBookValueAmt>
        <EOYFMVAmt>716543</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TARGA RESOURCES CORP, 129 SHRS</StockNm>
        <EOYBookValueAmt>25861</EOYBookValueAmt>
        <EOYFMVAmt>25861</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TESLA INC, 3,741 SHRS</StockNm>
        <EOYBookValueAmt>969518</EOYBookValueAmt>
        <EOYFMVAmt>969518</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TRADEWEB MARKETS INC, 2,172 SHRS</StockNm>
        <EOYBookValueAmt>322455</EOYBookValueAmt>
        <EOYFMVAmt>322455</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TWILIO INC, 3,828 SHRS</StockNm>
        <EOYBookValueAmt>374799</EOYBookValueAmt>
        <EOYFMVAmt>374799</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>US BANCORP, 44,345 SHRS</StockNm>
        <EOYBookValueAmt>1872246</EOYBookValueAmt>
        <EOYFMVAmt>1872246</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNITED THERAPEUTICS CORP, 379 SHRS</StockNm>
        <EOYBookValueAmt>116834</EOYBookValueAmt>
        <EOYFMVAmt>116834</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNIVERSAL HEALTH SERVICES INC, 2,730 SHRS</StockNm>
        <EOYBookValueAmt>512967</EOYBookValueAmt>
        <EOYFMVAmt>512967</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VENTAS INC, 1,744 SHRS</StockNm>
        <EOYBookValueAmt>119917</EOYBookValueAmt>
        <EOYFMVAmt>119917</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VERIZON COMMUNICATIONS INC, 14,687 SHRS</StockNm>
        <EOYBookValueAmt>666202</EOYBookValueAmt>
        <EOYFMVAmt>666202</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VISA INC, 2,611 SHRS</StockNm>
        <EOYBookValueAmt>915051</EOYBookValueAmt>
        <EOYFMVAmt>915051</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VISTRA CORP, 2,806 SHRS</StockNm>
        <EOYBookValueAmt>329537</EOYBookValueAmt>
        <EOYFMVAmt>329537</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WALMART INC, 1,643 SHRS</StockNm>
        <EOYBookValueAmt>144239</EOYBookValueAmt>
        <EOYFMVAmt>144239</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNITED THERAPEUTICS CORP, 1,256 SHRS</StockNm>
        <EOYBookValueAmt>387187</EOYBookValueAmt>
        <EOYFMVAmt>387187</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NETFLIX INC, 895 SHRS</StockNm>
        <EOYBookValueAmt>834614</EOYBookValueAmt>
        <EOYFMVAmt>834614</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FORTINET INC, 2,839 SHRS</StockNm>
        <EOYBookValueAmt>273282</EOYBookValueAmt>
        <EOYFMVAmt>273282</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>META PLATFORMS INC, 1,932 SHRS</StockNm>
        <EOYBookValueAmt>1113528</EOYBookValueAmt>
        <EOYFMVAmt>1113528</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ARISTA NETWORKS INC, 428 SHRS</StockNm>
        <EOYBookValueAmt>33161</EOYBookValueAmt>
        <EOYFMVAmt>33161</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MOTOROLA SOLUTIONS INC, 2,718 SHRS</StockNm>
        <EOYBookValueAmt>1189968</EOYBookValueAmt>
        <EOYFMVAmt>1189968</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NORTHROP GRUMMAN CORPORATION, 179 SHRS</StockNm>
        <EOYBookValueAmt>91650</EOYBookValueAmt>
        <EOYFMVAmt>91650</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>LILLY (ELI) &amp; CO COM STK NPV, 311 SHRS</StockNm>
        <EOYBookValueAmt>256858</EOYBookValueAmt>
        <EOYFMVAmt>256858</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PROGRESSIVE CORP OHIO COM, 4,151 SHRS</StockNm>
        <EOYBookValueAmt>1174775</EOYBookValueAmt>
        <EOYFMVAmt>1174775</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AMERICAN EXPRESS CO, 1,046 SHRS</StockNm>
        <EOYBookValueAmt>281426</EOYBookValueAmt>
        <EOYFMVAmt>281426</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AMAZON COM INC COM, 8,567 SHRS</StockNm>
        <EOYBookValueAmt>1629957</EOYBookValueAmt>
        <EOYFMVAmt>1629957</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MERCK &amp; CO INC, 9,163 SHRS</StockNm>
        <EOYBookValueAmt>822471</EOYBookValueAmt>
        <EOYFMVAmt>822471</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BRISTOL MYERS SQUIBB CO, 20,387 SHRS</StockNm>
        <EOYBookValueAmt>1243403</EOYBookValueAmt>
        <EOYFMVAmt>1243403</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>APPLE INC, 14,677 SHRS</StockNm>
        <EOYBookValueAmt>3260202</EOYBookValueAmt>
        <EOYFMVAmt>3260202</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CISCO SYSTEMS INC COM, 17,506 SHRS</StockNm>
        <EOYBookValueAmt>1080295</EOYBookValueAmt>
        <EOYFMVAmt>1080295</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALPHABET INC, 8,411 SHRS</StockNm>
        <EOYBookValueAmt>1314051</EOYBookValueAmt>
        <EOYFMVAmt>1314051</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALPHABET INC, 9,502 SHRS</StockNm>
        <EOYBookValueAmt>1469389</EOYBookValueAmt>
        <EOYFMVAmt>1469389</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>RESMED INC COM, 857 SHRS</StockNm>
        <EOYBookValueAmt>191839</EOYBookValueAmt>
        <EOYFMVAmt>191839</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MICROSOFT CORP COM, 5,848 SHRS</StockNm>
        <EOYBookValueAmt>2195281</EOYBookValueAmt>
        <EOYFMVAmt>2195281</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WALMART INC, 12,334 SHRS</StockNm>
        <EOYBookValueAmt>1082802</EOYBookValueAmt>
        <EOYFMVAmt>1082802</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PDD HOLDINGS INC, 12,500 SHRS</StockNm>
        <EOYBookValueAmt>1479375</EOYBookValueAmt>
        <EOYFMVAmt>1479375</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NU HOLDINGS LTD/CAYMAN ISLANDS, 567,667 SHRS</StockNm>
        <EOYBookValueAmt>5812910</EOYBookValueAmt>
        <EOYFMVAmt>5812910</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WISE PLC, 168,200 SHRS</StockNm>
        <EOYBookValueAmt>2051634</EOYBookValueAmt>
        <EOYFMVAmt>2051634</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CONFLUENT INC, 22,315 SHRS</StockNm>
        <EOYBookValueAmt>523064</EOYBookValueAmt>
        <EOYFMVAmt>523064</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CROWDSTRIKE HOLDINGS INC, 12,800 SHRS</StockNm>
        <EOYBookValueAmt>4513024</EOYBookValueAmt>
        <EOYFMVAmt>4513024</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DOXIMITY INC, 6,974 SHRS</StockNm>
        <EOYBookValueAmt>404701</EOYBookValueAmt>
        <EOYFMVAmt>404701</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>META PLATFORMS INC, 8,000 SHRS</StockNm>
        <EOYBookValueAmt>4610880</EOYBookValueAmt>
        <EOYFMVAmt>4610880</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FRESHWORKS INC, 18,841 SHRS</StockNm>
        <EOYBookValueAmt>265847</EOYBookValueAmt>
        <EOYFMVAmt>265847</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MAPLEBEAR INC, 80,000 SHRS</StockNm>
        <EOYBookValueAmt>3191200</EOYBookValueAmt>
        <EOYFMVAmt>3191200</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ROBINHOOD MARKETS INC, 50,000 SHRS</StockNm>
        <EOYBookValueAmt>2081000</EOYBookValueAmt>
        <EOYFMVAmt>2081000</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ROBLOX CORP, 54,000 SHRS</StockNm>
        <EOYBookValueAmt>3147660</EOYBookValueAmt>
        <EOYFMVAmt>3147660</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SAMSARA INC, 101,250 SHRS</StockNm>
        <EOYBookValueAmt>3880913</EOYBookValueAmt>
        <EOYFMVAmt>3880913</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SNOWFLAKE INC, 42,316 SHRS</StockNm>
        <EOYBookValueAmt>6184907</EOYBookValueAmt>
        <EOYFMVAmt>6184907</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
    </InvestmentsCorpStockSchedule>
    <InvestmentsOtherSchedule2 documentId="RetDoc2018100001">
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>JPM US LARGE CAP</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>178600044</BookValueAmt>
        <EOYFMVAmt>178600044</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SPDR TRUST SERIES I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>184715613</BookValueAmt>
        <EOYFMVAmt>184715613</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>JPM CORE BOND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1024328467</BookValueAmt>
        <EOYFMVAmt>1024328467</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>JPM SHORT DURATION BOND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>250849044</BookValueAmt>
        <EOYFMVAmt>250849044</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CHATHAM</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>113440052</BookValueAmt>
        <EOYFMVAmt>113440052</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CHATHAM OFFSHORE</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>111292568</BookValueAmt>
        <EOYFMVAmt>111292568</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CAMBER</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>153014742</BookValueAmt>
        <EOYFMVAmt>153014742</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED GENESIS FUND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>37527977</BookValueAmt>
        <EOYFMVAmt>37527977</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA CAP GLOBAL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>206953932</BookValueAmt>
        <EOYFMVAmt>206953932</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACADIAN FRONTIER</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19</BookValueAmt>
        <EOYFMVAmt>19</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIGHCLERE INTL SC</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>134563864</BookValueAmt>
        <EOYFMVAmt>134563864</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>LACM WORLD SMALL CAP</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>119401516</BookValueAmt>
        <EOYFMVAmt>119401516</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>MARATHON GLOBAL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>211603977</BookValueAmt>
        <EOYFMVAmt>211603977</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SILCHESTER INTL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>147151131</BookValueAmt>
        <EOYFMVAmt>147151131</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>BLACKROCK US DEBT</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>96977617</BookValueAmt>
        <EOYFMVAmt>96977617</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EIG ENERGY FUND XVI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>30133391</BookValueAmt>
        <EOYFMVAmt>30133391</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EIG ENERGY XV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1002113</BookValueAmt>
        <EOYFMVAmt>1002113</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EIG ENERGY XVII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6505004</BookValueAmt>
        <EOYFMVAmt>6505004</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FDAF DISLOCATED II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8202611</BookValueAmt>
        <EOYFMVAmt>8202611</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FDAF DISLOCATED III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>25456191</BookValueAmt>
        <EOYFMVAmt>25456191</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FDAF DISLOCATED IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>30329915</BookValueAmt>
        <EOYFMVAmt>30329915</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GSO CAPITAL SOLS II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2006596</BookValueAmt>
        <EOYFMVAmt>2006596</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BAYSIDE III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3232157</BookValueAmt>
        <EOYFMVAmt>3232157</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>MHR AXIOM</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>265837155</BookValueAmt>
        <EOYFMVAmt>265837155</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>MHR INST PARTNERS IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>61299374</BookValueAmt>
        <EOYFMVAmt>61299374</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>NEWMARKET IIFC</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6973612</BookValueAmt>
        <EOYFMVAmt>6973612</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ROYALTY II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>334374</BookValueAmt>
        <EOYFMVAmt>334374</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH FUND IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16748134</BookValueAmt>
        <EOYFMVAmt>16748134</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9271705</BookValueAmt>
        <EOYFMVAmt>9271705</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11675661</BookValueAmt>
        <EOYFMVAmt>11675661</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>27092782</BookValueAmt>
        <EOYFMVAmt>27092782</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>20568357</BookValueAmt>
        <EOYFMVAmt>20568357</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1500000</BookValueAmt>
        <EOYFMVAmt>1500000</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL INDIA V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12493701</BookValueAmt>
        <EOYFMVAmt>12493701</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL INDIA VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7439015</BookValueAmt>
        <EOYFMVAmt>7439015</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL INDIA VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4788163</BookValueAmt>
        <EOYFMVAmt>4788163</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL INDIA VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>480000</BookValueAmt>
        <EOYFMVAmt>480000</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL LEADERS 4</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22921263</BookValueAmt>
        <EOYFMVAmt>22921263</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL LEADERS FUND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>13524240</BookValueAmt>
        <EOYFMVAmt>13524240</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL LEADERS II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7276777</BookValueAmt>
        <EOYFMVAmt>7276777</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL LEADERS III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>30532173</BookValueAmt>
        <EOYFMVAmt>30532173</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5410664</BookValueAmt>
        <EOYFMVAmt>5410664</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>28342318</BookValueAmt>
        <EOYFMVAmt>28342318</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>13141628</BookValueAmt>
        <EOYFMVAmt>13141628</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XIV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8594510</BookValueAmt>
        <EOYFMVAmt>8594510</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6585862</BookValueAmt>
        <EOYFMVAmt>6585862</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XVI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>735234</BookValueAmt>
        <EOYFMVAmt>735234</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH 2024 MULTIPLEXER</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12737561</BookValueAmt>
        <EOYFMVAmt>12737561</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH BIO FUND I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5176647</BookValueAmt>
        <EOYFMVAmt>5176647</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH BIO FUND II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>14929368</BookValueAmt>
        <EOYFMVAmt>14929368</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH BIO III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16462239</BookValueAmt>
        <EOYFMVAmt>16462239</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH BIO IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7998035</BookValueAmt>
        <EOYFMVAmt>7998035</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH CNK IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8208321</BookValueAmt>
        <EOYFMVAmt>8208321</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH CNK SEED I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4301427</BookValueAmt>
        <EOYFMVAmt>4301427</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH FUND VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12034065</BookValueAmt>
        <EOYFMVAmt>12034065</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH FUND VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11590228</BookValueAmt>
        <EOYFMVAmt>11590228</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>49216024</BookValueAmt>
        <EOYFMVAmt>49216024</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH III PARALLEL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11126940</BookValueAmt>
        <EOYFMVAmt>11126940</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>30083291</BookValueAmt>
        <EOYFMVAmt>30083291</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH IV PARALLEL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11316856</BookValueAmt>
        <EOYFMVAmt>11316856</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH LSV FUND II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19257909</BookValueAmt>
        <EOYFMVAmt>19257909</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH LSV FUND III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>20045228</BookValueAmt>
        <EOYFMVAmt>20045228</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH LSV I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19976431</BookValueAmt>
        <EOYFMVAmt>19976431</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>44769088</BookValueAmt>
        <EOYFMVAmt>44769088</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH V PARALLEL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>33862315</BookValueAmt>
        <EOYFMVAmt>33862315</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>24736043</BookValueAmt>
        <EOYFMVAmt>24736043</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ANGELENO INV III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16937302</BookValueAmt>
        <EOYFMVAmt>16937302</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ARBORETUM III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1524062</BookValueAmt>
        <EOYFMVAmt>1524062</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ARBORETUM IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9387239</BookValueAmt>
        <EOYFMVAmt>9387239</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ARBORETUM V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>18895979</BookValueAmt>
        <EOYFMVAmt>18895979</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ARBORETUM VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6985934</BookValueAmt>
        <EOYFMVAmt>6985934</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>COLLER VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1828988</BookValueAmt>
        <EOYFMVAmt>1828988</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>COLLER VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16996428</BookValueAmt>
        <EOYFMVAmt>16996428</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>COLLER VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>30024784</BookValueAmt>
        <EOYFMVAmt>30024784</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CONGRUENT CONTINUITY</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9287107</BookValueAmt>
        <EOYFMVAmt>9287107</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CRESTVIEW ELO</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8183115</BookValueAmt>
        <EOYFMVAmt>8183115</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CRESTVIEW III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>26093392</BookValueAmt>
        <EOYFMVAmt>26093392</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CRESTVIEW IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>33243027</BookValueAmt>
        <EOYFMVAmt>33243027</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>46017551</BookValueAmt>
        <EOYFMVAmt>46017551</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>20172577</BookValueAmt>
        <EOYFMVAmt>20172577</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE OPP I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9089321</BookValueAmt>
        <EOYFMVAmt>9089321</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>23199567</BookValueAmt>
        <EOYFMVAmt>23199567</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17410140</BookValueAmt>
        <EOYFMVAmt>17410140</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EPIRIS ELEC CO INV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11385608</BookValueAmt>
        <EOYFMVAmt>11385608</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EPIRIS II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>23171624</BookValueAmt>
        <EOYFMVAmt>23171624</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EPIRIS III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16328049</BookValueAmt>
        <EOYFMVAmt>16328049</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FORTISSIMO IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19196561</BookValueAmt>
        <EOYFMVAmt>19196561</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FORTISSIMO V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22493956</BookValueAmt>
        <EOYFMVAmt>22493956</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FORTISSIMO VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9078435</BookValueAmt>
        <EOYFMVAmt>9078435</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER COINVEST 2</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5326646</BookValueAmt>
        <EOYFMVAmt>5326646</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER GTH BUYOUT X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>21632010</BookValueAmt>
        <EOYFMVAmt>21632010</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9082650</BookValueAmt>
        <EOYFMVAmt>9082650</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER OVERAGE</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>15831875</BookValueAmt>
        <EOYFMVAmt>15831875</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER PUBLIC FUND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22412499</BookValueAmt>
        <EOYFMVAmt>22412499</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER SUNMD CO INV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19746931</BookValueAmt>
        <EOYFMVAmt>19746931</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12252780</BookValueAmt>
        <EOYFMVAmt>12252780</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER XI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11103867</BookValueAmt>
        <EOYFMVAmt>11103867</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GAVEA IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1481298</BookValueAmt>
        <EOYFMVAmt>1481298</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GAVEA V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4823759</BookValueAmt>
        <EOYFMVAmt>4823759</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GENERL ATLANTIC 2013</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>56584009</BookValueAmt>
        <EOYFMVAmt>56584009</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GENERL ATLANTIC 2018</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>81061163</BookValueAmt>
        <EOYFMVAmt>81061163</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BRAZIL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4561515</BookValueAmt>
        <EOYFMVAmt>4561515</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BRAZIL LATAM B</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>13830119</BookValueAmt>
        <EOYFMVAmt>13830119</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BRAZIL LATAM C</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>13830119</BookValueAmt>
        <EOYFMVAmt>13830119</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG CAPITAL V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6919413</BookValueAmt>
        <EOYFMVAmt>6919413</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG GROWTH B&amp;E F II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5863861</BookValueAmt>
        <EOYFMVAmt>5863861</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG GROWTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9010867</BookValueAmt>
        <EOYFMVAmt>9010867</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG HEALTHBRIDGE</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12324531</BookValueAmt>
        <EOYFMVAmt>12324531</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG MID MARKET II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9689585</BookValueAmt>
        <EOYFMVAmt>9689585</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG MID MARKET III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>14609366</BookValueAmt>
        <EOYFMVAmt>14609366</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN EXP I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3085468</BookValueAmt>
        <EOYFMVAmt>3085468</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN GROWTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>95878511</BookValueAmt>
        <EOYFMVAmt>95878511</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN GROWTH IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>25673901</BookValueAmt>
        <EOYFMVAmt>25673901</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN GROWTH V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>27640078</BookValueAmt>
        <EOYFMVAmt>27640078</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN GROWTH VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>20523846</BookValueAmt>
        <EOYFMVAmt>20523846</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN GROWTH VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3545914</BookValueAmt>
        <EOYFMVAmt>3545914</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN VTR IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9697533</BookValueAmt>
        <EOYFMVAmt>9697533</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN VTR IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1322435</BookValueAmt>
        <EOYFMVAmt>1322435</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN VTR V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5824079</BookValueAmt>
        <EOYFMVAmt>5824079</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN VTR VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8559963</BookValueAmt>
        <EOYFMVAmt>8559963</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN VTR VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4923713</BookValueAmt>
        <EOYFMVAmt>4923713</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN VTR VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4325586</BookValueAmt>
        <EOYFMVAmt>4325586</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG BREYER</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8885912</BookValueAmt>
        <EOYFMVAmt>8885912</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG CHINA CAP III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>26363578</BookValueAmt>
        <EOYFMVAmt>26363578</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG CHINA VTR IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>23121637</BookValueAmt>
        <EOYFMVAmt>23121637</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG CHINA VTR V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>26625184</BookValueAmt>
        <EOYFMVAmt>26625184</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG-ACCEL CHINA CAP</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>10968798</BookValueAmt>
        <EOYFMVAmt>10968798</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG-ACCEL CHINA GWTH</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9016097</BookValueAmt>
        <EOYFMVAmt>9016097</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IRON POINT IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>18434932</BookValueAmt>
        <EOYFMVAmt>18434932</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>JPM PEG SECONDRY III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4230920</BookValueAmt>
        <EOYFMVAmt>4230920</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ASIA III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>60416564</BookValueAmt>
        <EOYFMVAmt>60416564</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ASIA IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22143164</BookValueAmt>
        <EOYFMVAmt>22143164</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ISRAEL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1901085</BookValueAmt>
        <EOYFMVAmt>1901085</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ISRAEL II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>18373039</BookValueAmt>
        <EOYFMVAmt>18373039</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED PI IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12366730</BookValueAmt>
        <EOYFMVAmt>12366730</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED PI VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8266524</BookValueAmt>
        <EOYFMVAmt>8266524</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED PI VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22037580</BookValueAmt>
        <EOYFMVAmt>22037580</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED PI VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>20222556</BookValueAmt>
        <EOYFMVAmt>20222556</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBMIED ASIA V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9096219</BookValueAmt>
        <EOYFMVAmt>9096219</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV GWTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12330411</BookValueAmt>
        <EOYFMVAmt>12330411</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV GWTH IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3179607</BookValueAmt>
        <EOYFMVAmt>3179607</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV SEA I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3021093</BookValueAmt>
        <EOYFMVAmt>3021093</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11804254</BookValueAmt>
        <EOYFMVAmt>11804254</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12978906</BookValueAmt>
        <EOYFMVAmt>12978906</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1240660</BookValueAmt>
        <EOYFMVAmt>1240660</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV VTR VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3398972</BookValueAmt>
        <EOYFMVAmt>3398972</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEP IV CORE</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>993669</BookValueAmt>
        <EOYFMVAmt>993669</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEP IV SUPPL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>415294</BookValueAmt>
        <EOYFMVAmt>415294</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEP VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>24448554</BookValueAmt>
        <EOYFMVAmt>24448554</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEP VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>771788</BookValueAmt>
        <EOYFMVAmt>771788</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PIATNGO VTR IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1248959</BookValueAmt>
        <EOYFMVAmt>1248959</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO GROWTH</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>61640072</BookValueAmt>
        <EOYFMVAmt>61640072</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO GROWTH II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22204708</BookValueAmt>
        <EOYFMVAmt>22204708</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO HEALTH II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2764419</BookValueAmt>
        <EOYFMVAmt>2764419</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO HEALTHTECH I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9827519</BookValueAmt>
        <EOYFMVAmt>9827519</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO SPV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>21958799</BookValueAmt>
        <EOYFMVAmt>21958799</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO VI, LP</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>26100607</BookValueAmt>
        <EOYFMVAmt>26100607</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO VTR VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>26088396</BookValueAmt>
        <EOYFMVAmt>26088396</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO VTR VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16931226</BookValueAmt>
        <EOYFMVAmt>16931226</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>RIDGEWOOD III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>32098781</BookValueAmt>
        <EOYFMVAmt>32098781</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>RIDGEWOOD IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>28194204</BookValueAmt>
        <EOYFMVAmt>28194204</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>S CAPITAL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17281159</BookValueAmt>
        <EOYFMVAmt>17281159</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>S CAPITAL II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11018147</BookValueAmt>
        <EOYFMVAmt>11018147</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>S CAPITAL III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4253438</BookValueAmt>
        <EOYFMVAmt>4253438</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SCF LIQUID PORTFOLIO</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>48081485</BookValueAmt>
        <EOYFMVAmt>48081485</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA GBL GRTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>99769116</BookValueAmt>
        <EOYFMVAmt>99769116</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA GG 3 CH ANX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16460729</BookValueAmt>
        <EOYFMVAmt>16460729</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA GLB GROWTH</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>29555443</BookValueAmt>
        <EOYFMVAmt>29555443</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA GLB GRWTH II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>39595153</BookValueAmt>
        <EOYFMVAmt>39595153</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA ISRAEL V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7530636</BookValueAmt>
        <EOYFMVAmt>7530636</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA SCOUT III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2279728</BookValueAmt>
        <EOYFMVAmt>2279728</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA SCOUT IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1334197</BookValueAmt>
        <EOYFMVAmt>1334197</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US ECO I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>917754</BookValueAmt>
        <EOYFMVAmt>917754</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US EXP I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>10005071</BookValueAmt>
        <EOYFMVAmt>10005071</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GROWTH V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>745209</BookValueAmt>
        <EOYFMVAmt>745209</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GRTH VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>10900783</BookValueAmt>
        <EOYFMVAmt>10900783</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GRWTH VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4075351</BookValueAmt>
        <EOYFMVAmt>4075351</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GWTH IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8557960</BookValueAmt>
        <EOYFMVAmt>8557960</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GWTH VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>810240</BookValueAmt>
        <EOYFMVAmt>810240</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GWTH X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5831950</BookValueAmt>
        <EOYFMVAmt>5831950</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US SEED V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>892249</BookValueAmt>
        <EOYFMVAmt>892249</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VENT XVI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12559632</BookValueAmt>
        <EOYFMVAmt>12559632</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VTR XIV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2869150</BookValueAmt>
        <EOYFMVAmt>2869150</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VTR XV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5144966</BookValueAmt>
        <EOYFMVAmt>5144966</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VTR XVII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5923830</BookValueAmt>
        <EOYFMVAmt>5923830</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VTR XVIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1822252</BookValueAmt>
        <EOYFMVAmt>1822252</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SQUOIA GG 3 US IN AX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>15234847</BookValueAmt>
        <EOYFMVAmt>15234847</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>STARWOOD X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11001661</BookValueAmt>
        <EOYFMVAmt>11001661</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>STARWOOD XI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>42603687</BookValueAmt>
        <EOYFMVAmt>42603687</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>STARWOOD XII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>39678065</BookValueAmt>
        <EOYFMVAmt>39678065</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>QMETCO</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>27754179</BookValueAmt>
        <EOYFMVAmt>27754179</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>WTI VLL IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>10474200</BookValueAmt>
        <EOYFMVAmt>10474200</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>WTI VLL VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6649000</BookValueAmt>
        <EOYFMVAmt>6649000</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>WTI VLL VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>10939495</BookValueAmt>
        <EOYFMVAmt>10939495</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>WTI VLL X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7561920</BookValueAmt>
        <EOYFMVAmt>7561920</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>YORK CO INVEST 1</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>996336</BookValueAmt>
        <EOYFMVAmt>996336</EOYFMVAmt>
      </InvestmentsOtherGrp>
    </InvestmentsOtherSchedule2>
    <LandEtcSchedule2 documentId="RetDoc2059000001">
      <LandEtcGrp>
        <CategoryOrItemTxt>FURNITURE, FIXTURES AND EQUIPMENT</CategoryOrItemTxt>
        <CostOrOtherBasisAmt>3154445</CostOrOtherBasisAmt>
        <AccumulatedDepreciationAmt>2231333</AccumulatedDepreciationAmt>
        <BookValueAmt>923112</BookValueAmt>
        <EOYFMVAmt>923112</EOYFMVAmt>
      </LandEtcGrp>
      <LandEtcGrp>
        <CategoryOrItemTxt>LEASEHOLD IMPROVEMENTS</CategoryOrItemTxt>
        <CostOrOtherBasisAmt>7446632</CostOrOtherBasisAmt>
        <AccumulatedDepreciationAmt>2514038</AccumulatedDepreciationAmt>
        <BookValueAmt>4932594</BookValueAmt>
        <EOYFMVAmt>4932594</EOYFMVAmt>
      </LandEtcGrp>
      <LandEtcGrp>
        <CategoryOrItemTxt>WORK IN PROGRESS</CategoryOrItemTxt>
        <CostOrOtherBasisAmt>1325</CostOrOtherBasisAmt>
        <AccumulatedDepreciationAmt>0</AccumulatedDepreciationAmt>
        <BookValueAmt>1325</BookValueAmt>
        <EOYFMVAmt>1325</EOYFMVAmt>
      </LandEtcGrp>
    </LandEtcSchedule2>
    <LegalFeesSchedule documentId="RetDoc2002100001">
      <LegalFeesGrp>
        <CategoryTxt>LEGAL FEES - INVESTMENTS</CategoryTxt>
        <LegalFeesAmt>184836</LegalFeesAmt>
        <NetInvestmentIncomeAmt>184836</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
      <LegalFeesGrp>
        <CategoryTxt>LEGAL FEES - PROGRAMS</CategoryTxt>
        <LegalFeesAmt>252018</LegalFeesAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>310816</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
      <LegalFeesGrp>
        <CategoryTxt>LEGAL FEES - GENERAL ADMINISTRATIVE</CategoryTxt>
        <LegalFeesAmt>118389</LegalFeesAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>123435</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
    </LegalFeesSchedule>
    <OtherAssetsSchedule documentId="RetDoc2046600001">
      <OtherAssetsScheduleGrp>
        <Desc>ACCRUED INCOME RECEIVABLE</Desc>
        <BOYBookValueAmt>1416200</BOYBookValueAmt>
        <EOYBookValueAmt>1680919</EOYBookValueAmt>
        <EOYFMVAmt>1680919</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>DUE FROM BROKER</Desc>
        <BOYBookValueAmt>25945689</BOYBookValueAmt>
        <EOYBookValueAmt>14137129</EOYBookValueAmt>
        <EOYFMVAmt>14137129</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>RETIREMENT PLAN ASSET</Desc>
        <BOYBookValueAmt>2162642</BOYBookValueAmt>
        <EOYBookValueAmt>2064360</EOYBookValueAmt>
        <EOYFMVAmt>2064360</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>ADVANCES AND OTHER RECEIVABLES</Desc>
        <BOYBookValueAmt>6037</BOYBookValueAmt>
        <EOYBookValueAmt>7040</EOYBookValueAmt>
        <EOYFMVAmt>7040</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>PROGRAM RELATED INVESTMENTS</Desc>
        <BOYBookValueAmt>18971538</BOYBookValueAmt>
        <EOYBookValueAmt>24011405</EOYBookValueAmt>
        <EOYFMVAmt>24011405</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>OPERATING LEASE RIGHT OF USE ASSET</Desc>
        <BOYBookValueAmt>7359283</BOYBookValueAmt>
        <EOYBookValueAmt>6372839</EOYBookValueAmt>
        <EOYFMVAmt>6372839</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>PREPAID FEDERAL EXCISE TAX</Desc>
        <EOYBookValueAmt>786796</EOYBookValueAmt>
        <EOYFMVAmt>786796</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
    </OtherAssetsSchedule>
    <OtherDecreasesSchedule documentId="RetDoc2049800001">
      <OtherDecreasesDetail>
        <Desc>UNREALIZED LOSS ON INVESTMENTS</Desc>
        <Amt>152784093</Amt>
      </OtherDecreasesDetail>
      <OtherDecreasesDetail>
        <Desc>UNREALIZED LOSS ON PROGRAM RELATED INVESTMENTS</Desc>
        <Amt>178498</Amt>
      </OtherDecreasesDetail>
      <OtherDecreasesDetail>
        <Desc>PROVISION FOR CREDIT LOSSES - RELATED TO PROGRAM RELATED INVESTMENTS</Desc>
        <Amt>8876050</Amt>
      </OtherDecreasesDetail>
    </OtherDecreasesSchedule>
    <OtherExpensesSchedule documentId="RetDoc2003200001">
      <OtherExpensesScheduleGrp>
        <Desc>AMERICAN DEPOSITARY RECEIPT FEE</Desc>
        <RevenueAndExpensesPerBooksAmt>10820</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>10820</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>CONSULTING REIMBURSEMENTS</Desc>
        <RevenueAndExpensesPerBooksAmt>34621</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>126</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>42173</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>CUSTODY, BANK, &amp; PERFORMANCE REPORTING FEES</Desc>
        <RevenueAndExpensesPerBooksAmt>731527</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>731477</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>50</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>STATE FILING FEES AND PENALTIES</Desc>
        <RevenueAndExpensesPerBooksAmt>163</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>INFORMATION TECHNOLOGY/COMPUTERS</Desc>
        <RevenueAndExpensesPerBooksAmt>1676118</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>254043</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>1559119</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>INSURANCE</Desc>
        <RevenueAndExpensesPerBooksAmt>415037</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>39955</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>374123</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>OFFICE EXPENSES</Desc>
        <RevenueAndExpensesPerBooksAmt>1000781</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>466522</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>513810</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>PORTFOLIO DEDUCTIONS</Desc>
        <RevenueAndExpensesPerBooksAmt>12723578</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>54775206</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
    </OtherExpensesSchedule>
    <OtherIncomeSchedule2 documentId="RetDoc2001500001">
      <OtherIncomeDetail>
        <Desc>FX TRANSACTION NET LOSS - TAX</Desc>
        <NetInvestmentIncomeAmt>-429874</NetInvestmentIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>CLASS ACTION PROCEEDS, NET</Desc>
        <RevenueAndExpensesPerBooksAmt>19132</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>19132</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>19132</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>OTHER PARTNERSHIP INCOME</Desc>
        <RevenueAndExpensesPerBooksAmt>25329605</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>22439795</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>25329605</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>SECTION 951(A) INCOME INCLUSION</Desc>
        <NetInvestmentIncomeAmt>2447781</NetInvestmentIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>OTHER INVESTMENT INCOME</Desc>
        <RevenueAndExpensesPerBooksAmt>42</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>42</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>42</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>GRANT RECOVERIES</Desc>
        <RevenueAndExpensesPerBooksAmt>7276276</RevenueAndExpensesPerBooksAmt>
        <AdjustedNetIncomeAmt>7276276</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>OTHER NON-TAXABLE INCOME</Desc>
        <RevenueAndExpensesPerBooksAmt>27454</RevenueAndExpensesPerBooksAmt>
        <AdjustedNetIncomeAmt>27454</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>FEDERAL EXCISE TAX BENEFIT</Desc>
        <RevenueAndExpensesPerBooksAmt>3842567</RevenueAndExpensesPerBooksAmt>
        <AdjustedNetIncomeAmt>3842567</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>FX TRANSACTION NET LOSS - BOOK</Desc>
        <RevenueAndExpensesPerBooksAmt>-496216</RevenueAndExpensesPerBooksAmt>
        <AdjustedNetIncomeAmt>-496216</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
    </OtherIncomeSchedule2>
    <OtherIncreasesSchedule documentId="RetDoc2049700001">
      <OtherIncreasesDetail>
        <Desc>DEFERRED FEDERAL EXCISE TAX BENEFIT</Desc>
        <Amt>2181205</Amt>
      </OtherIncreasesDetail>
    </OtherIncreasesSchedule>
    <OtherLiabilitiesSchedule documentId="RetDoc2065700001">
      <OtherLiabilitiesDetail>
        <Desc>DEFERRED FEDERAL EXCISE TAX</Desc>
        <BOYBookValueAmt>24836165</BOYBookValueAmt>
        <EOYBookValueAmt>22654960</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>RETIREMENT PLAN LIABILITY</Desc>
        <BOYBookValueAmt>2432030</BOYBookValueAmt>
        <EOYBookValueAmt>2948693</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>ACCRUED VACATION</Desc>
        <BOYBookValueAmt>1168550</BOYBookValueAmt>
        <EOYBookValueAmt>1342903</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>GRANT REFUNDS PENDING MODIFICATION</Desc>
        <BOYBookValueAmt>3852387</BOYBookValueAmt>
        <EOYBookValueAmt>38746</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>OPERATING LEASE LIABILITIES</Desc>
        <BOYBookValueAmt>8365590</BOYBookValueAmt>
        <EOYBookValueAmt>7261172</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>FEDERAL EXCISE TAX PAYABLE</Desc>
        <BOYBookValueAmt>4555771</BOYBookValueAmt>
        <EOYBookValueAmt>0</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>ALLOWANCE FOR CREDIT LOSSES</Desc>
        <BOYBookValueAmt>646935</BOYBookValueAmt>
        <EOYBookValueAmt>6171350</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>REFUNDABLE DEPOSITS</Desc>
        <BOYBookValueAmt>0</BOYBookValueAmt>
        <EOYBookValueAmt>419</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
    </OtherLiabilitiesSchedule>
    <OtherProfessionalFeesSchedule documentId="RetDoc2002300001">
      <OtherProfessionalFeesDetail>
        <CategoryTxt>GRANTS MANAGEMENT CONSULTING</CategoryTxt>
        <Amt>122100</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>151588</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>HUMAN RESOURCE CONSULTING</CategoryTxt>
        <Amt>79696</Amt>
        <NetInvestmentIncomeAmt>7000</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>75696</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>INFORMATION TECHNOLOGY CONSULTING</CategoryTxt>
        <Amt>406409</Amt>
        <NetInvestmentIncomeAmt>40896</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>348594</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>INVESTMENT ADVISORY</CategoryTxt>
        <Amt>513656</Amt>
        <NetInvestmentIncomeAmt>513656</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>INVESTMENT MANAGEMENT</CategoryTxt>
        <Amt>14260530</Amt>
        <NetInvestmentIncomeAmt>14260530</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>MANAGEMENT CONSULTING</CategoryTxt>
        <Amt>70936</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>110936</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>PROGRAM CONSULTING</CategoryTxt>
        <Amt>1182556</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>1375891</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>PUBLIC RELATIONS</CategoryTxt>
        <Amt>321574</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>385730</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>RECRUITMENT</CategoryTxt>
        <Amt>127045</Amt>
        <NetInvestmentIncomeAmt>25306</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>90073</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
    </OtherProfessionalFeesSchedule>
    <TaxesSchedule documentId="RetDoc2002500001">
      <TaxesDetail>
        <CategoryTxt>STATE UBI AND OTHER TAXES</CategoryTxt>
        <Amt>823811</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
      <TaxesDetail>
        <CategoryTxt>FOREIGN TAXES WITHHELD</CategoryTxt>
        <Amt>478700</Amt>
        <NetInvestmentIncomeAmt>3875590</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
    </TaxesSchedule>
    <TransfersFrmControlledEntities documentId="RetDoc2204900001">
      <TransfersFromControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MHR LONGEVITY PARTNERS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>40 WEST 57TH ST FLOOR 24</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10019</ZIPCd>
        </USAddress>
        <EIN>981471155</EIN>
        <Desc>DISTRIBUTION FROM PARTNERSHIP</Desc>
        <Amt>54725000</Amt>
      </TransfersFromControlledEntGrp>
      <TransfersFromControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER LP</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1325 NORTH BEACH STREET SUITE 201</AddressLine1Txt>
          <CityNm>PHILADELPHIA</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19125</ZIPCd>
        </USAddress>
        <EIN>981142649</EIN>
        <Desc>DISTRIBUTION</Desc>
        <Amt>8659313</Amt>
      </TransfersFromControlledEntGrp>
      <TotalAmt>66292906</TotalAmt>
    </TransfersFrmControlledEntities>
    <TransfersToControlledEntities documentId="RetDoc2205000001">
      <TransfersToControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>LACM WORLD SMALL CAP EQUITY FUND LP</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>11150 SANTA MONICA BLVD STE 200</AddressLine1Txt>
          <CityNm>LOS ANGELES</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>90025</ZIPCd>
        </USAddress>
        <EIN>832888004</EIN>
        <Desc>CONTRIBUTION OF CAPITAL</Desc>
        <Amt>20000000</Amt>
      </TransfersToControlledEntGrp>
      <TransfersToControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>ORION HOUSE 5 UPPER ST MARTINS LANE</AddressLine1Txt>
          <CityNm>LONDON</CityNm>
          <CountryCd>UK</CountryCd>
          <ForeignPostalCd>WC2H 9EA</ForeignPostalCd>
        </ForeignAddress>
        <EIN>611915057</EIN>
        <Desc>CONTRIBUTION OF CAPITAL</Desc>
        <Amt>30000000</Amt>
      </TransfersToControlledEntGrp>
      <TransfersToControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MHR LONGEVITY PARTNERS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>40 WEST 57TH ST FLOOR 24</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10019</ZIPCd>
        </USAddress>
        <EIN>981471155</EIN>
        <Desc>CONTRIBUTION OF CAPITAL</Desc>
        <Amt>54725000</Amt>
      </TransfersToControlledEntGrp>
      <TransfersToControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER LP</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1325 NORTH BEACH STREET SUITE 201</AddressLine1Txt>
          <CityNm>PHILADELPHIA</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19125</ZIPCd>
        </USAddress>
        <EIN>981142649</EIN>
        <Desc>MANAGEMENT FEES</Desc>
        <Amt>8659313</Amt>
      </TransfersToControlledEntGrp>
      <TotalAmt>113384313</TotalAmt>
    </TransfersToControlledEntities>
  </ReturnData>
</Return>